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1. Research Summary 
 
HIV-1 infection is accompanied by profound B cell alterations that impede responsiveness to 
novel antigens. Disease progression leads to loss of lymphoid architecture affecting the 
development of high-affinity antibody responses, polyclonal B cell activation, hypergamma-
globulinemia and increased frequencies of activated (AM) and exhausted tissue-like (TLM) 
memory B cells. Despite these severe perturbations the elicitation of potent broadly neutralizing 
antibodies (bnAbs) against HIV-1 depends on years of exposure to HIV-1. Definition of why 
bnAbs preferentially develop in a stage where B cell responses generally are impaired is of 
outmost importance as current vaccine development struggles to elicit bnAb responses.  
The aim of my thesis was to provide the basis for future research aiming to resolve the evolution 
of bnAb responses by establishing a comprehensive phenotypic map of peripheral B cell subsets 
in healthy and HIV-1 infected individuals that can be utilized to reveal B cell signatures related to 
HIV-1 infection that may be associated with the induction of potent neutralizing antibody 
responses.  
The first experimental chapter of my thesis (Chapter 2.1) describes the development of a 16 
color flow cytometry panel that was developed to define phenotypic alterations. To obtain 
insights into the dynamics of B cell repertoire alterations in HIV-1 infection I analyzed the 
composition of the B cell population during acute and chronic HIV-1 infection and assessed the 
effect of antiretroviral treatment (ART) in work described in Chapters 2.2. and 2.3. 
Chapter 2.2 describes the emergence of CD21neg naïve and CD21neg marginal zone (MZ) B cells 
during HIV-1 infection. These subsets are characterized by altered chemokine receptor 
signatures switching their migration potential from lymphoid tissues to sites of inflammation. 
Functional analysis suggests that CD21neg naïve and CD21neg MZ B cells are activated and 
anergic based on increased CD95 and FcRL4 expression, increased frequency of proliferating 
cells and impaired response to BCR-mediated stimulation. Collectively the data suggest that 
HIV-1 infection leads to the accumulation of large fractions of anergic naïve and MZ B cells that 
are impaired in responding to their cognate antigen. The identification of these subsets highlights 
that even antigen-inexperienced B cells are affected by HIV-1 infection and with this a crucial 
cell population required for elicitation of de novo responses is impaired in HIV-1 infection.  
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Chapter 2.3 describes a detailed analysis of the memory B cell and plasmablast compartment in 
the same patient cohort. Using computational algorithms for dimensionality reduction (t-SNE) 
and clustering (SPADE/Ward’s hierarchical clustering) to process the high-content cytometry 
data, the study revealed a previously underappreciated phenotypic diversity of memory B cells 
beyond subsets stratified for expression of B cell receptor isotype and classification by 
CD21/CD27 expression. Likewise, I identified a phenotypic variability among plasmablasts. 
Importantly, the newly defined clusters of memory B cells and plasmablasts show unique 
dynamics during HIV-1 infection and some alterations are not reversed when ART is initiated 
late highlighting the complexity of HIV-1 dependent B cell alterations. Surprisingly, t-SNE 
analysis revealed that IgG3pos memory B cells contain the highest levels of AM and TLM B cells 
compared to IgA- and IgG1-expressing memory B cell subsets in healthy and HIV-1 infected 
individuals. Furthermore IgG3pos resting memory B cells are characterized by expression of 
chemokine receptor signature associated with activation suggesting that induction of IgG3 
responses have distinct requirements in terms of activation or characteristics of antigen resulting 
in more pronounced activation phenotype.  
In summary, I established in my thesis an in-depth phenotypic analysis of the peripheral B cell 
compartment that revealed a highly complex landscape of B cell subsets both in healthy donors 
and HIV-1 infection. Dynamics of these subsets at different disease stages that my studies 
revealed will aid future functional studies aiming to define relevant B cell subsets that are linked 
with the development of bnAbs.  
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2. Zusammenfassung 
 
Die HIV-1 Infektion führt zu ausgeprägten B Zell-Veränderungen, die eine Beeinträchtigung der 
Antikörperantwort gegen neue Antigene zur Folge hat. Im Verlauf der Krankheit wird die 
Architektur der Lymphorgane beschädigt und dadurch die Entwicklung hoch-affiner Antikörper 
gestört. Zusätzlich treten polyklonale B–Zell-Aktivierung, Hypergammaglobulinämie und 
vermehrt aktivierte (AM) und erschöpfte Gewebe-ähnliche (TLM) Gedächtnis-B Zellen auf. Trotz 
dieser Veränderungen bilden sich in manchen HIV-1 infizierten Patienten potente breit-
neutralisierende Antikörper (bnAbs) gegen HIV-1 aus. Die Entwicklung dieser bnAbs benötigt 
jedoch mehrere Jahre aktive HIV-1 Infektion. BnAbs treten demnach mehrheitlich in einem 
Stadium der Infektion auf, welches von Beeinträchtigung der B Zellen geprägt ist. Es ist von 
speziellem Interesse, die Gründe dafür zu definieren, da es Ziel der HIV-Impfstoffentwicklung ist, 
solche bnAbs zu induzieren, dies sich aber als äusserst schwierig erwiesen hat.  
Das Ziel meiner Dissertation bestand darin, eine umfangreiche phänotypische Analyse der 
peripheren B Zell-Subtypen in gesunden und HIV-1 infizierten Menschen zu erstellen, welche 
die zukünftige Erforschung der Entwicklung von bnAbs unterstützt. Fokus meiner 
Untersuchungen war es B Zell-Signaturen zu definieren, welche charakteristisch für eine HIV-1 
Infektion sind und dadurch möglicherweise mit der Entwicklung von potenten 
Antikörperantworten gegen HIV-1 assoziiert sein könnten.   
Im ersten Kapitel der Resultate meiner Dissertationsarbeit (Kapitel 2.1) wird die Entwicklung 
eines 16-Farben Durchflusszytometrie-Färbepanels beschrieben, das ich speziell entwickelt 
habe um phänotypische Veränderungen an B Zellen bestimmen zu können. Mit diesem Panel 
habe ich in Folge B Zellen während der akuten und chronischen Phase der HIV-1 Infektion 
analysiert, um die B Zell-Dynamik während der HIV-1 Infektion zu bestimmen und mit gesunden 
Spendern verglichen. Zusätzlich habe ich die Wirksamkeit der anitretroviralen Therapie (ART), 
HIV-1 abhängige B Zell-Veränderungen zu normalisieren, ermittelt. Diese Analysen sind in 
Kapitel 2.2 und 2.3 beschrieben. 
Kapitel 2.2 beschreibt das Auftreten von CD21neg naiven und CD21neg Marginalzonen (MZ) B 
Zellen. Diese B Zell-Subtypen zeigen eine veränderte Expression von Chemokinrezeptoren auf, 
welche die Migration zu Lymphorganen reduziert und stattdessen die Migration zu 
Entzündungsorten fördert. Funktionelle Analysen zeigten, dass  CD21neg naive und CD21neg MZ 
B Zellen eine erhöhte Expression von CD95 und FcRL4, erhöhte Häufigkeit an proliferierenden 
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Zellen und beeinträchtigte Reaktion auf Stimulierung aufweisen. Dies deutet darauf hin, dass, 
diese Zellen aktiviert und anergisch sind. Eine HIV-1 Infektion scheint daher zu einem Auftreten 
von CD21neg naiven und CD21neg MZ B Zellen, die in ihrer Funktion gestört sind, zu führen. 
Dadurch sind im HIV-1 infizierten Menschen ein grosser Teil von antigen-unerfahrenen B Zell-
Subtypen beeinträchtigt, welche eine wichtige Rolle für de novo Antikörperantworten spielen.  
Kapitel 2.3 beschreibt eine detaillierte Analyse der Gedächtnis-B Zellen und Plasmablasten 
innerhalb der gleichen Patienten. Dabei wurden mittels automatisierten Algorithmen zur 
Dimensionsreduktion (t-SNE) und Clusteranalyse (SPADE/Ward-basierende hierarchische 
Clusteranaylse) die multidimensionalen Durchflusszytometrie-Daten analysiert. Die Analysen 
zeigten, dass Gedächtnis-B Zellen eine hohe Diversität aufweisen, die über die Definition von 
Subtypen über exprimierte B Zellrezeptor-Isotypen und der Klassifizierung basierend auf 
CD21/CD27 hinausgeht. In ähnlicher Weise konnte ich eine phänotypische Diversität von 
Plasmablasten aufzeigen. Die in dieser Studie neu definierten Cluster von Gedächtnis-B Zellen 
und Plasmablasten zeigen unterschiedliche Dynamiken während der HIV-1 Infektion auf. Zudem 
konnten einige HIV-1 induzierte Veränderungen mittels ART nicht normalisiert werden, wenn die 
Therapie zu einem späten Zeitpunkt der HIV-1 Infektion begonnen wurde, was die Komplexität 
der HIV-1 abhängigen B Zell-Veränderungen weiter unterstreicht. Interessanterweise zeigte die 
t-SNE Analyse, dass IgG3pos Gedächtnis-B Zellen in gesunden und HIV-1 infizierten Personen 
im Vergleich zu IgA- und IgG1-exprimierenden B Zellen die höchsten Werte an AM und TLM B 
Zellen aufweisen. Zusätzlich zeigen ruhende IgG3pos Gedächtnis-B Zellen ein Expressions-
muster von Chemokinrezeptoren, welches mit B Zell-Aktivierung assoziiert ist. Dies deutet 
darauf hin, dass es Unterschiede in der Entwicklung der verschiedenen Isotypen-Antworten gibt 
und IgG3 Antikörperantworten eventuell andere Voraussetzungen in Bezug auf Aktivierung oder 
Antigene benötigt, die auch den Phänotyp mitbestimmen. 
Zusammenfassend habe ich im Rahmen dieser Dissertation eine vertiefte phänotypische 
Analyse der peripheren B Zellen durchgeführt, welche die Komplexität der B Zellen in gesunden 
und HIV-1 infizierten Patienten aufzeigt. Die in dieser Arbeit beschriebenen HIV-1 abhängigen 
Dynamiken dieser B Zell-Subtypen, können zukünftige Studien unterstützen, die zum Ziel haben, 
die für die Entwicklung von bnAbs relevanten B Zell-Subtypen zu untersuchen.  
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3.  Introduction 
3.1 B cell biology 
3.1.1 B cell development 
The development of mature B cells from hematopoietic stem cells (HSC) is a complex 
process taking place in the bone marrow where B cell progenitors transit several 
developmental stages associated with a tightly regulated program with the goal to acquire a 
functional and diverse yet not autoreactive B cell receptor [reviewed in (LeBien and Tedder 
2008; Melchers 2015)]. The transition from HSC to early B cell progenitors is characterized 
by expression of enzymes such as RAG1/2 and TdT important for V(D)J recombination, an 
important step resulting in the unique diversity of B cell receptors (LeBien 2000; LeBien and 
Tedder 2008; Schatz and Ji 2011).  The human immunoglobulin loci contains multiple genes 
for V (variable), D (diversity) and J (joining) elements resulting in a first line of B cell receptor 
diversity (Lefranc 2001; Watson, Steinberg et al. 2013). The enzyme TdT randomly extends 
the DNA double breaks initiated during V(D)J recombination by randomly adding and 
removing nucleotides, which ensures an additional level of B cell receptor (BCR) diversity 
[reviewed in (Schatz and Ji 2011; Schatz and Swanson 2011)]. During the development to 
mature B cells the D-J and subsequent V-D-J recombination happens in early and pro-B 
cells, respectively [reviewed in (LeBien 2000; LeBien and Tedder 2008)]. These two subsets 
are the earliest committed to the B cell fate and include important steps to guarantee the 
expression of the pre-BCR receptor [reviewed in (LeBien 2000; Monroe 2006; LeBien and 
Tedder 2008)]. This receptor is composed of a mature heavy chain associated with a 
surrogate light chain (SLC) containing the λ5 and VpreB proteins [reviewed in (Monroe 
2006)]. It has been shown that mice lacking the SLC have a dramatically delayed 
development of mature B cells pinpointing to an important function of a proper pre-BCR 
(Kitamura, Kudo et al. 1992). The pre-BCR supports the development of B cell progenitors 
into mature cells by providing tonic BCR signaling, an important survival and proliferation 
signal (Monroe 2006; Nemazee 2006). The pre-B cell subsets, divided in subsets I and II, 
initiate VJ recombination of the light chain and as these cells become immature B cells they 
express a functional mature BCR (LeBien 2000; LeBien and Tedder 2008). However, a high 
fraction of these cells express autoreactive BCR and could be potentially harmful when 
leaving the bone marrow [reviewed in (Pillai, Mattoo et al. 2011; Melchers 2015)]. In order to 
eliminate or edit autoreactive BCR several immune tolerance mechanisms occur which 
involve deletion by apoptosis, receptor editing or anergy [reviewed in (Meffre and 
Wardemann 2008; Meffre 2011; Melchers 2015)]. The fate of an autoreactive B cell is 
determined by its affinity to the autoantigen (Lang, Jackson et al. 1996; Nemazee 2006). 
5
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Strong affinity results in apoptosis whereas intermediate affinity initiates the process of 
receptor editing [reviewed in (Nemazee 2006)]. In case of cells with low affinity the state of 
unresponsiveness defined as anergy can be induced and these B cells egress from bone 
marrow [reviewed in (Nemazee 2006)]. Receptor editing includes the exchange of the light 
chain or the replacement of the VH element altering the specificity of the BCR [reviewed in 
(Nemazee 2006)]. In vivo studies in mice support the high efficiency of receptor editing in 
altering autoreactive BCR and that the majority of autoreactive B cells are edited rather than 
deleted (Halverson, Torres et al. 2004). Dysregulated immune tolerance can result in the 
emergence of autoreactive naïve B cells as observed for autoimmune and inflammatory 
diseases such as systemic lupus erythematodes (SLE) and rheumatoid arthritis (RA) 
[reviewed in (Meffre and Wardemann 2008)]. Impaired BCR signaling and dysregulated 
soluble factors regulating B cell survival such as B cell-activating factor of the tumor-necrosis 
family (BAFF) are observed among these diseases and are thought to contribute to the 
survival and egress of autoreactive mature B cells into the periphery [reviewed in (Meffre and 
Wardemann 2008; Meffre 2011)]. Edited immature B cells egress the bone marrow and are 
defined as transitional B cells developing into mature naïve B cells in the periphery (Chung, 
Silverman et al. 2003; Sims, Ettinger et al. 2005).  
 
3.1.2 B cell activation and Germinal center reaction 
In order to scan the environment for antigens naïve B cells shuttle constantly between the 
periphery and lymphoid tissues such as lymph nodes or the spleen (von Andrian and 
Mempel 2003; Coelho, Natale et al. 2013). Lymph nodes are highly specialized tissues to 
guarantee optimal and efficient immune responses and contain areas designated for B and T 
cells called B cell follicle and T cell area, respectively [reviewed in (von Andrian and Mempel 
2003; Lederman and Margolis 2008; Batista and Harwood 2009)]. B cell follicles are adjacent 
to T cell areas and the subcapsular sinus (SCS) (Junt, Moseman et al. 2007; Phan, 
Grigorova et al. 2007; Kuka and Iannacone 2014). The location of these areas guarantees 
efficient drainage of antigens from the SCS and close proximity of T cells in T cell area, 
respectively, to initiate optimal B cell responses [reviewed in (Batista and Harwood 2009; 
Roozendaal, Mempel et al. 2009; Gonzalez, Degn et al. 2011)]. The B cell follicles contain 
mostly mature B cells and a network composed of follicular dendritic cells (FDC) whereas the 
T cell area is characterized by fibroblastic reticular cells (FRC) [reviewed in (von Andrian and 
Mempel 2003)]. The latter express CCL19 and CCL21, which are important chemokines 
attracting CCR7-expressing cells such as B cells, T cells and dendritic cells (DC) (Link, Vogt 
et al. 2007; Fletcher, Acton et al. 2015). B cells are usually entering the lymph node via high 
endothelial venules (HEV) by attaching to the endothelial cells via L-selectin (CD62L) and 
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LFA-1, a process which requires CCR7 signaling (von Andrian and Mempel 2003; Park, 
Hwang et al. 2012; Coelho, Natale et al. 2013). B cells in the lymph node move along the 
FRC network in a CXCR5- and LFA-1-dependent manner towards B cell follicles in mice (von 
Andrian and Mempel 2003; Coelho, Natale et al. 2013). The FDC in the follicles produce 
CXCL13 which results in a gradient from the follicle into the T cell area attracting B cells 
known to express high levels of CXCR5, the receptor for CXCL13, to the follicle (Ansel, Ngo 
et al. 2000; Heesters, Myers et al. 2014). The CXCL13/CXCR5 axis plays a crucial role in 
attracting B and T cells to and allowing entrance into B cell follicles in order to optimally 
induce germinal center reaction (Cyster 2010; Griffith, Sokol et al. 2014).  
FDC express high levels of complement receptor 1 (CR1; CD35) and 2 (CR2; CD21) and 
show the ability to retain and present complement-opsonized antigens and immune 
complexes to B cells in the follicle (Roozendaal and Carroll 2007; Heesters, Chatterjee et al. 
2013; Heesters, Myers et al. 2014). Interestingly, FDC show the ability to present the 
antigens for prolonged time in the range of weeks to months (Heesters, Chatterjee et al. 
2013; Heesters, Myers et al. 2014). The prolonged retention of antigens ensures the 
maintenance of the GC and GC-associated processes such as SHM to improve antibody 
responses (Heesters, Chatterjee et al. 2013; Heesters, Myers et al. 2014). Since antigens 
are derived from afferent lymphatic vessels and only antigens with less than 70 kDa can 
diffuse through the porous layer of SCS macrophages it was for a long time puzzling how 
bigger antigens can reach the follicles (Kuka and Iannacone 2014). It has been shown that 
SCS macrophages can take up antigens in a complement- and Fc receptor-dependent 
manner and present them on the basal site adjacent to the follicles (Junt, Moseman et al. 
2007; Batista and Harwood 2009; Gonzalez, Degn et al. 2011; Kuka and Iannacone 2014).  
Naïve B cells can shuttle the opsonized antigens from the SCS macrophages to FDC 
transferring the antigens to sites of antigen presentation in the follicle (Phan, Grigorova et al. 
2007; Cinamon, Zachariah et al. 2008). Although antigen presentation via FDC is thought to 
be the main mechanism of B cell activation there are others such as capturing of dendritic 
cell (DC)-derived antigens in the T cell area or soluble small antigens diffusing into the 
follicles [reviewed in (Batista and Harwood 2009)]. The former requires that DC do not digest 
the antigens since B cells can recognize the antigens in their native form [reviewed in 
(Batista and Harwood 2009)]. T cell area-resident DC are shown to present antigens to B 
cells through several mechanisms such as on FcRγIIB or DC-SIGN (DC-specific ICAM-3 
grabbing non-integrin; CD209), both receptors inducing internalization into compartments not 
associated with protein denaturation and digestion (Bergtold, Desai et al. 2005; Batista and 
Harwood 2009).  While Fc receptors can only bind immune complexes through the Fc region 
of the antibodies, DC SIGN is a type II C-type lectin receptor and can bind carbohydrate 
moieties of antigens directly [reviewed in (Svajger, Anderluh et al. 2010)]. B cells recognizing 
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antigens via their BCR become activated and migrate towards the border of the T and B cell 
area (Figure 1A) (Liu, Zhang et al. 1991; Okada, Miller et al. 2005). Activated B cells present 
antigen via MHCII to interact with antigen-specific T cells for prolonged time and to thereby 
receive T-cell help that supports B cell proliferation and differentiation into GC B cells or 
short-lived plasmablasts (Figure 1A) (Parker 1993; Okada, Miller et al. 2005). The decision 
between differentiation towards GC B cells or plasmablasts is affinity-dependent with high-
affinity antigen binding associated with differentiation towards extrafollicular plasmablasts 
(Mills and Cambier 2003; Paus, Phan et al. 2006; Schwickert, Victora et al. 2011). 
Interestingly, extrafollicular plasmablasts further divide and express activation-induced 
deaminase, an important enzyme for somatic hypermutation (SHM) [reviewed in (Zhang, 
Garcia-Ibanez et al. 2016)]. This suggests that extrafollicular plasmablasts known to be 
important for the early antibody response possess the ability to adapt and improve the early 
antibody response although excluded from the GC (Toellner, Jenkinson et al. 2002; 
MacLennan, Toellner et al. 2003). However, extrafollicular plasmablasts are shown to only 
slightly increase mutations in the variable regions (Toellner, Jenkinson et al. 2002; Zhang, 
Garcia-Ibanez et al. 2016). Interestingly, antibody responses against Salmonella have been 
shown to develop extrafollicularly emphasizing that dependent on the antigen different 
mechanism of antibody response maturation can occur (Di Niro, Lee et al. 2015).  
The T:B cell interaction clusters can be observed within 1-2 days after antigen administration 
and subsequently a fraction of activated B cells differentiating into GC B cells migrate back to 
the follicle where they build a foci close to the FDC network characterized by proliferating 
blasts [reviewed in (De Silva and Klein 2015)]. During the T:B cell interactions class-switch 
recombination (CSR) occurs highlighting that switching to another isotype can occur early 
and before affinity maturation [reviewed in (Toellner, Gulbranson-Judge et al. 1996; Toellner, 
Luther et al. 1998; Zhang, Garcia-Ibanez et al. 2016)]. 
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The activated T cells can further differentiate into follicular helper T cells (TFH) characterized 
by expression of CXCR5, PD-1, ICOS and the master regulator bcl-6 and secretion of IL-4 
and IL-21 [reviewed in (De Silva and Klein 2015; Vinuesa, Linterman et al. 2016)]. IL-21 is 
 
Figure 1: Germinal center (GC) reaction and development of high-affinity antibodies 
(A) T:B cell interaction results in full activation of B cells and differentiation to GC B cells, migration to B 
cell follicle and GC formation. (B) GC B cells proliferate in the dark zone of the GC. During this process 
somatic hypermutation (SHM) occurs. (C) After several rounds of proliferation and SHM GC B cells 
migrate to the light zone, capture antigens presented on the surface of FDC, process and present the 
antigens via MHC II to TFH cells. (D) GC B cells receiving sufficient T cell help re-enter the dark zone 
by up-regulating CXCR4 while GC B cells lacking T cell help undergo apoptosis. After several rounds of 
proliferation and SHM and selection based on TFH cell help GC B cells leave the GC and become 
either memory B cells or plasma cells.  Reprinted by permission from Annual Reviews: Annual Reviews 
Immunology 30: 429-457. © 2012. 
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known to support a plethora of pathways of T cell-dependent B cell responses (Ettinger, 
Sims et al. 2005; Good, Bryant et al. 2006; Ettinger, Kuchen et al. 2008; Linterman, Beaton 
et al. 2010; Zotos, Coquet et al. 2010; Crotty 2011; Eto, Lao et al. 2011; Lee, Rigby et al. 
2011; Deenick, Avery et al. 2013; Moens and Tangye 2014; Spolski and Leonard 2014; 
Tangye 2015). This differentiation results in the re-location of TFH cells into the B cell follicle 
[reviewed in (De Silva and Klein 2015; Vinuesa, Linterman et al. 2016)]. After 5-7 days the 
follicle is highly expanded due to the rapid proliferation of GC B cells and a polarization of the 
GC occurs with the dark zone characterized by proliferating B cells and the light zone where 
FDC and TFH cells are located [reviewed in (Victora and Nussenzweig 2012; Victora and 
Mesin 2014; De Silva and Klein 2015)]. The dark zone is characterized by a network of 
reticular cells expressing CXCL12 [reviewed in (Victora and Nussenzweig 2012; Victora and 
Mesin 2014; De Silva and Klein 2015)]. Proliferating B cells in the dark zone express high 
levels of CXCR4 and are therefore attracted to this site (Victora, Schwickert et al. 2010; 
Victora, Dominguez-Sola et al. 2012), where they undergo SHM resulting in randomly 
distributed mutations and diversification of the BCR (Figure 1B). GC B cells in the dark zone 
down-regulate CXCR4 and up-regulate co-stimulatory molecules CD80 and CD86 and transit 
to the light zone of the GC where selection of B cell clones with the highest affinity for 
antigens occur (Figure 1C and D) (Victora, Schwickert et al. 2010; Victora and Nussenzweig 
2012; Victora and Mesin 2014; De Silva and Klein 2015). B cells are shuttling between light 
and dark zone of the GC in a CXCR4-dependent manner and undergo several cycles of 
affinity-based selection and proliferation before leaving the GC.  
What factors limit selection of B cells with highest affinity has been debated for long 
[reviewed in (Victora and Nussenzweig 2012)]. One possibility is that the antigen presented 
by FDC is limiting and therefore only high-affinity clones can capture, process and present a 
sufficient amount of antigen via MHC class II to TFH cells [reviewed in (Victora and 
Nussenzweig 2012)]. However, others reported that the availability of antigens on FDC may 
not be limited. Therefore high-affinity B cell clones can process and present more antigens 
and thus are more likely to receive sufficient T cell help in the light zone from the limited 
numbers of TFH cells and as a result continue to migrate to the dark zone for further 
proliferation and SHM instead of undergoing apoptosis due to “death-by-neglect” (Figure 1C 
and D) (Victora, Schwickert et al. 2010; Victora and Nussenzweig 2012). The strength of the 
T cell help in the light zone determines the proliferation rate and SHM of GC B cells 
highlighting that high-affinity B cell clones undergo an enhanced selection and maturation 
resulting in large clonal families within the GC (Gitlin, Mayer et al. 2015; Mesin, Ersching et 
al. 2016; Tas, Mesin et al. 2016). Interestingly the existing antibody repertoire can compete 
with the B cell clones for antigens in the GC and therefore support affinity maturation by 
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outcompeting B cells with lower affinity than the antibody repertoire  [reviewed in (Zhang, 
Garcia-Ibanez et al. 2016)]. 
GC B cells differentiate into memory B cells and plasma cells after undergoing GC reaction 
[reviewed in (De Silva and Klein 2015)]. Memory B cells are characterized by long 
persistence in the body and the unique ability to respond to re-occurring antigens with fast 
kinetics and potency (Amanna, Carlson et al. 2007; Kurosaki, Kometani et al. 2015). The 
determinants of the memory B cell or plasma cell fate are less well known than the GC 
reaction and is partially due to technical limitations foremost the accessibility of these cells  
[reviewed in (Mesin, Ersching et al. 2016)]. There are several factors known to contribute to 
plasma cell differentiation which are in agreement with T cell help such as CD40:CD40L 
interaction, IL-21 and PD-1 resulting in a dramatic change of transcriptional signature 
[reviewed in (Nutt, Hodgkin et al. 2015)]. CD40 ligation is associated with increased 
expression of the transcription factor IRF4 which results in down-regulation of Bcl-6, the 
master transcriptional factor for GC B cells. In addition differentiation of plasma cells is 
associated with up-regulation of the transcription factors Blimp-1 and XBP-1, which coincides 
with down-regulation of Bcl-6 and up-regulation of IRF4 (Klein, Casola et al. 2006; Todd, 
McHeyzer-Williams et al. 2009; Victora and Nussenzweig 2012; Nutt, Hodgkin et al. 2015; 
Minnich, Tagoh et al. 2016). Although the mechanisms of memory B cell and plasma cell 
differentiation are well characterized it is poorly understood what the decisive factors are that 
induce differentiation into the different post-GC subsets (Good-Jacobson and Shlomchik 
2010; Shlomchik and Weisel 2012). It has been shown that memory B cells and plasma cells 
can derive from the same GC B cell clone suggesting that descendants of naïve B cells can 
differentiate into distinct subsets and that naïve B cells can reconstitute a variety of different 
subsets as elegantly shown by in vivo limiting dilution studies in mice (Taylor, Pape et al. 
2015). The kinetics of GC egress shows that cells leaving GC early are committed to the 
memory B cell fate whereas plasma cells occur at later stages during the GC maturation 
(Shlomchik and Weisel 2012; Weisel, Zuccarino-Catania et al. 2016). This is supported by in 
vivo experiments with impaired functions of important GC-related molecules resulting in 
premature termination of the GC reaction. As a consequence the formation of plasma cells 
was abrogated whereas the memory B cell differentiation remained intact [reviewed in 
(Good-Jacobson and Shlomchik 2010; Shlomchik and Weisel 2012)]. Isotype switching and 
differentiation of plasma cells are thought to be stochastic processes linked to number of 
divisions suggesting that B cell-intrinsic mechanism can determine memory B cell and 
plasma cell differentiation (Hasbold, Corcoran et al. 2004). Interestingly cytokines can 
influence the division numbers necessary to differentiate into plasma cells in vitro suggesting 
that many factors play a role and that the differentiation between memory B cells and plasma 
cells is tightly regulated (Hasbold, Corcoran et al. 2004). In contrast to plasma cells, memory 
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B cells are able to re-enter the GC reaction during secondary immune responses resulting in 
further diversification of their BCR which allows the maturation of memory B cells towards 
higher affinities (Bende, van Maldegem et al. 2007; McHeyzer-Williams, Milpied et al. 2015).  
 
3.1.3 T cell-independent B cell responses 
Antibody responses against highly ordered repetitive antigens can be induced without T cell 
help (Bachmann, Rohrer et al. 1993; Mond, Lees et al. 1995; Vos, Lees et al. 2000). These T 
cell-independent (TI) antigens can be divided in two subgroups. TI-1 antigens are mitogenic 
interacting through antigen-unspecific mechanism whereas TI-2 antigens are repetitive and 
highly-ordered as seen for bacterial polysaccharides or viral particles (i.e. vesicular stomatitis 
virus) (Bachmann, Rohrer et al. 1993; Zinkernagel 1996; Mond and Brunswick 2003; 
Hangartner, Zinkernagel et al. 2006). T cell-independent B cell responses require multivalent 
B cell receptor cross-linking and cluster formation in combination with additional stimulation 
such as Toll-like receptor signaling [as reviewed in (Vos, Lees et al. 2000)]. An additional 
signal for T cell-independent responses can be provided by the CD19/CD21 complex, which 
has been shown to modulate the threshold of B cell activation enhancing stimulation (Vos, 
Lees et al. 2000; Cherukuri, Cheng et al. 2001; Roozendaal and Carroll 2007). T cell-
independent B cell responses have been proven to be important for vaccines against 
polysaccharides such as Streptococcus pneumoniae although their efficiency could be 
improved when switched to T cell-dependent immune responses by conjugating 
polysaccharides to proteins [reviewed in (Avci and Kasper 2010; Nuccitelli, Rinaudo et al. 
2015)].  
Two major B cell subsets are described with the ability to undergo T cell-independent B cell 
responses, namely B1 and marginal zone (MZ) B cells (Martin, Oliver et al. 2001). B1 cells 
were first described in mice and are thought to act as a first line of defense through secretion 
of natural polyreactive IgM and are therefore sometimes referred as innate-like B cells 
(Baumgarth 2013). However, although B1 cells can be readily detected in the peritoneal and 
pleural cavities of mice the identification of this subset in human is controversial (Descatoire, 
Weill et al. 2011; Griffin, Holodick et al. 2011; Griffin, Holodick et al. 2011; Covens, 
Verbinnen et al. 2013; Tangye 2013). Therefore this introduction focuses on marginal zone B 
cells, known to be relevant in humans and key players of T cell-independent antibody 
responses against bacterial polysaccharides (Martin, Oliver et al. 2001). Their crucial role in 
T cell-independent responses is supported by the fact that infants aged under 2 years who 
lack T cell-independent B cell responses through a suggested immaturity of Spleen and MZ 
B cells as well as patients who underwent splenectomy harbor reduced levels of MZ B cells 
12
Chapter 3  Introduction 
 
 
and have been shown to be at higher risk to acquire bacterial infections (Kruetzmann, 
Rosado et al. 2003; Weill, Weller et al. 2009). 
Human MZ B cells can be found in the blood and the marginal zone of the spleen. MZ B cells 
from both compartments show a similar surface marker phenotype of 
IgMhighIgDlowCD27+CD21+CD23-CD1c+ and are therefore likely circulating between those two 
compartments (Weller, Braun et al. 2004; Weill, Weller et al. 2009). The spleen is an 
important immune organ connected to blood circulation playing a crucial role in defense 
against encapsulated microorganisms [reviewed in (Mebius and Kraal 2005; Cerutti, Cols et 
al. 2013)]. The origin and function of peripheral MZ B cells, often referred as IgD+IgM+CD27+ 
memory B cells, is still a matter of debate due to the fact that these cells share many features 
with classical memory B cells and it has therefore been proposed that MZ B cells could 
originate from classical GC-dependent reactions but leave the GC early as IgM-producing 
early effector cells (Tangye and Good 2007; Seifert and Kuppers 2009; Seifert, Przekopowitz 
et al. 2015). Although sharing many similarities there are substantial differences between 
human memory B cells and MZ B cells [reviewed in (Weill, Weller et al. 2009)]. MZ B cells 
show a different immunoglobulin repertoire compared to classical memory B cells analyzed 
by deep-sequencing and therefore it is supposed that MZ B cells undergo a distinct 
developmental path (Wu, Kipling et al. 2010). Strong evidence that MZ B cells emerge 
through a distinct pathway can be observed in patients with hyper-IgM syndrome (HIGM) due 
to CD40L deficiency resulting in the absence of GC (Weller, Faili et al. 2001; Jesus, Duarte 
et al. 2008; Berkowska, Driessen et al. 2011). These patients show almost no classical 
memory B cells although MZ B cells are still detectable in the periphery albeit at reduced 
frequencies highlighting their independence of GC reaction (Weller, Faili et al. 2001; 
Berkowska, Driessen et al. 2011). However the reduced levels of MZ B cells suggest that at 
least a fraction of MZ B cells arise from GC-dependent pathways (Berkowska, Driessen et al. 
2011). Interestingly, MZ B cells in HIGM patients show mutated B cell receptors emphasizing 
that MZ B cell diversify their BCR in a GC-independent manner (Weller, Faili et al. 2001; 
Weller, Braun et al. 2004). In addition it has been shown that MZ B cell pre-diversify their 
BCR in an antigen-independent manner within the first month of life although T cell-
independent MZ B cell responses against encapsulated bacteria are absent (Weller, Faili et 
al. 2001; Weller, Braun et al. 2004; Weller, Mamani-Matsuda et al. 2008; Weill, Weller et al. 
2009). In favor of this, the mutated MZ B cell repertoire emerging during T cell-independent 
responses is elicited early during infection and precedes the emergence of mutated GC-
dependent B cells and therefore supporting the notion that MZ B cells contain a pre-
diversified BCR repertoire [reviewed in (Weill, Weller et al. 2009)]. 
As a further prove of pre-diversification, a study identified an ancestor MZ B cell clone 
carrying mutations in the variable loop prior to polysaccharide-based vaccination, which was 
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clonally related to the major MZ B cell clone emerging upon vaccination emphasizing that 
pre-diversified MZ B cells are optimally equipped to quickly respond to T cell-independent 
antigens (Weller, Braun et al. 2004; Weill, Weller et al. 2009).   
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3.2 B cell alterations during HIV-1 infection 
3.2.1 HIV-1 dependent changes in lymphoid organs  
HIV-1 infection is associated with remarkable changes of lymphoid organs resulting in 
inflammatory lymphadenopathy already at early stage of the infection [reviewed in 
(Lederman and Margolis 2008; Estes 2013)]. The increased size of lymph nodes is 
associated with follicular hyperplasia as a result from massive activation and proliferation of 
B cells [reviewed in (Lederman and Margolis 2008; Estes 2013)]. Fibrosis occurs in lymph 
nodes as a consequence of maintained inflammation and therefore impairs the migration and 
communication between immune cells important for the induction of efficient antibody 
responses [as reviewed in (Estes, Haase et al. 2008; Estes 2013)]. In certain circumstances 
follicular involution can occur resulting in the disappearance of GC. During acute HIV-1 
infection structural alterations and loss of GC in lymphoid tissues of intestinal mucosa was 
observed suggesting that GC damage occurs early during HIV-1 infection (Levesque, Moody 
et al. 2009). During acute HIV-1 infection a massive depletion of CD4+ T cells occurs in the 
intestinal mucosa and/or gut-associated lymphoid tissue (GALT) and therefore the lack of 
CD4 T cells might impair T:B cell interaction and B cell survival [reviewed in (Grossman, 
Meier-Schellersheim et al. 2006; Brenchley and Douek 2008)]. Interestingly, massive cell 
death of B cells occurred in the GC most likely due to the lack of appropriate T cell help 
(Levesque, Moody et al. 2009). Although some HIV-1 dependent lymph node pathologies 
such as lymphadenopathy can be reversed with highly active anti-retroviral therapy (ART) 
many abnormalities persist such as follicular hyperplasia and reduced levels of CD4+ T cells 
in the lymph node. Considering that ART reduced the viral load and elevated peripheral CD4 
counts in these patients underlines that the damage of lymphoid tissue is irreversible and 
therefore supports recent recommendations to induce ART early to prevent continuous 
deterioration of the immune system (Bucy, Hockett et al. 1999; Schacker, Nguyen et al. 
2002; Lederman and Margolis 2008; Estes 2013; Gunthard, Saag et al. 2016).  
During acute HIV-1 infection cytotoxic CD8+ T cells can be observed within the GC of 
mucosal tissues and may contribute to the massive cell death in lymph nodes (Levesque, 
Moody et al. 2009). However, in non-human primate studies rhesus monkeys with the ability 
to control SIV, so-called elite controllers, showed efficient extrafollicular CD8+ T cell 
responses capable of maintaining low viral loads [reviewed in (Deeks and Walker 2007; 
Walker and Yu 2013)]. Nevertheless TFH cells which constitute a main target cell of HIV-1, 
are productively infected in B cell follicles and spread is not restricted by cytotoxic T cells as 
only low levels of CD8+ T cells are able to enter the follicle due to the lack of CXCR5 
expression (Connick, Mattila et al. 2007; Tjernlund, Zhu et al. 2010; Perreau, Savoye et al. 
2013; Fukazawa, Lum et al. 2015; Banga, Procopio et al. 2016; Pallikkuth, Sharkey et al. 
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2016). Recently, the emergence of cytotoxic CXCR5+ CD8 T cells in lymph nodes of HIV-1 
infected individuals was reported (He, Hou et al. 2016). Of particular note, the frequency of 
peripheral HIV-1 specific CXCR5+ CD8+ T cells inversely correlated with viral load 
emphasizing that a population of cytotoxic CD8+ T cells possess the capability to enter B cell 
follicles and presumably eliminate HIV-1 infected T cells (He, Hou et al. 2016). While these 
CXCR5+ CD8+ T cells are highly intriguing, their effect on the HIV-1 infected TFH cell pool yet 
has to be determined.  
 
3.2.2 Direct interactions between HIV-1 and B cells  
The devastating damage of lymphoid tissues, the preferred infection of TFH cells, which play 
a crucial role in the process of eliciting high-affinity antibodies in the GC, and the lack of 
CD8+ T cell response in B cell follicles likely lay the foundation for the impaired B cell 
responses observed in HIV-1 infection. However, HIV-1 does not only affect immune cells 
and lymphoid tissues important for high-affinity B cell responses but can impair B cells via 
direct and indirect mechanisms. HIV-1 dependent alterations of B cells were recognized 
already early during HIV-1 epidemics (Lane, Masur et al. 1983; Schnittman, Lane et al. 1986; 
Yarchoan, Redfield et al. 1986). Initial observations showed increased levels of 
immunoglobulin known as hypergammaglobulinemia as well as hyperactivity and polyclonal 
activation of B cells characterized by spontaneous secretion of immunoglobulins (Lane, 
Masur et al. 1983; Schnittman, Lane et al. 1986; Yarchoan, Redfield et al. 1986; Shirai, 
Cosentino et al. 1992; Morris, Binley et al. 1998; De Milito, Nilsson et al. 2004). 
Hypergammaglobulinemia and peripheral antibody-secreting cells are reduced upon ART 
highlighting that their emergence is associated with viremia and associated immune 
activation (Morris, Binley et al. 1998). However, the etiology of hypergammaglobulinemia and 
polyclonal B cell stimulation is still not completely resolved and involves likely a range of 
contributing factors (Haas, Zimmermann et al. 2011). 
In accordance with the CD4 T cell decline and increased immune activation, alterations in the 
B cell compartment increase during the progression of HIV-1 infection. Several factors are 
associated with B cell hyperactivity including a range of cytokines. Elevated levels of TNF-α, 
IFN-α, IL-10, soluble CD40L and BAFF can be observed in viremic patients and these factors 
are known to directly influence B cells [as reviewed in (Moir and Fauci 2009; McMichael, 
Borrow et al. 2010; Moir and Fauci 2013)]. However, virus-derived proteins themselves can 
also directly influence B cells. Gp120 can bind to α4β7 on naïve B cells and initiate an 
abortive proliferation response rendering B cells less permissive to T cell-dependent 
stimulation  (Jelicic, Cimbro et al. 2013). In addition, the co-stimulatory molecule CD80 is up-
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regulated to a lower magnitude upon stimulation and therefore these B cells are less likely to 
provide co-stimulatory signals to T cells (Jelicic, Cimbro et al. 2013). Integrin α4β7 
engagement by gp120 on B cells leads to the production of the anti-inflammatory cytokine 
TGF-β1 highlighting that HIV-1 can directly influence B cells and their responsiveness to 
stimulation (Jelicic, Cimbro et al. 2013). HIV-1 and in particular gp120 are associated with 
induction of B cell stimulation and proliferation and can potentially act as a superantigen 
(Schnittman, Lane et al. 1986; Patke and Shearer 2000). However, this activity was found to 
be restricted to a population of B cells expressing members of the VH3 family (Berberian, 
Goodglick et al. 1993; Goodglick, Zevit et al. 1995; Neshat, Goodglick et al. 2000). The HIV-1 
accessory protein Nef shows divergent effects on B cells. It was reported to have the ability 
to inhibit class-switching in lymphoid tissues and has also been indicated to induce the 
secretion of ferritin from macrophages which can support polyclonal activation of B cells by 
inducing proliferation of resting B cells (Swingler, Zhou et al. 2008; Xu, Santini et al. 2009). In 
addition, Nef has been shown to induce the expression of inflammatory chemokines MIPα 
and β (CCL3 and CCL4, respectively) which can influence immune regulation and therefore 
presumably also B cell activation (Swingler, Mann et al. 1999). Although only a minority of 
peripheral B cells express CCR1 and CCR5, the receptors for CCL3 and CCL4, these 
receptors are up-regulated in B cells in tonsils and lymph nodes and show migration upon 
MIPα stimulation suggesting that CCL3 and CCL4 can have direct effects on B cells (Schall, 
Bacon et al. 1993; Buri, Korner et al. 2001; Corcione, Tortolina et al. 2002; Trentin, Cabrelle 
et al. 2004; Ehrhardt, Hsu et al. 2005; Henneken, Dorner et al. 2005; Griffith, Sokol et al. 
2014). In addition, the viral Tat protein impairs proliferation upon BCR-mediated stimulation 
but increased responsiveness to CD40/IL-4 mediated stimulation, emphasizing that Tat can 
modulate the pathways of B cell activation (Lefevre, Krzysiek et al. 1999).  
The interaction of B cells with HIV-1 virions is multifold and B cells can capture virions 
through several mechanisms.  DC-SIGN is known to bind gp120 resulting in internalization, 
transfer of virions to and infection of CD4+ T cells. This trans infection mechanism is a mode 
for highly efficient HIV-1 infection of CD4+ T cells as the virions are protected intracellularly in 
the DC-SIGN bearing cells and presented to CD4+ T cells that attach to these cells 
(Geijtenbeek, Kwon et al. 2000; Kwon, Gregorio et al. 2002). The DC-SIGN trans-infection 
mechanism was originally described for myeloid DC but was later also identified to be 
relevant in the interaction of DC-SIGN expressing B cells and CD4+ T cells (Geijtenbeek, 
Kwon et al. 2000; Kwon, Gregorio et al. 2002; Rappocciolo, Piazza et al. 2006).  DC-SIGN 
itself is not sufficient for HIV-1 entry, thus the  DC-SIGN bearing cells that do not express 
CD4 and coreceptors may remain uninfected. In DC however, which express the HIV-1 entry 
receptors, DC-SIGN trapped virus can engage CD4 on DC and therefore support productive 
infection of DC (Geijtenbeek, Kwon et al. 2000; Kwon, Gregorio et al. 2002; Burleigh, Lozach 
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et al. 2006). Resting B cells do not express DC-SIGN but DC-SIGN can be induced through 
B cell stimulation as demonstrated in vitro and is highly efficient in trans infection of CD4+ T 
cells (Rappocciolo, Piazza et al. 2006). In addition the complement receptor 2 (CR2; CD21), 
known to capture complement-opsonized pathogens or immune complexes, is highly 
expressed on B cells and can trap replication-competent HIV-1 on the surface of B cells 
(Moir, Malaspina et al. 2000; Roozendaal and Carroll 2007). In vitro studies confirmed that 
only HIV-1 immune complexes in combination with complement efficiently bind to B cells in a 
process that depends on CD21 (Jakubik, Saifuddin et al. 1999; Doepper, Stoiber et al. 2000; 
Jakubik, Saifuddin et al. 2000). HIV-1 envelope glycoproteins can also directly activate the 
complement cascade  (Solder, Schulz et al. 1989; Ebenbichler, Thielens et al. 1991; Spear, 
Jiang et al. 1991; Stoiber, Thielens et al. 1994; Ji, Gewurz et al. 2005; Stoiber 2009). While 
this also leads to HIV-1 trapping to B cells via CD21 the efficiency of trapping of immune 
complexed and complement opsonized particles is markedly higher (Jakubik, Saifuddin et al. 
1999; Doepper, Stoiber et al. 2000; Jakubik, Saifuddin et al. 2000). The interaction between 
CD21-dependent HIV-1 bearing B cells and CD4+ T cells results in efficient infection of T 
cells emphasizing that B cells can enhance infection of CD4+ T cells with HIV-1 through a 
complement-dependent pathway (Doepper, Stoiber et al. 2000; Jakubik, Saifuddin et al. 
2000; Moir, Malaspina et al. 2000; Doepper, Wilflingseder et al. 2003).  
 
3.2.3 B cell exhaustion in HIV-1 infection 
It has been long realized that HIV-1 infection leads to the emergence of CD21neg B cells that 
form several different subsets (Benedetto, Di Caro et al. 1992; Moir, Malaspina et al. 2000; 
Moir, Malaspina et al. 2001; Moir and Fauci 2008; Moir, Ho et al. 2008; Moir and Fauci 2009; 
Moir and Fauci 2013). The first indication for a shift towards CD21neg B  cell subsets stems 
from a study published in 1987 by Martínez-Maza et al. describing elevated frequencies of B 
cells expressing CD10 and Plasma cell antigen-1 (CD203a) suggesting that immature 
transitional B cells and plasmablasts/plasma cells are increased in HIV-1 infection, 
respectively, both of which are known to lack CD21 expression (Martinez-Maza, Crabb et al. 
1987; Moir and Fauci 2009; Moir and Fauci 2013).  
Further studies confirmed the increased frequency of CD10+ transitional B cells in viremic 
individuals and showed that their frequencies correlated inversely with CD4+ T cell counts 
and positively with serum IL-7 concentration and viral load (Figure 2) (Malaspina, Moir et al. 
2006). IL-7 plays a crucial role in T cell homeostasis and increased levels of IL-7 in HIV-1 
infection is thought to be mechanism to counteract T cell loss (Napolitano, Grant et al. 2001; 
Bradley, Haynes et al. 2005). Interestingly, idiopathic CD4+ T cell lymphocytopenia, a 
disease with unknown etiology manifested by dramatically reduced CD4+ T cell numbers, is 
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also characterized by elevated IL-7 and transitional B cell levels supporting the notion that 
the relevant factor in HIV-1 infection are solely the reduced CD4+ T cell numbers which 
prompt increases in IL-7 levels and result in elevated frequencies of transitional B cells 
independent of  viral load (Malaspina, Moir et al. 2007; Zonios, Sheikh et al. 2012).  
A further CD21neg subset elevated in HIV-1 infection are CD10-CD27highCD38high 
plasmablasts which may be upregulated due to the polyclonal hyperactivation of B cells 
(Figure 2) (Lane, Masur et al. 1983; Shirai, Cosentino et al. 1992; Morris, Binley et al. 1998; 
Moir, Malaspina et al. 2001). Seminal studies on the dysregulation of B cell subsets in HIV-1 
infection in viremic patients revealed that several distinct populations of CD21neg B cells 
exists that are phenotypically distinct from classical transitional B cells and plasmablasts 
(Moir, Malaspina et al. 2001; Moir, Malaspina et al. 2004; Malaspina, Moir et al. 2006). These 
cells were found to belong to memory B cell subsets either expressing or lacking CD27 and 
were defined as activated memory (AM) B cells and tissue-like memory (TLM) B cells, 
respectively (Figure 2) (Moir, Ho et al. 2008). AM B cells are characterized by high 
expression of CD80 and CD95, two important activation marker (Moir, Malaspina et al. 2004; 
Moir, Ho et al. 2008; Moir and Fauci 2013). The classical CD21+CD27+ resting memory (RM) 
B cell subset representing the major memory B cell subset in healthy individuals was found 
to be dramatically reduced during HIV-1 infection whereas AM and TLM B cell frequencies 
are increased (Moir, Ho et al. 2008). The processes that lead to CD21 downregulation in 
HIV-1 infection are not well understood. A mechanism of CD21 downregulation on B cells 
upon  binding of immune complexes was proposed but may not be the sole component as  
CD21 mRNA transcription is also dramatically reduced in CD21neg B cells (Moir, Malaspina et 
al. 2000; Moir, Malaspina et al. 2001).  
The CD21-CD27- TLM B cells express Fc receptor-like 4 (FcRL4), which is known to bind IgA 
and functions as an inhibitory receptor (Ehrhardt, Davis et al. 2003; Wilson, Fuchs et al. 
2012). This cell type was first described for a tonsil B cell population that lacked CD27 and 
had reduced CD21 levels (Ehrhardt, Hsu et al. 2005) and peripheral CD21-CD27- memory B 
cells are thought to share a common phenotype with tissue-resident memory B cells (Moir, 
Ho et al. 2008). Emergence of TLM B cells has been observed in other chronic diseases 
such as malaria and hepatitis C virus infection supporting the notion that they result from a 
continuous stimulation (Oliviero, Mantovani et al. 2015; Portugal, Tipton et al. 2015; Sullivan, 
Kim et al. 2015). Phenotypic and functional analysis of TLM B cells in HIV-1 infection 
revealed that these cells up-regulate inhibitory receptors such as CD22, CD85j, LAIR-1 and 
CD72 and FcRL-4 (Moir, Ho et al. 2008; Moir and Fauci 2014). These inhibitory receptors 
contain immunoreceptor tyrosine-based inhibitory motifs (ITIM) which recruit protein tyrosine 
phosphatase SHP-1 resulting in inhibition of BCR-mediated activation [reviewed in (Nitschke 
2005)]. TLM B cells further show an increased expression of CXCR3, the receptor for the 
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inflammatory chemokines CXCL9-11 secreted at sites of inflammation, whereas CD62L and 
CXCR5, two chemokine receptors important for lymph node and B cell follicle entry, 
respectively, are down-regulated suggesting that these TLM B cells show a distinct migratory 
potential and that their responsiveness is likely to be impaired by the inhibitory receptors 
(Moir, Ho et al. 2008; Weiss, Crompton et al. 2009; Groom and Luster 2011; Dauby, 
Kummert et al. 2014; Griffith, Sokol et al. 2014). Although TLM B cells proliferate in vivo they 
were shown to have a reduced diversity of the BCR variable genes and an impaired 
responsiveness both BCR-dependent and -independent stimulation compared to classical 
memory B cells assessed for proliferation or differentiation to antibody-secreting cells in vitro 
(Moir, Ho et al. 2008; Moir and Fauci 2013; Meffre, Louie et al. 2016). Therefore TLM B cells 
which can be a large fraction of memory B cells are defined as exhausted (Moir, Ho et al. 
2008). Interestingly their exhausted state can be reversed by knocking down inhibitory 
receptors such as FcRL4 or SIGLEC-6 by small interfering RNA highlighting that indeed part 
of their exhaustion is determined by the expression of these inhibitory receptors (Kardava, 
Moir et al. 2011).  
Noteworthy, CD21neg B cells have been also observed in autoimmune diseases such as SLE 
and RA and common variable immunodeficiencies (CVID). These cells show phenotypic and 
functional similarities with TLM B cells found in HIV-1 infection although some of these 
populations express IgM and IgD and are therefore thought to be naïve B cells (Rakhmanov, 
Keller et al. 2009; Isnardi, Ng et al. 2010; Saadoun, Terrier et al. 2013; Tipton, Fucile et al. 
2015; Flint, Gibson et al. 2016). It is therefore thought that CD21neg B cells that express IgM 
and IgD and lack CD27 resemble recently activated naïve B cells in SLE (Tipton, Fucile et al. 
2015). The CD21neg B cell populations are enriched for autoreactive BCR in autoimmune 
diseases and CVID emphasizing that activation due to the cognate self-antigen results in 
exhaustion in autoimmune disease and that immune tolerance breakdown results in the 
increased frequencies of exhausted autoreactive B cells (Meffre and Wardemann 2008; 
Rakhmanov, Keller et al. 2009; Isnardi, Ng et al. 2010; Saadoun, Terrier et al. 2012; Tipton, 
Fucile et al. 2015). 
Exhaustion is a state induced by chronic activation due to persistent antigen exposure and 
therefore it is tempting to speculate that a high fraction of HIV-1 specific B cells should be 
found within the TLM B cell subset in viremic individuals. Indeed this was confirmed by flow 
cytometry in several studies (Wherry 2011; Kardava, Moir et al. 2014; Wherry and Kurachi 
2015). In addition a high frequency of HIV-1 specific memory B cells resembled AM and TLM 
B cells but only few HIV-1 specific RM B cells could be found (Kardava, Moir et al. 2014). 
These observations confirm that chronic exposure of B cells to its cognate antigen is 
contributing to the exhausted state of HIV-1 specific B cells. Interestingly in chronically HIV-1 
infected individuals, influenza and tetanus-specific B cells showed decreased and increased 
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levels of TLM and RM B cells, respectively, compared to HIV-1 specific B cells (Kardava, 
Moir et al. 2014). A recent study revealed that RM B cells in HIV-1 infection harbor elevated 
frequencies of BCR mutations compared to TLM B cells and express BCR with neutralizing 
activity against HIV-1 whereas TLM B cells showed dramatically reduced frequencies of 
clones with neutralization activity. These observations strongly suggest that TLM B cells are 
impaired in the development towards high-affinity antibodies due to their exhausted state 
(Meffre, Louie et al. 2016).   
 
 
 
 
  
 
 
Figure 2: B cell alterations in HIV-1 infection 
HIV-1 infection results in elevated transitional B cells dependent on low CD4+ T cell levels and 
elevated IL-7 concentrations. Due to chronic polyclonal and antigen-specific activation memory B cells 
with an activated (CD21-CD27+) and exhausted tissue-like (CD21-CD27-) phenotype emerge while 
classical memory B cells (CD21+CD27+) are reduced compared to healthy individuals. Due to 
polyclonal activation short-lived antibody-secreting B cells emerge contributing to hypergamma-
globulinemia. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Immunology 9: 
235-245. © 2009. 
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3.2.4 Highly active anti-retroviral therapy and restoration of B cell alterations 
Since many of the B cell alterations that accompany HIV-1 infection appear to be driven by 
virus replication it has been hoped that inhibiting virus replication by ART leads to a complete 
normalization of the B cell compartment. Indeed, the HIV-1 induced elevated frequency of 
plasmablasts and hypergammaglobulinemia normalize during ART (Morris, Binley et al. 
1998; Moir, Buckner et al. 2010). In addition ART restores the perturbations observed 
amongst B cells by decreasing frequencies of transitional, AM and TLM  B cells, while at the 
same time increasing RM B cell frequencies (Moir, Malaspina et al. 2008). However, a recent 
study challenges the notion that ART can fully restore the B cell compartment. Particularly 
when ART is initiated at later stages of the disease, AM and TLM B cells remain elevated 
(Moir, Buckner et al. 2010). It has been hypothesized that these sustained B cell alterations 
might be a consequence of residual virus replication despite ART (Pallikkuth, Sharkey et al. 
2015; Banga, Procopio et al. 2016; Lorenzo-Redondo, Fryer et al. 2016) but causes have not 
been fully unraveled. Of note, it has been long realized that also a low level of T cell 
activation is sustained during ART (Corbeau and Reynes 2011; Hatano, Jain et al. 2013; 
Wilson and Sereti 2013; Cobos Jimenez, Wit et al. 2016; Fromentin, Bakeman et al. 2016) 
supporting the notion that ART cannot fully restore a normal (non-activated) immune system. 
Early initiation of ART is thus recommended to limit irreversible alterations of the immune 
system and has been shown to be effective in restoring the B cell compartment to a close to 
normal setting  (Moir, Buckner et al. 2010; Gunthard, Saag et al. 2016). 
 
3.2.5 B cell alterations and HIV-1 – What are the implications for neutralizing 
antibody responses? 
The impaired B cell compartment has implications for B cell responses against HIV-1 but also 
for antibody responses to co-infections and the efficacy of vaccines. The envelope (Env) 
specific antibody response against HIV-1 is the most intensely studied as Env antibodies are 
the only ones that can neutralize the virus by blocking entry into target cells. The Env 
antibody response is characterized by a first wave of antibodies against immunodominant 
epitopes within gp41 followed by antibodies against the variable loop 3 (V3) of the viral 
envelope protein (Tomaras, Yates et al. 2008; Tomaras and Haynes 2009). These first 
antibodies commonly are not neutralizing. Neutralizing antibodies emerge only after several 
weeks to months after infection, (Wei, Decker et al. 2003; Haynes, Moody et al. 2011; 
Overbaugh and Morris 2012). The prototypic first neutralizing antibodies to appear are V3-
directed, type specific (neutralize only the autologous strain) and are subject to rapid escape 
(Wei, Decker et al. 2003; Bunnik, Pisas et al. 2008; Davis, Gray et al. 2009; Tomaras and 
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Haynes 2009; Tang, Robinson et al. 2011; Overbaugh and Morris 2012). Interestingly, 
several studies suggest that the initial B cell response to gp41 is derived from preexisting 
cross-reactive memory B cells reacting with diverse antigens including commensal bacteria 
raising the possibility that at least certain HIV-1 specific antibodies are not elicited de novo by 
activation of naïve B cells (Haynes, Moody et al. 2011; Liao, Chen et al. 2011; Trama, Moody 
et al. 2014). While neutralizing antibodies emerge essentially in all HIV-1 infected individuals 
and the antibody response continuously adapts to the emerging virus escape variants, the 
virus stays always ahead of the antibody response in this cat and mouse game. Whether this 
is due to particulars of the virus or whether the impaired B cell responses are the underlying 
reason for the inefficacy of antibodies to control HIV-1 infection has not been fully resolved 
(Ferreira, Merino-Mansilla et al. 2013; Derdeyn, Moore et al. 2014; Meffre, Louie et al. 2016). 
While B cell responses are sustained, it has been suggested that the multifaceted B cell 
alterations contribute to a delayed emergence of HIV-1 neutralizing antibodies [reviewed in 
(Haynes, Moody et al. 2011)].  
The neutralizing antibodies to HIV-1 are to a large extent type specific, i.e. they only 
neutralize the patient’s own isolates. The capacity to centralize also heterologous viruses 
(referred to as cross-reactivity) develops later but not in all individuals (Simek, Rida et al. 
2009; Doria-Rose, Klein et al. 2010; Rusert, Kouyos et al. 2016). Greater breadth (signified 
by the capacity to neutralize HIV-1 strains of divergent subtypes) and so called elite 
neutralizing capacity (signified by high breadth and potency) develop only in 10-25% and 1% 
of individuals, respectively ((Doria-Rose, Klein et al. 2010; Rusert, Kouyos et al. 2016). 
These so called broadly neutralizing antibodies (bnAbs) are often characterized by unusual 
sequence features such as long CDRH3 and high frequency of somatic hypermutations 
emphasizing that B cell clones undergo extensive selection until they gain breadth [reviewed 
in (Mascola and Haynes 2013; Burton and Hangartner 2016)].  
Considering the severe dysregulation of the immune system in HIV-1 infection and in 
particular the perturbation of the B cell repertoire, it is striking that nevertheless a highly 
functional envelope-specific B cell response emerges and continuously adapts. Interestingly, 
amongst the factors that influence the development of bnAbs most potently are high viral 
loads and infection length suggesting that exposure to high antigen levels is key (Gray, 
Moore et al. 2007; Sather, Armann et al. 2009; Moore, Williamson et al. 2015; Rusert, 
Kouyos et al. 2016). The prolonged co-evolution of HIV-1 and the B cell response further 
exposes the immune system to an ever increasing diversity of envelope antigen that results 
from the continuous evolution of the virus and its escape from the neutralizing antibody 
pressure (Liao, Lynch et al. 2013; Moore, Williamson et al. 2015) and diversity has been 
shown to be a critical factor in shaping bnAb responses (Liao, Lynch et al. 2013; Moore, 
Williamson et al. 2015; Rusert, Kouyos et al. 2016). Current HIV-1 vaccine design thus 
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focuses on developing antigens for sequential immunization  to mimic the diversity of the 
naturally evolving Env quasispecies that lead to bnAb evolution  (Haynes, Kelsoe et al. 2012; 
Mascola and Haynes 2013; Escolano, Steichen et al. 2016). 
HIV-1 infection has also been described to have profound effects on pre-existing memory B 
cells resulting in the loss immunological memory for a variety of pathogens such as 
Streptococcus pneumoniae, influenza and measles (Titanji, De Milito et al. 2006; Wheatley, 
Kristensen et al. 2016). HIV-1 infection also is associated with impaired antibody responses 
against co-infections with other pathogens as described for HCV, Salmonella and malaria 
(MacLennan, Gilchrist et al. 2010; Chang, Crane et al. 2013). The same is true for antibody 
responses against vaccines as shown for vaccine responses to influenza, tetanus and 
pneumococcal antigens (Ballet, Sulcebe et al. 1987; Kroon, Vandissel et al. 1994; Kroon, van 
Dissel et al. 1997; Malaspina, Moir et al. 2005; Crum-Cianflone and Wallace 2014; Kerneis, 
Launay et al. 2014; Mena, Garcia-Basteiro et al. 2015).   
In sum these studies highlight that B cell alterations during HIV-1 infection can result in 
profound impairments in clearing co-infections or inducing protection with vaccines. A rapid 
restoration of B cell responses by initiating ART early after infection to prevent permanent B 
cell is thus key to ensure immunity against co-infections. 
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3.3 Single cell analysis technologies 
Flow cytometry is a widely used technology that allows the analysis of several fluorescence 
parameters on single cells and has been instrumental in shaping our understanding of the 
cellular networks that form the immune system (Roederer 2002; Perfetto, Chattopadhyay et 
al. 2004; Bendall, Nolan et al. 2012). The principle of flow-based analysis was the first time 
commercially implemented in the 1950’s from Wallace Coulter when the principle of an 
impedance-based hemocytometer was described (Coulter 1956). About the same time 
fluorescence activation cell sorting (FACS) was invented by Mack Fulwyler in 1964 and 
further developed by Leonard Herzenberg in Stanford (Fulwyler 1965; Hulett, Bonner et al. 
1969). The group of Leonard Herzenberg started combining the technologies of hybridoma 
and flow cytometry to characterize immune cells (Herzenberg, Parks et al. 2002). Ever since 
flow cytometry has become a widely used technology.  
In particular due to the emergence of the HIV-1 epidemics the technical development of flow 
cytometry was boosted [reviewed in (Roederer 2002; Kestens and Mandy 2016)]. Monitoring 
of HIV-1 infection requires a tight control of the CD4 T cell counts in peripheral blood as 
important clinical parameter for disease progression (Kestens and Mandy 2016). Beyond this 
flow cytometry gain tremendous importance in deciphering the alteration of the immune 
system that occur in HIV-1 infection [as reviewed in (Roederer 2002; Cossarizza, De Biasi et 
al. 2013; Kestens and Mandy 2016)].  
The technical and optical development as well as the ever-increasing number of available 
fluorochromes allows nowadays the measurement of 18 fluorescence parameters 
simultaneously. Most recent developments allow the analysis of 28 colors with the goal to 
reach 50 parameters [as reviewed in (Perfetto, Chattopadhyay et al. 2004; Bendall, Nolan et 
al. 2012)]. A drawback of these high numbers of parameters is that the development of 
multicolor panels is technically challenging, labor-intensive and increases the complexity of 
data analysis (Mahnke and Roederer 2007; Saeys, Van Gassen et al. 2016).  
Flow-cytometry analyses with high dimensionality is thus mostly restricted to dedicated 
research groups due to both, the need for highly advanced cytometers and cytometry 
experts. Recent years have highlighted the immense potential of the technology as it allowed 
the identification of new immune cell types. For example, flow cytometry has shed light on 
the phenotypic diversity of T cells and proven to be valuable in detecting very rare cell 
populations such as antigen-specific T and B cells in addition to determining their phenotype 
(Gattinoni, Lugli et al. 2011; Bacher and Scheffold 2013; Kardava, Moir et al. 2014; Wei, 
Feng et al. 2015). In addition to surface markers, the stimulation and the subsequent 
production of cytokines in T cells were analyzed intracellularly to elucidate correlates of 
vaccine protection or disease progression (Seder, Darrah et al. 2008; Lin, Finak et al. 2015).  
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While the technology is powerful in detecting specificities of single-cells, machine settings 
and parameters need to be carefully validated and standardized to allow comparisons. This 
is particularly critical in large multicenter flow cytometry projects or longitudinal studies. 
Among the most common variations are reagents, sample processing and storage, protocols, 
instrument configurations and performance and analysis, which have to be standardized in 
order to allow comparability of data among different research centers or in longitudinal 
studies according to guidelines from different flow cytometry consortia (Maecker, Rinfret et al. 
2005; Kalina, Flores-Montero et al. 2012; Maecker, McCoy et al. 2012; Kalina, Flores-
Montero et al. 2015; Finak, Langweiler et al. 2016). These guidelines propose to use the 
same reagents, same protocol for staining and sample preparation and cryopreservation, 
regular optimizing and monitoring of instrument performance across multiple centers and 
automated data analysis to avoid analysis variation. 
Due to the increasing number of parameters measured simultaneously and large sample 
numbers that need to be processed, manual analysis of flow cytometry data has become 
difficult. As a consequence a range of algorithms for automated gating algorithms, clustering 
of cells into subsets with similar phenotypes, dimensionality reduction to visualize cell 
population heterogeneity, determining trajectories of cell development and even tools to 
estimate cell populations differing between study groups have been developed (Qiu, 
Simonds et al. 2011; Amir, Davis et al. 2013; Bruggner, Bodenmiller et al. 2014; Lin, Finak et 
al. 2015; Verschoor, Lelic et al. 2015; Anchang, Hart et al. 2016; Mair, Hartmann et al. 2016; 
Saeys, Van Gassen et al. 2016; Setty, Tadmor et al. 2016). These algorithms allowed the 
identification of new subsets, correlation of subsets with clinical outcome of diseases or 
treatments and provide an unprecedented resolution of cell subsets (Aghaeepour, 
Chattopadhyay et al. 2012; Newell, Sigal et al. 2012; Bruggner, Bodenmiller et al. 2014; 
Gaudilliere, Fragiadakis et al. 2014; Lin, Finak et al. 2015). 
In parallel to the advance of flow cytometry new technologies are emerging allowing the 
measurement of more parameters per cell. A technology similar to flow cytometry is mass 
cytometry or CyTOF (Cytometry time-of-flight). The CyTOF technology uses metal isotype-
tagged antibodies and stained cells are introduced into a plasma mass spectrometer 
(Bendall, Nolan et al. 2012). A big advantage of the CyTOF technology is that there is no 
spectral overlap which limits the resolution in flow cytometry (Mahnke and Roederer 2007; 
Bendall, Nolan et al. 2012). To date panels can analyze up 37 parameters (Bendall, Nolan et 
al. 2012). The disadvantage of mass cytometry is the irreversible loss of cells, the lower 
sample throughput, lower sampling efficiency and lower per-channel sensitivity [reviewed in 
(Bendall, Nolan et al. 2012; Chattopadhyay, Gierahn et al. 2014)].  
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A further technology that allows single-cell analysis is single-cell RNA sequencing which 
allows the analysis of the whole transcriptomics as reviewed in (Kolodziejczyk, Kim et al. 
2015; Gawad, Koh et al. 2016).  
Collectively these new single cell technologies have a tremendous capacity to measure even 
high numbers of parameters that will allow unprecedented insight into the diversity of the 
immune system and the hope is that this will allow a targeted identification of correlates of 
disease control, progression or vaccine efficacy, areas which are under high investigation in 
the setting of HIV-1 infection (Seder, Darrah et al. 2008; Chattopadhyay, Gierahn et al. 
2014). 
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3.4 Aim of this study 
Despite a wealth of knowledge on B cell alterations in HIV-1 infection a detailed delineation 
of perturbations in B cell subsets as possible through multidimensional cytometry analysis 
has thus far not been accomplished. Such a fine-mapping of the B cell landscape across 
different disease stages of HIV-1 infection could however have a tremendous potential in 
aiding our understanding which components of the B cell population are affected and at 
which stages of the infection. This information is particular important to understand the 
limitations in restoring the B cell compartment to normal function by ART and the 
consequence of permanent alterations for common immune responses to infections and 
vaccination.  
In my thesis I therefore aimed to reveal the phenotypic landscape of B cells at different 
stages of HIV-1 infection using multiparametric flow cytometry. In the first experimental part 
of my thesis (Chapter 4) I describe the development of a 16-color flow cytometry panel to 
phenotypically characterize B cells. The panel includes staining for classical B cell marker 
such as CD10, CD19, CD27, CD38 and IgD allowing the identification of main B cell subsets, 
different isotypes like IgA, IgG1, IgG3 to study different memory B cell subsets and 
phenotypic marker such as chemokine receptors (CCR7, CXCR3, CXCR4 and CXCR5), IL-
21R and proliferation marker Ki-67 in order to determine phenotypic differences and 
migratory potential of the several B cell subsets.  
In Chapters 5 and 6 I applied this 16-color B cell phenotyping panel to analyze the landscape 
of B cells in HIV-1 infected and healthy donors. Using peripheral mononuclear blood samples 
(PBMC) from patients enrolled in Zurich Primary HIV Infection (ZHPI) cohort study I studied 
the B cell repertoire during acute and chronic infection and the capacity of antiretroviral 
treatment (ART) in reversing HIV-1 inflicted perturbations of the B cell population.   
Chapter 5 summarizes my findings on the naïve and marginal zone (MZ) B cell population in 
HIV-1 infection. Using multidimensional flow cytometry I discovered the presence of two 
previously unidentified subsets, namely CD21neg naïve B cells and CD21neg MZ B cells. 
These subsets emerge alongside with the rise in of the CD21neg memory B cell populations 
highlighting that also antigen-inexperienced B cells are affected by HIV-1 infection. This 
finding raises the possibility that alterations in the naïve repertoire could contribute to the 
decreased antibody responses observed to co-infections and vaccines in HIV-1 infected 
individuals. Noteworthy my analyses further reveal that frequencies of CD21neg naïve and 
CD21neg MZ B cells are restored by ART to levels observed for healthy donors. To 
understand the potential impact of the CD21neg naïve and CD21neg MZ B cell subtypes on B 
cell functionality, the phenotypic analysis was followed by a functional analysis of these B cell 
subsets. By monitoring the proliferative state, expression of activation and exhaustion 
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marker, frequency of apoptotic cells and BCR-mediated phosphorylation upon BCR-
mediated stimulation clear functional differences of CD21neg naïve and CD21neg MZ B cells 
and their CD21+ counterparts became evident. I found that a large fraction of CD21neg naïve 
and CD21neg MZ B cells that emerge during chronic HIV-1 infection are activated and anergic 
and thus may be a driving reason why de novo induction of antibody responses is impaired. 
In Chapter 6 I used the 16-color B cell phenotyping panel to analyze the memory B cell 
compartment in the same patient cohort to retrieve a fine-mapping of the subset 
diversification amongst memory B cells that are inflicted by HIV-1 infection. Using 
dimensionality reduction analysis t-SNE I obtained intriguing novel insights on the 
composition of the main memory B cell subsets. Memory B cells grouped based on CD21 
and CD27 expression into the four known subsets, namely intermediate (IM; CD21+CD27-), 
resting (RM; CD21+CD27+), activated (AM; CD21-CD27+) and tissue-like (TLM; CD21-CD27-) 
memory B cells, proved to contain distinct distributions of IgA-, IgG1- and IgG3-expressing B 
cells with TLM B cells containing the highest frequency of IgG3+ cells. In line with this, IgG3+ 
B cells express higher levels of CXCR3, known to be expressed on activated and exhausted 
memory B cells. Interestingly, the elevated CXCR3 expression observed on several memory 
B cell subsets was not reduced to healthy donor levels when ART was initiated late - in the 
chronic stage of HIV-1 infection -  compared to patients with early ART who initiated 
treatment during the acute phase. Although the functional consequences of the sustained 
phenotypic alterations of AM and TLM B cell still need to be unraveled, that fact that these 
perturbations are not fully restored when ART is initiated at later disease stages highlights 
the importance of early onset of ART. To provide a basis for future phenotypic and functional 
characterization of the memory B cell subsets in HIV-1 infection, I subjected the data 
obtained in my study to the cluster analysis SPADE in combination with hierarchical 
clustering to obtain a fine-mapping of the memory B cell phenotypes. This analysis revealed 
a high diversity of memory B cells that go well beyond the classically defined subsets that are 
solely based on CD21/CD27 and isotype expression. My data highlight that our current view 
of the memory B cell compartment is limited to only few categories that do not fully 
appreciate the diversity of the memory B cell network. The drivers of this diversification and 
the functional properties of the individual memory B cell species thus need to be unraveled to 
understand their impact in health and disease. 
In the frame of my thesis I conducted a thorough analysis of the B cell compartment in HIV-1 
infection which provides a starting point for an in depth analysis of the B cell landscape in 
both healthy and compromised immune systems.  
29
Chapter 4  Flow cytometry panel design 
4. Optimized Multicolor Immunofluorescence Panel (OMIP): High-
dimensional characterization of human B cells 
 
 
Manuscript in preparation. My contributions include designing the flow cytometry panel, 
generating, analyzing and plotting all data. I prepared all figures and wrote the manuscript 
which was commented on by the coauthors. 
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4.1  Purpose and appropriate sample type 
The present panel was designed to allow a detailed dissection of human B cell subsets and 
their phenotype in peripheral blood mononuclear cells in both healthy donors and in the 
context of chronic diseases such as infection with Human Immunodeficiency Virus (HIV)-1. 
The panel encompasses a range of backbone markers that ensure accurate definition of 
common B cell subsets in combination with diverse phenotypic markers (chemokine 
receptors, cytokine receptor, B cell receptor isotypes, and proliferation marker) that allow 
highly detailed phenotypic and functional investigations of B cell subsets. The panel was 
validated and used for cryopreserved peripheral blood mononuclear cells (PBMC) from 
healthy and HIV-1 infected donors (Table 1). 
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4.2 Background 
Chronic viral diseases such as HIV and HCV result in dramatic perturbations of the B cell 
compartment, most strikingly a shift towards mature and exhausted phenotypes and 
increased levels of immature CD10+ transitional B cells (1, 2). As a consequence B cell 
responses in HIV-1 infection are frequently impaired resulting in delayed and in part 
insufficient humoral responses to diverse infectious agents and vaccines (3-9).  
B cells can be defined by expression of the canonical marker CD19. We used a Dump 
channel including CD3, CD14, CD16 and a Live/Dead dye to achieve an optimal resolution 
between CD19+ and CD19- cell types and dead cells to allow definition and inclusion of 
CD19dim plasmablasts into the analysis (Figure 1A). 
For detection of transitional B cells CD10 was included in the panel. While transitional B cells 
can also be defined by the classical Bm1-Bm5 classification of B cells according to their 
CD38 and IgD expression (10), we found that the relying on the latter separation is usually 
less pronounced compared to inclusion of CD10 (10, 11). Inclusion of CD38 and IgD in the 
panel allowed a dissection of CD10- mature B cells in IgD+ unswitched B cells (CD38+IgD+), 
class-switched memory B cells (CD38dimIgD-) and plasmablasts (CD38++IgD-) based on the 
expression pattern of CD38 and IgD (Figure 1B).  
IgD+ unswitched B cells encompass antigen-inexperienced naïve B cells and marginal zone 
(MZ) B cells (12, 13) which can be distinguished by the differential expression of the memory 
B cell marker CD27. Naïve B cells do not express CD27 but express high levels of IgD 
whereas IgD on MZ B cells is lower and paired with expression of CD27 (12). 
IgD is a well-established marker to define the B cell population which underwent class-
switching (14) as the majority of memory B cells lose IgD expression and only low 
frequencies of IgD+ memory B cells in the periphery have been described (15, 16).  
Analysis of B cell subsets based on CD21 and CD27 expression has been frequently used in 
the literature but bears a limitation as naive B cells with a phenotype of CD21+CD27- are 
commonly not distinguished from memory B cells with the same expression profile (4, 7, 8, 
17). The present OMIP panel defines the naïve B cell population separately based on IgD 
and CD27 expression which allows to exclude this subset from the analysis of memory B 
cells and to define so-called intermediate memory B cells characterized by CD21+CD27- 
expression (17). The differential expression of CD21 and CD27 allows the definition of 
resting memory B cells (RM, CD21+CD27+), activated memory B cells (AM, CD21-CD27+) 
and tissue-like memory B cells (TLM, CD21-CD27-) as described (Figure 1C) (17, 18). To 
obtain a refined dissection of phenotypic differences amongst the memory B cell subsets our 
staining panel monitors IgA, IgG1 and IgG3 B cell receptor isotypes (Figure 1C). 
To provide insight into the potential tissue destination and migratory profiles of the diverse B 
cell subsets chemokine receptors CCR7, CXCR3, CXCR4 and CXCR5 are monitored by our 
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panel (Figure 1C-E). CCR7 plays an important role to guide cells to the T cell area in 
secondary lymph organs (SLO). In B cell follicles follicular dendritic cells secrete high levels 
of CXCL13, which attract CXCR5-expressing B cells towards the GC. CXCR3 binds to 
CXCL9 and CXCL10. Both chemokines are secreted in inflamed tissues and attract B cells to 
these sites with ongoing immune activation. CXCR4, the chemokine receptor for CXCL12, is 
important for homing of B cells to bone marrow and lymphoid organs including the spleen 
(19, 20). 
A further marker included in our panel is IL-21R (Figure 1D). IL-21, mainly secreted by 
follicular helper T cells in the GC, supports SHM and isotype switching through signaling of 
the IL-21R and is crucial for the development of high-affinity antibody responses (21-25). 
Inclusion of IL-21R in the B cell panel allows analysis of the dynamics of IL-21R expression 
in order to define whether chronic viral infections manipulate the responsiveness of B cells to 
SHM and isotype class switching through regulation of IL-21R (22, 23, 26). 
Inclusion of the proliferation marker Ki67, allows the characterization of recently activated B 
cells and their phenotype which allows insights in alterations of concurrent B cell phenotypes 
when performing longitudinal assessments of the B cell repertoire (Figure 1F) (27). 
Combining classical lineage markers with a range of phenotypic parameters (Table 2) our 
comprehensive 16-parameter B cell panel provides the possibility for a highly detailed   
characterization of the B cell compartment in healthy individuals, as well as in response to 
infections or in autoimmune diseases. 
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4.3 Table and figure legends 
 
Table 1: Summary table for application of OMIP. 
 
Table 2: Reagents used for OMIP. 
 
Figure 1: Characterization of B cell subsets by flow cytometry.  
 
(A) A Time vs SSC-A gate was set to exclude fluorescence intensity fluctuations due to eventual 
irregular acquisition of the flow cytometer. Single cells were further defined based on SSC-A and 
FSC-A and a gate for doublet discrimination based on a FSC-H/FSC-A gate. B cells were defined 
as Dump-negative (Dump set as CD3, CD14, CD16 positive and, dead cells) and CD19-positive 
cells. A major B cell subset discrimination is based on CD10 and therefore B cells were divided in 
CD10- and CD10+ subpopulations. (B) CD10+ B cells can be further refined in transitional B cells 
(CD38+IgD+). CD10- B cells comprise IgD+ unswitched B cells (IgD+), class-switched B cells 
(CD38lowIgD-) and plasmablasts (CD38highIgD-), which can be defined based on the surface 
expression pattern of CD38 and IgD. The unswitched IgD+ fraction can be further divided in naïve 
(CD27-IgDhigh) and marginal zone B cells (CD27+IgD+). (C) To characterize memory B cell 
subsets based on their expressed B cell receptor isotype we included IgG1, IgG3 and IgA in our 
panel. To define  memory B cell subsets based on their maturation state expression patterns of 
CD21 and CD27 were analyzed as described (17, 18, 28). Intermediate (CD21+CD27-) and 
resting memory (CD21+CD27+) memory B cells are defined as quiescent states, whereas 
activated memory B cells are CD21-CD27+. Tissue-like memory B cells, an exhausted subset, do 
not express CD21 and CD27. In HIV-1 infected patients the distribution is known to be skewed 
towards activated and tissue-like memory B cells (17, 18, 28). Analysis of cell samples from HIV-
1 infection was thus useful to verify sufficient resolution of CD21 staining. (D) In order to 
characterize the potential migratory activity of B cell subsets, we included antibodies for the 
chemokine receptors CCR7, CXCR3, CXCR4 and CXCR5 in our panel. To measure 
responsiveness to IL-21, an important cytokine for development of high-affinity antibody 
responses, IL-21R levels were measured. The resolution of anti-CXCR4, -CXCR5 and –IL-21R 
antibodies was good as judged by staining differences between the full stained sample (blue) and 
the corresponding FMO control (grey). (E) Resolution of CCR7 proved high so that FMO was not 
necessary to define positive populations. (F) In healthy donors the frequency of CXCR3 and Ki67 
expressing B cells is genuinely low necessitating FMO controls. FMO control and fully stained 
sample are shown as a dot plot in combination with CD27. Both markers show a sufficient 
separation in combination with full staining panel.  
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4.4 Tables and figures 
 
Table 1 
 
 
 
 
 
 
 
 
 
 
  
PURPOSE                                       B CELLS 
 
Species    Human 
Cell types    PBMC 
Cross-reference   n.a. 
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Table 2 
 
SPECIFICITY  CLONE  FLUOROCHROME  PURPOSE 
       
CD3  SK7  APC-Cy7  Dump 
CD14  HCD14  APC-Cy7  Dump 
CD16  3G8  APC-Cy7  Dump 
Dead cells  -  Near-infrared  Dump 
CD19  SJ25C1  Brilliant violet 786  Lineage 
CD10  HI10a  BV650  B cell subsets 
IgD  IA6-2  PE-Cy5 
(in-house conjugation) 
 B cell subsets  
CD38  HIT2  AF700  B cell subsets  
CD21  B-ly4  BV711  B cell subsets/Exhaustion 
CD27  M-T271  PE-CF594  Differentiation, Memory 
IgG1  HP6001  PE  IgG1 class-switched B cells 
IgG3  Polyclonal 
Sheep IgG 
 FITC  IgG3 class-switched B cells 
IgA  Polyclonal 
goat IgG 
 APC  IgA class-switched B cells 
CCR7  G043H7  BV605  Migration pattern 
CXCR3  G025H7  PE-Cy7  Migration pattern 
CXCR4  12G5  PE-Cy5.5 
(in-house conjugation) 
 Migration pattern 
CXCR5  RF8B2  BV510  Migration pattern 
IL-21R  2G1-K12  BV421  Cytokine receptor 
Ki67  20Raj1  PerCP-eFluor710  Proliferation marker 
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Figure 1 
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4.5 Supplementary info 
4.5.1 Developmental strategy 
The chosen markers were classified according priority, which includes the availability of 
fluorochromes as well as the allocation of bright fluorochromes to difficult to stain (e.g. low-
level expressed) targets such as IL-21 receptor and some of the chemokine receptors 
(Supplementary table 1). For chemokine receptors and B cell subset markers different 
fluorochromes are available, which allows testing several reagent combinations and 
optimization. The panel was optimized for a BD Fortessa cytometer with the specifications 
listed in supplementary table 2. 
All reagents were carefully titrated (Supplementary table 3 and 4 and Supplementary figure 
1). Most markers were tested in combination with the Dump channel reagents and the B cell 
lineage specific anti-CD19 antibody to estimate the optimal antibody concentration on B 
cells, especially when the target is expressed on only a small subset of cells (Supplementary 
figure 1B). The concentrations of antibodies used for the panel were estimated as the lowest 
concentration which had no effect on the negative population but provided staining of the 
positive population in the saturation range. Reagents tested but not included in the final 
panel are listed in supplementary table 5. 
Since antibodies specific for IgD and CXCR4 conjugated with PE-Cy5 and PE-Cy5.5, 
respectively, were not commercially available, these antibodies had to be conjugated in-
house. The Lightning-link kits from Innova Biosciences were used according to 
manufacturer’s recommendations.  After each new batch preparation coupled antibodies 
were titrated and compared with the previous batch in order to guarantee comparable 
staining intensities. 
In few cases reagents (CD27 PE-CF594 and IgA APC) reagents were diluted below 
saturation to avoid excessive spreading error into other channels as further described below.  
An initial 10 color B cell panel (Supplementary table 6, panel 1) was built using a progressive 
approach as described (29). The resolution of the chemokine receptors CXCR3 and CXCR4 
was insufficient and needed further optimization. The resolution of CXCR4 PE-Cy5 was 
dramatically reduced due to spill-over from anti-IgA APC even though a good separation of 
CXCR4 was expected on B cells which highly express CXCR4 and therefore could 
potentially allow overcoming the spill-over dependent loss of resolution (Supplementary 
figure 2A and B). As this was not the case, several changes were implemented. IgD was 
switched to IgD PE-Cy5 because IgD and IgA are exclusively expressed on naïve B cells and 
a subset of memory B cells, respectively. Therefore it was expected that the large spill-over 
between PE-Cy5 and APC would not impair the definition of IgA+ memory B cells and IgD+ 
naïve B cells. Furthermore, due to good separation between negative and positive 
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population, the APC-conjugated anti-IgA antibody was used at lower concentrations as 
described in the initial 10 color panel. This further reduced the spill-over into the PE-Cy5 
detector (Supplementary figure 3). The combination of IgD PE-Cy5 and IgA APC proved to 
be useful during the progressive panel design towards 16 markers. 
The first 10-color panel included CXCR3 assigned to the fluorochrome PerCP-Cy5.5 
(Supplementary table 6, Panel 1). However, the resolution was not acceptable due to 
tremendous spill-over from CD27 PE-CF594 and weak staining with CXCR3 PerCP-Cy5.5. In 
order to decrease the CD27 PE-CF594 dependent spill-over the antibody was used at 
concentrations below saturation (1:400-1:800), without significant loss of resolution between 
CD27 positive and negative events. However, the decreased staining showed a notable loss 
of spreading into the PerCP-Cy5.5 channel (Supplementary figure 4). Nevertheless, the 
CXCR3 staining remained insufficient to resolve CXCR3+ B cells. Therefore CXCR3 was 
switched to the brighter fluorochrome PE-Cy7 to further increase the resolution 
(Supplementary figure 5A).  
Since the spreading error into the PerCP-Cy5.5 was decreased after using CD27 PE-CF594 
at a lower concentration and due to the high expression of CXCR4 on B cells, CXCR4 was 
switched to PerCP-Cy5.5 (Supplementary table 6, Panel 2). 
Several further optimization measures were tested such as different incubation temperature, 
resting of cells overnight and the effect of cryopreservation on CXCR3 expression.  
The staining of CXCR3 could not be improved by staining at 4°C or 37°C instead of room 
temperature (RT) (Supplementary figure 5B). Cryopreservation had only marginal effects on 
CXCR3 expression as shown by decreased detectable frequencies of CXCR3+ B cells. 
Resting of B cells at 37°C overnight in complete RPMI medium could not recover the surface 
CXCR3 levels but lead to increased CXCR4 levels possibly due to relocation of intracellularly 
stored CXCR4 to the cell membrane during the incubation period (Supplementary figure 6). 
As expression pattern were thus altered compared to freshly isolated or thawed cells no 
resting steps were performed in further analyses (Supplementary figure 6). 
 
As a next step the panel was expanded to 13 markers (Supplementary table 6, panel 3). One 
demand for our forthcoming studies was a refined discrimination of the IgG+ B cell population 
into IgG1+ and IgG3+ memory B cells. Due to the fact that the range of commercially 
available IgG3-specific antibodies is limited we assigned this marker to the FITC fluorchrome 
and IgG1 to PE since the IgG1 antibody was only available conjugated with PE. As a 
consequence we had to omit CCR10 from the PE channel.  
In addition, since IL-21R is a crucial molecule we tested sought to improve its staining 
resolution. IL-21R was consequently assigned to the brightest available fluorochrome 
(BV421) which finally allowed us to achieve a sufficient resolution to distinguish clearly IL-
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21R expressing B cells (Figure 1D). In addition CCR7 BV605 and CXCR5 BV510 were 
included. Since CD19 BV510 showed limited resolution and therefore could not resolve 
CD19dim plasmablasts sufficiently we changed CD19 to the brighter BV711 and used 
CXCR5 BV510 as CXCR5 is highly expressed on B cells and consequently showed sufficient 
separation with the dim fluorochrome BV510 (figure 1D). 
 
In a last round of adaptation the 13 color B cell panel was expanded to 16 markers to include 
CD10, CD21 and Ki67 (Supplementary table 6, panel 4). To achieve this the panel had to be 
rearranged. CD19 was changed to BV786 and CD21 was assigned to BV711 because this 
antibody was not available with the BV786 conjugate. In addition CD10 BV650 was used due 
to the fact that this channel was not used and suffers from limited spill-over from other 
fluorochromes. This was critical as CD10 is usually only weakly expressed on transitional B 
cells. Furthermore, since CXCR5 (BV510), CCR7 (BV605) and CD21 (BV711) can be 
expressed on the same B cell population it could affect the resolution of these markers if an 
additional marker expressed by the same cell would be stained with BV650 as these 
fluorochromes are close in their spectral behavior. By using BV650 for CD10 we avoided 
having BV650 on the main B cell populations of our interest in forthcoming studies such as 
naïve and memory B cells.  
 
Our initial plan to change CCR10 from PE to PerCP was discarded as although we used the 
same antibody clone, and CCR10 PE resulted in a decent staining of CCR10+ cells, CCR10 
PerCP unfortunately showed insufficient resolution. When double-stainings were performed 
this was confirmed showing that cells with high CCR10 PE signal showed only low signal 
with CCR10 PerCP and were not resolved from the background noise (Supplementary figure 
7).  
 
The expansion of the panel from 13 to 16 color was again done in a progressive manner as 
described in the literature showing that none of the newly included markers had dramatic 
effects on other markers and that the populations defined by the newly included markers are 
well resolved (Supplementary figure 8) (29). Since the addition of the marker CD10 BV650, 
CD21 BV711 and CXCR4 PE-Cy5.5 did not affect the resolution in the PerCP-Cy5.5 channel 
we decided to use Ki67 PerCP-eFluor710 since this marker is highly expressed in 
proliferating cells and showed a sufficient resolution to resolve Ki67+ B cells (figure 1F).  
The final panel (Supplementary table 6, panel 4) showed sufficient separation to define the 
major B cell subsets and to assess the expression of phenotypic marker for characterizing B 
cell subsets of interest and is therefore suitable for our further studies. 
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4.5.2 Staining protocol 
 
1. Thaw PBMC vial (approx. 5x106 cells) gently in a water bath pre-warmed at 37°C. 
2. Transfer cells to pre-warmed FACS buffer (37°C; PBS, 2% FCS, 2mM EDTA) 
containing 20μg/ml DNase. 
3. Centrifuge cells 10’ at 450g at RT. 
4. Wash again with FACS buffer/DNase. 
5. Centrifuge 10’ at 450g at RT. 
6. Stain cells with Live/Dead NIR at optimal concentration diluted in PBS and incubate 
for 30min. 
7. Wash cells twice as described above with FACS buffer/DNase. 
8. Resuspend cells in 50μl Brilliant violet stain buffer with 20µg/ml DNase containing 
cocktail of surface staining antibodies. 
9. Incubate 30’ at room temperature. 
10. Wash cells three times as described above with FACS buffer/DNase and once with 
permeabilization buffer from the Foxp3 / Transcription Factor Staining Buffer Set 
according to manufacturer’s description. 
11. Fix cells with the 100μl Fixation/Permeabilization buffer from Foxp3 / Transcription 
Factor Staining Buffer Set as described in the manufacturer’s protocol for 45 minutes 
at 4°C. 
12. Without washing 150μl of permeabilization buffer was added and cells were 
centrifuged at 750g for 10 minutes at room temperature. These centrifugation settings 
were used for the entire protocol after the fixation step. 
13. Wash cells twice with 200μl permeabilization buffer. 
14. Resuspend cells with 50μl of permeabilization buffer containing anti-Ki67 PerCP-
eFluor710 antibody at optimal concentration as determined by antibody titration. 
15. Incubate cells for 30min at room temperature. 
16. Wash cells two times with 200μl permeabilization buffer and once with FACS buffer. 
17. Resuspend cells in FACS buffer and analyze with the flow cytometer. 
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4.5.3 Supplementary table and figure legends 
 
Supplementary table 1: Priority characterization of reagents. 
 
Supplementary table 2: Instrument configuration of the BD Fortessa cytometer used for 
establishing the B cell panel. 
 
Supplementary table 3: Commercially available reagents included in the B cell panel. 
 
Supplementary table 4: In house conjugated reagents with the corresponding labeling kit 
used. Unlabeled antibodies are listed on the left side and the corresponding fluorochrome-
labeling kit on the right side. 
 
Supplementary table 5: Reagents tested but not included in final panel. 
 
Supplementary table 6: Step-wise panel design towards final 16 color B cell phenotyping 
panel. 
 
Supplementary table 7: Reagents used for staining. 
 
Supplementary figure 1: Antibody titrations and analysis on whole (A) PBMC or (B) on pre-
gated viable CD19+ B cells. 
 
Supplementary figure 2: Resolution of CXCR4 PE-Cy5 is impaired by spill-over from IgA 
APC. (A) Dot plots of naïve (top row) and memory B cells (bottom row) are shown of FMO 
control for CXCR4 PE-Cy5 (left column) and fully stained sample (right column). IgA+ 
memory B cells show dramatic spreading into the CXCR4 channel (lower right dot plot; FMO 
CXCR4 PE-Cy5) resulting in decreased resolution of CXCR4 staining on IgA+ memory B 
cells. Naïve B cells do not express IgA and therefore resolution of CXCR4 PE-Cy5 staining is 
not affected by IgA APC.  (B) In addition, memory B cells showed lower expression of 
CXCR4 compared to naïve B cells as indicated by the overlay histograms which demonstrate 
that an improved separation between negative and positive events must be found. Cells were 
stained with panel 1 listed in supplementary table 6 and pre-gated on viable Dump-CD19+ B 
cells.  
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Supplementary figure 3: Dilution of IgA APC below saturation concentration decreased 
spreading error from APC into PE-Cy5. As IgD+ B cells showed unspecific IgA staining at 
high concentrations of anti-IgA APC, lower anti-IgA APC concentration as determined by 
titration was used. Cells were stained with panel 1 listed in supplementary table 6 and pre-
gated on viable Dump-CD19+ B cells.  
 
Supplementary figure 4: PE-CF594 conjugated anti-CD27 showed dramatic spill-over into 
the PerCP-Cy5.5 channel. Since PerCP-Cy5.5 was assigned to the dim marker CXCR3, 
CD27 PE-CF594 would mask the CXCR3 staining. Therefore CD27 PE-CF594 was titrated 
down below optimal saturating concentration showing dramatic improvement of the spill-over 
effect into the PerCP-Cy5.5 channel. A dilution of 1:800 shows dramatically reduced 
spreading and was therefore used. Cells were pre-gated on viable CD19+ B cells stained with 
Panel 1 as indicated in supplementary table 6. Backbone staining contains all marker in 
Panel 1 without CD27 PE-CF594 and CXCR3 PerCP-Cy5.5 
 
Supplementary figure 5: (A) Changing CXCR3 from PerCP-Cy5.5 to the brighter 
fluorochrome PE-Cy7 dramatically increased the resolution of CXCR3. The spill-over of PE-
CF594, APC and PE-Cy5 into the PerCP-Cy5.5 channel resulted in spreading lowering the 
resolution of PerCP-Cy5.5 staining (left column). The spill-over into the PE-Cy7 channel was 
moderate without negative influence on the CXCR3 PE-Cy7 staining (right column). (B) To 
increase the resolution of CXCR3 PE-Cy7 cells were stained at different temperatures. As no 
temperature setting improved resolution all further stainings were performed at room 
temperature. Cells were stained with panel 1 in case of CXCR3 PerCP-Cy5.5 and panel 2 in 
case of CXCR3 PE-Cy7 as indicated in supplementary table 6. Cells were pre-gated on 
viable CD19+ B cells. 
 
Supplementary figure 6: Effect of cryopreservation on CXCR3 and CXCR4 expression on B 
cells was determined. CXCR3 and CXCR4 expression after isolation, after cryopreservation 
with resting overnight at 37°C in complete RPMI media and after cryopreservation without a 
resting phase was assessed. Dot plots showing CXCR3 expression and corresponding FMO 
control are shown in top two rows. CXCR3+ B cells are gated and percentage is shown. 
Histogram overlay with CXCR4 expression (blue) and the corresponding FMO control (grey) 
at the different conditions are shown in bottom row. Expression was analyzed on viable 
CD19+ B cells stained with Panel 2 listed in supplementary table 6. 
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Supplementary figure 7: Dual CCR10 staining with the same clone at equal concentrations 
derived from the same company labeled with PE and PerCP showed in CD4 T cells and B 
cells that CCR10 PerCP does not show sufficient separation of CCR10+ events compared to 
the CCR10 PE antibody. Therefore CCR10 PerCP was omitted from the panel. CD4 T cells 
were gated as a control due to higher frequency of CCR10+ events.  
 
Supplementary figure 8: Progressive panel design from 13 to 16 colors by adding CD10 
BV650, CD21 BV711 and CXCR4 PE-Cy5.5 sequentially showed no dramatic effect on the 
staining of all other markers and the additional markers exhibited sufficient separation 
between negative and positive events (red boxes). First column shows all cells gated by FSC 
and SSC. The subsequent columns are pre-gated on Dump-CD19+ B cells as they are the 
cell type of interest. No Ki67 staining was included to assess the spill-over into and the 
resolution of the PerCP-Cy5.5 channel showing the potential of using anti-Ki67 labeled with 
PerCP-eFluor710. 
 
 
 
 
 
 
 
45
Chapter 4  Flow cytometry panel design 
4.5.4 Supplementary tables and figures 
 
Supplementary table 1 
 
Priority 
ranking 
 Category  Rationale for priority level  Reagents 
1  Dump channel  The dim fluorochrome APC-Cy7 
requires highly expressed lineage 
markers to reach sufficient resolution. 
In addition, availability of reagents with 
APC-Cy7 is limited. 
 
 Live/Dead NIR, CD3, 
CD14 and CD16 
2  B cell subset 
marker 
 Optimal separation of B cell subsets 
and reason for development 
 
 CD19, CD21, CD27, 
CD38, IgD,  
3  Chemokine 
receptor  
 Further characterization of B cell 
subsets 
 
 CCR7, CXCR3, 
CXCR4, CXCR5 
4  Luxury markers  Interesting markers which are only 
included when the magnitude of spill-
over and the resolution are acceptable 
 IL-21R, Ki67 
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Supplementary table 2 
 
        Optical filters   
Laser 
wavelength 
[nm] 
Laser 
power 
[mW] 
Laser 
type 
Spectral 
range for 
detector [nm] 
 Dichroic 
#1 [nm] 
Band pass 
[nm] 
 Fluorochrome 
405nm 50 DPSS* 425-575  - 450/50  BV421 
   500-550  505LP 525/50  BV510 
   600-620  600LP 610/20  BV605 
   655-685  630LP 670/30  BV650 
   685-735  685LP 710/50  BV711 
   775-825  735LP 800/50  BV786 
488nm 50 DPSS* 515-545  505LP 530/30  FITC 
   675-715  685LP 695/40  PerCP-
eFluor710 
561nm 50 DPSS* 578.5-593.5  - 586/15  PE 
   600-620  600LP 610/20  PE-CF594 
   655-685  635LP 670/30  PE-Cy5 
   685-735  685LP 710/50  PE-Cy5.5 
   750-810  750LP 780/60  PE-Cy7 
640nm 40 DPSS* 663-677  - 670/14  APC 
   707.5-752.5  690LP 730/45  AF700 
   750-810  750LP 780/60  APC-Cy7 
*Diode-pumped solid-state laser 
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Supplementary table 3 
 
SPECIFICITY  CLONE  FLUOROCHROME  VENDOR CATALOG 
NUMBER 
DILUTION 
         
CD3  SK7  APC-Cy7  Biolegend 344818 1:100 
CD14  HCD14  APC-Cy7  Biolegend 325620 1:100 
CD16  3G8  APC-Cy7  Biolegend 302018 1:100 
Dead cells  -  Near-infrared  Life Technologies L10119 1:1000 
CD19  SJ25C1  Brilliant violet 786  BD Pharmingen 563326 1:10 
CD10  HI10a  BV650  BD Pharmingen 563734 1:40 
CD38  HIT2  AF700  Biolegend 303524 1:50 
CD21  B-ly4  BV711  BD Pharmingen 563163 1:40 
CD27  M-T271  PE-CF594  BD Pharmingen 562297 1:400 
IgG1  HP6001  PE  Southern Biotech 9054-09 1:800 
IgG3  Polyclonal 
Sheep IgG 
 FITC  AbD Serotec OBT5096F 1:6400 
IgA  Polyclonal 
goat IgG 
 APC  Jackson Immuno 109-135-011 1:6400 
CCR7  G043H7  BV605  Biolegend 353224 1:10 
CXCR3  G025H7  PE-Cy7  Biolegend 353719 1:100 
CXCR5  RF8B2  BV510  BD Pharmingen 563105 1:50 
IL-21R  2G1-K12  BV421  Biolegend 347809 1:10 
Ki67  20Raj1  PerCP-eFluor710  eBiosciences 46-5699-42 1:40 
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Supplementary table 4 
 
 
 
 
 
  
SPECIFICITY CLONE VENDOR CATALOG 
NUMBER 
FLUORO-
CHROME 
VENDOR CATALOG 
NUMBER 
DYE:AB 
RATIO 
DILUTION 
         
CXCR4 12G5 Biolegend 306502 PE-Cy5.5 Innova 
Biosciences 
761-0010 1:1 1:80 
IgD IA6-2 Biolegend 348202 PE-Cy5 Innova 
Biosciences 
760-0010 1:1 1:1600 
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Supplementary table 5 
 
SPECIFICITY  CLONE  FLUOROCHROME  VENDOR CATALOG 
NUMBER 
DILUTION 
         
CCR10  3143058 
(25µg/ml) 
 PE  R&D systems FAB3478P 1:20 
CCR10  314305 
(25µg/ml) 
 PerCP  R&D systems FAB3478C 1:20 
CD19  SJ25C1  BV510  BD Pharmingen 562947 1:50 
CD19  SJ25C1  BV711  BD Pharmingen 563038 1:50 
CXCR3  G025H7  PerCP-Cy5.5  Biolegend 353713 1:100 
CXCR4  12G5  PE-Cy5  Biolegend 306507 1:200 
CXCR4  12G5  PerCP-Cy5.5  Biolegend 306513 1:100 
IgD  IA6-2  PE-Cy7  Biolegend 348209 1:200 
IgG  Ployclonal 
goat f(ab’)2 
 FITC  Southern Biotech 2042-02 1:3200 
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Supplementary table 6 
 
 Optical filters  Panel 1 Panel 2 Panel 3 Panel 4 
Spectral 
range for 
detector 
[nm] 
Dichroic 
#1 [nm] 
Band 
pass 
[nm] 
Fluoro-
chrome 
    
425-575 - 450/50 BV421   IL-21R IL-21R 
500-550 505LP 525/50 BV510 CD19 CD19 CXCR5 CXCR5 
600-620 600LP 610/20 BV605   CCR7 CCR7 
655-685 630LP 670/30 BV650    CD10 
685-735 685LP 710/50 BV711   CD19 CD21 
775-825 735LP 800/50 BV786    CD19 
515-545 505LP 530/30 FITC IgG IgG IgG3 IgG3 
675-715 685LP 695/40 PerCP-
eFluor710 
CXCR3 
(PerCP-
Cy5.5) 
CXCR4 
(PerCP-
Cy5.5) 
CXCR4 
(PerCP-
Cy5.5) 
Ki67 
578.5-593.5 - 586/15 PE CCR10 CCR10 IgG1 IgG1 
600-620 600LP 610/20 PE-CF594 CD27 CD27 CD27 CD27 
655-685 635LP 670/30 PE-Cy5 CXCR4 IgD IgD IgD 
685-735 685LP 710/50 PE-Cy5.5    CXCR4 
750-810 750LP 780/60 PE-Cy7 IgD CXCR3 CXCR3 CXCR3 
663-677 - 670/14 APC IgA IgA IgA IgA 
707.5-752.5 690LP 730/45 AF700 CD38 CD38 CD38 CD38 
750-810 750LP 780/60 APC-Cy7 CD3, 
CD14, 
CD16, 
Live/Dead 
CD3, 
CD14, 
CD16, 
Live/Dead 
CD3, 
CD14, 
CD16, 
Live/Dead 
CD3, 
CD14, 
CD16, 
Live/Dead 
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Supplementary table 7 
 
REAGENT  VENDOR CATALOG 
NUMBER 
    
FoxP3/Transcription Factor  
staining kit 
 eBiosciences 00-5523 
Brilliant violet stain buffer  BD Biosciences 563794 
PBS  Life Technologies 14190-094 
Heat-inactviated FCS  Life Technologies 10270-106 
EDTA  Sigma Aldrich E7889-100ML 
Compensation beads 
Anti-mouse 
 BD Biosciences 552843 
Compensation beads 
Anti-rat/hamster 
 BD Biosciences 552844 
DNase  Sigma Aldrich DN25-100MG 
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Supplementary figure 1 
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Supplementary figure 2 
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Supplementary figure 3 
 
 
 
 
 
 
 
 
  
55
Chapter 4  Flow cytometry panel design 
Supplementary figure 4 
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Supplementary figure 5 
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Supplementary figure 6 
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Supplementary figure 7 
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Supplementary figure 8 
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5.  Wide spread perturbations of the B cell repertoire in HIV-1 
infection afflict naïve and marginal zone B cells  
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5.1 Abstract 
Perturbations of the B cell response including hypergammaglobulinemia and a diminished 
capacity to mount novel antibodies are a hallmark of HIV-1 infection. Alterations of the B cell 
repertoire are signified by increased numbers of activated memory B cells with a 
characteristic CD21neg exhausted phenotype that is thought to be a consequence of a 
continuous antigen-specific and bystander activation in HIV-1 infection. Using high-
dimensional flow cytometric analysis we demonstrate here for the first time that the same 
exhausted phenotype is prevalent amongst antigen-inexperienced cells. We found that 
already in acute infection a substantial percentage of peripheral naïve and also marginal 
zone (MZ) B cells down-regulate CD21, and, in agreement with an exhausted phenotype, do 
not respond to B cell receptor-dependent stimulation. These CD21neg naïve and CD21neg MZ 
B cells differed from the respective CD21pos populations by an altered migratory capacity as 
evidenced by a distinct expression pattern of chemokine receptors CCR7, CXCR3, CXCR4 
and CXCR5 that promote infiltration of inflamed tissues. In line with an HIV-dependent 
activation, CD21neg naïve and CD21neg MZ B cells showed increased expression of the 
proliferation marker Ki-67 and higher frequencies of apoptotic cells. This emergence of 
anergic CD21neg naïve and CD21neg MZ B cells is remarkable as it demonstrates a wider-
spread impairment of B cells including antigen-inexperienced cells than previously 
appreciated. The reduced capacities of the exhausted, CD21neg naïve B cells population to 
respond to stimulation we demonstrate here is in line with the functional defects in mounting 
novel B cell responses in HIV-1 infection. Importantly, as we show here, successful 
antiretroviral treatment leads to a normalization of the peripheral naïve and MZ B population 
further underlining the importance of effective treatment.  
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5.2 Introduction 
The humoral immune response against HIV-1 is characterized by a vigorous binding 
antibody response (1-3). Neutralizing antibodies appear within weeks to months but are 
subject to rapid escape by the virus (4-7). This sets the scene for a continuous interplay of 
virus and antibody co-evolution that leads to the evolution to neutralizing antibodies with 
improved potency and breadth (7-10). While the neutralizing antibody response to HIV-1 
never succeeds in controlling virus replication and the virus even escapes the most potent 
antibodies known to date, the so-called broadly neutralizing antibodies (bnAbs) that develop 
in a fraction of individuals (9-14), this constant evasion suggests that their impact on 
controlling viral replication must be considerable. This is further substantiated by a recent 
report where B cell depletion during lymphoma treatment in an HIV-1 infected individual 
resulted in immediate increase of virus load (15). What effect B cell perturbation has on the 
development of HIV-1 neutralizing antibodies remains uncertain (16, 17). The neutralizing 
antibody response co-evolves with the virus until late disease stages (4, 8, 18). Yet, effective 
neutralizing responses, particularly bnAbs require prolonged times to develop. While a 
number of factors have been suggested that shape the development of bnAbs (19-22), 
disturbed functionality of the B cell population may be an additional reason why bnAbs 
develop late and only in a fraction of individuals (16, 17, 23).  While the influence of B cell 
impairment on the autologous HIV-specific antibodies is difficult to assess due to the high 
variability of HIV and differential disease courses, HIV-1 infection has been shown to lead to 
impaired antibody responses against other pathogens and vaccines highlighting that general 
deficiency in mounting adequate antibody responses exists (24-34) .   
HIV-1 infection is accompanied by massive bystander immune activation impairing many 
components of the innate and adaptive immune system including the B cell compartment 
(35-37). Perturbations of the B cell population have been in particular demonstrated for 
memory B cells (38-40). HIV-1 infection is accompanied with increased frequencies of 
activated (AM) and tissue-like (TLM) memory B cells (38, 39, 41, 42). TLM B cells exhibit an 
exhausted phenotype and are characterized by a reduced diversification of the variable 
regions of immunoglobulins and an impaired capacity to proliferate upon stimulation (38, 39, 
41, 43). AM and TLM B cells are distinguished by the loss of the complement receptor 2 
(CD21) expression, which supports B cell activation through binding of complement-
opsonized antigens (38, 39, 41, 42, 44-47). In addition TLM B cells down-regulate the co-
stimulatory molecule CD27, a canonical marker of memory B cells that provides crucial 
activating signal. Both AM and TLM B cells show different expression pattern of activation 
molecules and chemokine receptors as compared to resting memory B cells, the main 
memory B cell subset found in healthy subjects [reviewed in (38, 39, 48)]. CCR7 and CXCR5 
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chemokine receptors that are required to reach and enter T cell zones and B cell follicles in 
lymph nodes, respectively, and thus are required for B cells to enter GC reaction and to 
undergo class-switch recombination (CSR) and affinity maturation are downregulated in TLM 
B cells (38, 39, 41, 49-54). By losing the capacity to migrate towards B cell follicles and as a 
result to participate in GC reaction impairs TLM B cells in acquiring high-affinity B cell 
receptors [reviewed in (38)]. In contrast, CXCR3 expression is increased in TLM B cells 
suggesting that their migratory potential is orientated towards inflamed tissues where 
chemokines CXCL9-CXCL11 are secreted (38, 41) underlining that TLM B cells must partake 
in different type of immune interactions than conventional memory B cells (38, 55).  
The highly elevated TLM B cells frequencies in HIV-1 infection are thought to be a result of 
the chronic activation (38, 40-42, 56). Owing to the inefficiency of TLM B cells to partake in 
GC reactions, substantial fraction of HIV-specific memory B cells are likely to be impaired in 
developing effective antibodies with high affinity by somatic hypermutation (17). Despite a 
wealth of information on the alteration in the memory B cell compartment in HIV-1 infection 
(38-40, 42, 57), it is currently not known if only memory B cells are compromised or if HIV-1 
infection has even wider spread effects on the B cell population. Considering that de novo 
antibody responses to vaccine and other pathogens can be significantly reduced impairment 
beyond the memory B cell repertoire including antigen-inexperienced naïve B cells could be 
envisaged. In the current study we applied high-dimensional flow cytometry to assess the 
dynamics of B cell subsets during the course of HIV-1 infection using pheripheral blood 
mononuclear cell (PBMC) samples to obtain a comprehensive phenotypic analysis of a wide 
range of B cell subsets. Our analysis thereby sought to define the influence of HIV-1 infection 
on different B cell subsets at acute and chronic disease stages and the potential of 
antiretroviral therapy (ART) in reversing the alterations of the B cell population inflicted by the 
virus. Our results confirmed that the B cell signature in HIV-1 infected patients differs 
dramatically from healthy controls but revealed for the first time that these alterations are not 
restricted to shifts in the memory B cell subset frequencies and increased levels of 
transitional B cells but also include newly emerging CD21- naïve and CD21- marginal zone B 
cells. These cell types are phenotypically and functionally related to previously described 
anergic polyreactive naïve B cells in autoimmunity (58-61) raising the possibility that these 
cell populations may underlie the highly polyreactive HIV-1 specific antibody responses that 
are in part observed (62-64). Importantly, our results emphasize that HIV-1 influences B cell 
responses at early stages of B cell maturation and that their anergic state might be an 
explanation for the delayed and impaired antibody responses against co-infections and 
vaccines. 
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5.3 Results  
5.3.1 Longitudinal changes of major B cell subsets in HIV-1 infection 
The main intent of our study was to gain insight if perturbation of the B cell population in HIV-
1 infection extend beyond the alterations known to occur amongst memory B cells (38, 39, 
41) to enable an advanced understanding of the deficiencies observed in humoral responses 
in HIV-1 infection (24-32). To assess changes of B cell subsets during the course of HIV 
infection we analyzed peripheral blood from healthy controls and samples from HIV-1 
infected individuals enrolled in the Zurich Primary HIV Infection Study (ZHPI) collected at 
different disease stages using multi-parametric flow cytometry. Patients were followed form 
acute to chronic infection stages and stratified into two groups – early and late ART, 
respectively, according to when they started therapy (Supplementary Table 1 and 2). 
Patients from the early ART group initiated ART in the acute infection stage, patients in the 
late ART group in the chronic infection stages. For each included individual three longitudinal 
PBMC samples encompassing acute infection, 2 years of chronic infection, and 1 year of 
ART were analyzed (Supplementary Table 1 and 2). Healthy donor controls were analyzed 
from single time points. 
Using our 16-parameter B cell staining panel, our gating strategy allows the definition of 
major B cell subsets according to their maturation state, namely transitional, naïve, marginal 
zone and memory B cells, different memory B cell subsets including intermediate (IM), 
resting (RM), activated (AM) and tissue-like (TLM) memory B cells and plasmablasts 
(Supplementary figure 2). Interestingly, in addition to the these subsets, our multiparametric 
B cell staining panel revealed a CD10+ B cell population with an unusual phenotype in both 
healthy and HIV-1 infected donors (Figure 1A and Supplementary figure 2A). CD10 is 
normally expressed on transitional B cells, germinal center B cells and B cell subsets 
associated with GC, the so-called GC founder B cells (65, 66). Whereas GC B cells are 
usually not detectable in the periphery, GC founder B cells are thought to be activated and 
migrate from the periphery towards lymphoid tissues while still exhibiting a phenotype similar 
to naïve B cells (65). Both, GC B cells and GC founder B cells express CD38 while GC B 
cells express CD27 and lack IgD (67-69). In contrast, GC founder B cells express high levels 
of IgD but do not express CD27 (65). The observed CD10+ B cell subset in our study 
expresses only low levels of CD38 and no IgD (Supplementary figure 2A). Instead this CD10+ 
B cell subset is characterized by the expression of CD27 and shows expression of IgG1, 
IgG3 and IgA as observed for classical memory B cells emphasizing that these cells are 
closely related to the maturation state of memory B cells (Supplementary figure 3A-C). 
Interestingly, although frequencies of IgA- and IgG3-expressing cells are comparable, CD10+ 
memory B cells contain a higher frequency of IgG1-expressing cells compared to class-
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switched B cells (Supplementary figure 3C).  While the functional properties of these cells 
need to be defined, we refer to them based on their staining patterns as CD10+ memory-like 
B cells.  
Monitoring changes in the B cell subsets during HIV-1 infection we found that among the 
main B cell subsets (transitional, naïve, MZ and memory B cells and plasmablasts) only 
transitional B cells and plasmablasts showed increased frequencies in HIV-1 infected 
individuals compared to healthy donors. Transitional B cells had a peak frequency during the 
chronic phase of infection, whereas plasmablasts were highly increased during acute stage 
and declined during chronic progression (Figure 1A). Importantly, ART treatment reversed 
the elevated frequencies of transitional B cell and plasmablast levels to healthy donor levels 
showing that these cell types are not increased during therapy. Interestingly while frequency 
of classical memory B cells (IgD-CD27+CD38low) were not affected, we observed decreased 
levels of CD10+ memory-like B cells in the chronic phase (Figure 1A).  
In line with the described B cell alterations in HIV-1 infection and effects of ART (41, 42, 56, 
70), frequencies of memory B cell subsets were also distorted in our cohort showing 
increased levels of activated (AM) and tissue-like exhausted (TLM) memory B cells in 
contrast to decreased levels of intermediate (IM) and resting (RM) memory B cells during 
chronic HIV-1 infection (Figure 1B). A hallmark of activated and tissue-like memory B cells is 
the loss of CD21 expression (38, 39, 41, 71, 72). Most strikingly, we not only observed a 
down-regulation of CD21 on memory B cells in response to HIV-1 infection but also on naïve 
and marginal zone (MZ) B cells ( Figure 1C).  MZ B cells showed after 2 years of untreated 
HIV-1 infection a loss of CD21 in up to 70% (median 53.5%) of the cells. A significant loss of 
CD21 amongst naïve B cells was also evident compared to healthy controls (median 15.8%). 
As seen for the memory B cell subsets except for RM and TLM B cells, levels of CD21- naïve 
and CD21- MZ B cell levels reverted to healthy donor levels upon successful ART (Figure 1C). 
 
5.3.2 Assessing B cell subset signature 
To next we explored if B cell subsets in chronic HIV-1 infection form distinct signatures 
compared to healthy donors. When we subjected the B cell subsets transitional, naïve, MZ, 
CD10+ memory and CD10- memory B cells, plasmablasts and the memory B cell subsets 
intermediate, resting, activated and tissue-like memory B cells measured in chronic infection 
and in healthy donors (Figure 1A-C) to a spearman correlation analysis we observed that 
most (15 of 21) chronically infected patients segregated into a separate cluster (Chronic 
Cluster) that was distinct from healthy donors (Figure 1D). Three HIV-1 infected individuals 
however clustered with the healthy donors (Healthy Cluster). Intriguingly, these patients had 
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significantly higher CD4 counts, lower viral load and lower plasma IgG levels highlighting that 
their infection was markedly less progressed which was linked with a normal B cell subset 
distribution (Figure 1E). A smaller third cluster (Intermediate Cluster) that formed contained 
healthy controls and HIV-1 infected patients with an intermediate B cell phenotype. Of note, 
HIV-1 infected patients within this cluster showed similar clinical parameters as patients 
within the Chronic Cluster, thus were equally far progressed. 
 
5.3.3 Influence of ART initiation on B cell subset normalization 
We next assessed the B cell subsets in the early and late ART initiation group separately to 
assess potential influences of the timing of ART initiation on B cell subset normalization. 
Interestingly, only few differences were observed between the two groups (Supplementary 
figure 4). Sampling time points for the acute, chronic 2 year and ART 1 year time points were 
matched as closely as possible in the early and late ART group. Owing to sample availability 
the acute infection sampling time point was earlier in the early ART group than in the late 
ART group (Supplementary table 1). This difference in sampling timing is likely to be the 
reason why we observed a lower MZ B cell frequency in the early compared to the late ART 
group (Supplementary figure 4A). Interestingly, plasmablasts frequencies were lower in the 
early ART group after two years of chronic infection following ART interruption which may 
suggest that early ART restores a B cell repertoire closer to healthy donors that is not rapidly 
distorted by the rebound of HIV-1 (Supplementary figure 4A).  
The onset of ART made a notable difference only within the CD10+ memory B cell subset 
which was reversed to normal levels by early but not late initiation of ART after one year of 
treatment (Supplementary figure 4D). While for the remaining B cell subsets, early and late 
ART had the same effect, ART was not able to fully restore normal B cell profiles as 
described (42). Even after 1 year of ART tissue-like memory (TLM) B cell frequencies 
remained increased compared to healthy controls with levels similar to frequencies found in 
the acute phase and remained elevated also during chronic infection. Likely as a 
consequence of these fluctuations RM B cells remained reduced after 1 year of ART 
compared to healthy controls (Figure 1B).  
 
5.3.4 Appearance of CD21neg naïve and CD21neg MZ B cells is linked with clinical 
parameters of HIV-1 infection 
The loss of CD21 on naïve and MZ B cells in HIV-1 infection revealed for the first time by our 
analysis emphasizes that B cell perturbations in HIV-1 infection go beyond memory B cells 
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and can even affect antigen-inexperienced B cells. This loss of CD21 may have implications 
for the efficacy in responding to antigen and could thus provide a further factor that attributes 
to the observed delayed capacity of HIV-1 infected individuals to mount high-affinity B cell 
responses to novel antigens (45, 46, 71, 73). To obtain insight to which HIV-1 associated 
factors drive the appearance of CD21- naïve and CD21- MZ B cells we explored their 
association with viral load, CD4 count and plasma IgG levels. While we observed no linear 
relationship of the magnitude of CD21 down-regulation on naïve B cells with either of the 
three parameters in acute or chronic infection, the emergence of CD21- MZ B cells was 
strongly linked with decreasing CD4 T cell counts and increases in viral load but not plasma 
IgG levels during the chronic phase (Figure 2). As shown in chapter 6 of this thesis, the 
emergence of activated and tissue-like memory B cells is also tightly linked with viral load 
and CD4 counts, underscoring strong effect of HIV-1 infection on antigen-experienced cells 
including both memory and MZ B cells. 
 
5.3.5 Differential chemokine receptors and IL-21R expression of CD21neg and 
CD21pos naïve and CD21neg and CD21pos MZ B cell subsets in healthy and HIV-1 
infected donors  
CD21- B cell populations in autoimmune diseases and chronic viral diseases have been 
described to have a divergent surface expression profile (40, 58-61, 74-76) and therefore we 
analyzed the expression of chemokine receptors CCR7, CXCR3, CXCR4, CXCR5 and IL-
21R on CD21- and CD21+ naïve and CD21- and CD21+ MZ B cells (Figure 3A-C and 
Supplementary figure 5A and B). Overall alterations in frequencies were linked with a general 
up- or down-regulation of the respective receptors in the naïve and MZ B cells populations 
(Figure 3D). 
We found that CD21- naïve B cells in both, healthy donors and chronically HIV-1 infected 
patients, have decreased frequencies of cells expressing CCR7, CXCR5 and IL-21R with 
overall lower levels in HIV-1 infection for both CD21- and CD21+ naïve B cells (Figure 3B and 
C and Supplementary figure 5B). In contrast CD21- naïve B cells showed higher frequencies 
of CXCR3+ cells compared to CD21+ naïve B cells in both healthy individuals and HIV-1 
infection paired with a higher CXCR3 expression in both CD21+ and CD21- naïve B cells in 
HIV-1 infection compared to healthy controls (Figure 3B and C and Supplementary figure 5B). 
Differences in receptor expression for MZ B cells were similar, with reduced frequencies of 
CCR7, CXCR5 and IL-21R in both CD21- MZ B cells healthy and HIV-1 infected donors. 
Alterations inflicted by HIV-1 infection where however in part less pronounced (Figure 3C). 
Unlike what we observed for naïve B cells, expression of IL-21R did not change in CD21- MZ 
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B cells in healthy controls but was elevated in CD21- MZ B cells from HIV-1 infected patients 
compared to CD21+ MZ B cells possibly suggesting different requirements of IL-21R 
signaling for B cell responses induced by CD21- naïve and CD21- MZ B cells (Figure 3B). In 
HIV-1 infection CD21+ MZ B cells further showed higher frequencies of CXCR3-expressing 
cells, while amongst CD21- MZ B cells more CCR7-bearing cells were detected (Figure 3C).  
Most interestingly, CXCR4 expression proved to be differentially steered in healthy and HIV-
1 infected individuals showing a decreased expression in CD21- naïve and CD21- MZ B cells 
in healthy donors whereas CXCR4 was not altered in CD21- naïve B cells and upregulated in 
CD21- MZ B cells in chronic HIV-1 infection (Figure 3B and D). This upregulation/preservation 
of CXCR4 in HIV-1 infection was accompanied by an overall increase in receptor expression 
(Figure 3D and Supplementary figure 5B). B cell exhaustion is known to be accompanied by 
an up-regulation of CD19 (58, 72). In line with this we observed increased CD19 expression 
levels CD21- naïve and CD21- MZ B cells of HIV-1 infected donors (Figure 3E and 
Supplementary figure 5B).  
We next analyzed the longitudinal changes of phenotypic markers expressed on CD21- naïve 
and CD21- MZ B cells across different stages of HIV-1 infection covering acute, chronic 
infection and ART time points (Figure 4). Patients in the early ART initiation group started 
treatment during acute infection and interrupted after >1 year (Supplementary figure 1 and 2). 
Samples of chronic infection of these individuals were collected after 1 and 2 years after ART 
discontinuation. Patients in the late ART initiation group remained initially untreated and only 
started ART in their chronic infection phase. This setting allowed us to compare potential 
effects of early and late ART on the restoration of B cell phenotypes. Interestingly, we 
observed more longitudinal parameter changes in the early ART (Figure 4). As a comparison 
of the acute phase highlights, patients in the early ART group harbored CD21- naïve cells 
that expressed higher CCR7 and lower CD19 levels than patients in the late ART group 
(Figure 4). This suggests in line with the estimated infection dates (Supplementary figure 1 
and 2) that patients in the late ART group were already more progressed at the available 
acute infection sample time point. Overall we observed with ongoing virus replication a 
gradual alteration in the parameters that were found to markedly differ in HIV-1 infection 
compared to healthy donors (Figure 3 and 4).  
 
5.3.6 CD21neg naïve B cells form a heterogeneous population  
The high-dimensional parameter data we collected allowed us to explore the subset 
heterogeneity with using unsupervised clustering algorithms. We focused the analysis on 
CD21- naïve B cells as cell numbers of CD21- MZ B cells are too low to allow reliable 
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formation of clusters in this analysis. We used the recently described clustering algorithm 
spanning-tree progression analysis of density-normalized events (SPADE) (77, 78) and 
applied it to the data  from CD21- naïve B cells from 17 HIV-1 infected patients including four 
time points of the different disease stages (acute infection, year 1 and 2 chronic infection and 
ART 1 year) and data from 15 healthy donors (Figure 5A). SPADE allows clustering similar 
cells based on multidimensional expression pattern of markers visualizing clusters in a tree-
like structure (78). We used CCR7, CXCR3, CXCR5 and IL-21R for clustering. All four 
parameters were characterized by bimodal expression patterns to guarantee best possible 
cluster allocation. The generated SPADE trees showed a clear allocation of cells in clusters 
with specific expression patterns and provided an intriguing insight of the high diversity within 
CD21- naïve B cells (Figure 5A). In addition, CXCR4 and CD19 which both were not included 
in clustering, also showed areas with increased expression revealing a certain overlap of the 
expression pattern of different markers (Figure 5A and B). A drawback of clustering 
algorithms is the necessary over-clustering in order to be able to define rare B cell subsets. 
To verify the data obtained by SPADE further, we applied the individual SPADE clusters to a 
second hierarchical clustering by the Ward method  that was based on the expression 
pattern of the clusters defined by SPADE (79). Using the Ward method we identified 10 
different main clusters that portrayed distinct expression patterns of CCR7, CXCR3, CXCR5 
and IL-21R (Figure 5C and Supplementary figure 6A). Of note, also the Ward analysis 
highlighted the overlap of CXCR4 and CD19 with other markers as observed within the 
SPADE trees (Figure 5B). We next analyzed interdependencies of the phenotypic marker 
expression intensities and clinical parameters in CD21- and CD21+ naïve and MZ B cells in 
chronic HIV-1 infected patients (2 years of active infection). Interetsingly, CXCR3 and 
CXCR4 expression correlated with CD19 and IL-21R, respectively, on CD21- naïve B cells 
(Supplementary figure 7).   
To verify the validity of the Ward analysis we performed a manual analysis of the 10 defined 
Ward clusters which confirmed distinct expression patterns for the majority of clusters 
(Supplementary figure 6B). We next analyzed the dynamics of these clusters during HIV-1 
infection again stratifying HIV-1 infected individuals based on the two ART initiation groups 
and compared them with CD21- naïve B cell Ward clusters from healthy controls. 
Interestingly, differences compared to healthy controls were apparent in clusters 1-3, which 
increased and cluster 7 which decreased in HIV-1 infection (Figure 5D and Supplementary 
table 3). The clusters that increased were associated with either high IL-21R expression 
(cluster 1 and 2) and in addition with CXCR3 (cluster 3) whereas the decreased cluster 7 
was characterized mainly by high expression of CCR7. As observed in the manual analysis 
(Figure 4), longitudinal changes of the identified Ward subsets were only apparent in the 
early ART group (Figure 5D). Interestingly, the increase of clusters expressing high levels of 
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CXCR3 and decreased frequencies of clusters with high CCR7 expression seem to develop 
longitudinally during ongoing viral replication and most pronounced differences occur at 2 
years of chronic infection, the latest time point measured in our study. This again 
emphasizes that with prolonged HIV infection the already reduced CCR7 levels of CD21- 
naïve B cells decrease whereas clusters associated with markers expressed in inflammatory 
environment such as CXCR3, CXCR4, IL-21R as well as CD19 increase.  
Importantly, the clustering analysis reveals that the altered expression of the markers is not 
evenly distributed but is linked to phenotypically distinct subsets of CD21- naïve B cells which 
emerge or decline during HIV-1 infection. These results highlight that within CD21- naïve B 
cells a high variability of different subsets exists. In this respect it is interesting to note that 
during HIV-1 infection CD21- naïve B cells with a phenotype of CCR7-CXCR3highCXCR5+IL-
21R-CXCR4+CD19high (cluster 5) and CCR7-CXCR3+CXCR5-IL-21R+CXCR4highCD19high 
(cluster 3) emerge emphasizing that subpopulations within CD21- naïve B cells with the 
ability to migrate towards inflamed tissues but excluded from lymphoid tissues and to some 
extent with higher sensitivity to IL-21 and BCR signaling are developed. While the precise 
function of these subsets needs to be further investigated, their presence highlights that HIV 
infection results in  emergence of unique CD21- naïve B cell subsets. 
 
5.3.7 CD21neg naïve and CD21neg MZ B cells have distinct functional properties 
The emergence of anergic naïve B cells with reduced responsiveness to activation has been 
documented in healthy donors but also in the context of autoimmunity, primary 
immunodeficiency or viral diseases (58-61). These cells are sometimes linked to reduced 
expression of CD21 and increased levels of CD19 along with other markers (58, 60, 72). One 
of these observed anergic naïve B cell populations is characterized by loss of surface IgM 
expression whether this is also  linked with lower CD21 expression levels remains unclear 
(80). In order to probe if CD21- naïve B cells and CD21- MZ B cells share similarities with 
anergic B cells, we analyzed IgM, CD95 and FcRL4 expression in a set of chronically HIV-1 
infected individuals ( N= 7) and healthy controls (N= 29) (Figure 6A and B). CD21- naïve B 
cells showed low frequencies of IgMlow B cells and therefore can be classified as naïve B 
cells based on co-expression of IgD and the lack of CD27 (Figure 6A and B and 
Supplementary figure 2). Interestingly, healthy controls had higher levels of IgMlow cells within 
the CD21+ naïve B cells compared to HIV-infection. CD95 expression is elevated in activated 
B cells and renders them permissive to cell death signals through Fas ligand (41, 81, 82). 
FcRL4 is reported to be up-regulated in exhausted memory B cells and widely used to 
determine exhausted B cells in the context of infectious diseases (38, 39, 41, 44). When we 
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examined the expression of these two markers on the different memory B cell subsets we 
observed, as expected, that CD95 and FcRL4 are highly expressed on AM and TLM and to 
lower extent on IM and RM B cells. However, only CD95 is upregulated with disease 
progression (Supplementary figure 8). CD21+ and CD21- naïve and CD21- MZ B cells also 
showed elevated levels of CD95 compared to healthy controls already in acute HIV-1 
infection, emphasizing that activation of naïve and MZ B cells must occur early after 
transmission. Similarly FcRL4 was s increased in CD21+ and CD21- MZ B cells during the 
acute phase. Importantly, ART successfully reduced CD95 and FcRL4 to healthy donor 
levels.   
Interestingly, FcRL4 was upregulated only on CD21- but not on CD21+ naïve B cells starting 
with the acute phase of HIV infection (Figure 6B). Comparisons of CD21+ and CD21- naïve or 
CD21+ and CD21- MZ B cells in healthy controls or at chronic stage of HIV disease further 
highlighted that CD95 and FcRL4 are expressed at higher levels in CD21- naïve and CD21- 
MZ B cells compared to the respective CD21+ subsets (Figure 6C).  
In sum our analyses highlighted that CD21- naïve B cells are classical naïve B cells based on 
their expression of IgD and IgM, but based on their increased expression levels of CD95 and 
FcRL4 emphasize that CD21- naïve B cells experienced recent activation events. The latter 
is also true for CD21- MZ B cells.  
As dependent on the strength of the activation signal proliferation can be induced, we next 
probed whether CD21- naïve and CD21- MZ B cells entered cell cycling and proliferation. In 
line with their activation marker expression, CD21- naïve and CD21- MZ B cells showed 
significantly increased expression of the proliferation marker Ki-67 in healthy donors (Figure 
6D and E). Interestingly though, the same was not true for HIV-1 infection likely due to the 
fact that there also CD21+ subsets had elevated proliferation compared to healthy donors 
supporting the notion of a generalized immune activation.  
Since CD21- naïve and CD21- MZ B cells showed an increased expression of CD95 
rendering these cells sensitive to extrinsic pro-apoptotic signals we next investigated whether 
these cells are apoptotic ex vivo. To do this we analyzed two major events during apoptosis, 
the cleavage of caspase 3 and the exposure of phosphatidylserine on the outer leaflet of the 
cell membrane by flow cytometry. Indeed, CD21- naïve and CD21- MZ B cells showed higher 
frequencies of  
caspase 3+Annexin V+ apoptotic cells (Figure 6F and G). Interestingly, in chronic HIV-1 
infection CD21- naïve B cells portrayed a higher frequency of apoptotic cells emphasizing 
that chronic HIV infection drives programmed cell death in naïve B cells (figure 6F and G).  
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5.3.8 Reduced potential for stimulation of CD21neg naïve and CD21neg MZ B cells  
To probe if CD21- naïve and CD21- MZ B cells are anergic we next tested their potential to 
respond to B cell receptor-dependent stimulation. To do this we applied phosflow (83), to 
measure tyrosine phosphorylation on untreated or upon anti-IgA/-IgM/-IgG stimulation in 
CD21+ and CD21- naïve and CD21- MZ B cells, as well as memory B cell subsets (IM, RM, 
AM, TLM) as defined by CD21 and CD27 expression (figure 7A-C). RM B cells, known to be 
in a quiescent state, had the highest potential to respond to stimulation (Fig 7B and C). As 
expected from their described exhausted phenotype TLM B cells (CD21-CD27-) showed in 
both, healthy controls and HIV-1 infection a decreased ability to respond to BCR cross-
linking compared to other memory B cell subsets (Figure 7B and C). Of note basal 
phosphorylation levels were increased in the two activated and exhausted memory B cell 
subsets AM and TLM, proving that these cells experienced recent stimulation in vivo (Figure 
7B and C). Similarly, compared to CD21+ cells, CD21- naïve and CD21- MZ B cells showed 
increased basal phosphorylation in both, healthy and HIV-infected individuals emphasizing 
that these B cell subsets underwent recent activation-induced phosphorylation in vivo (Figure 
7C). In line with this, CD21- naïve B cells had a diminished response to stimulation compared 
to CD21+ naïve B cells, suggesting that CD21+ naïve B cells are in an anergic state (Figure 
7C). CD21- and CD21+ MZ B cells were indistinguishable in their response to BCR triggering 
in healthy donors while in HIV-1 infected patients CD21- MZ B cells showed a reduced 
phosphorylation (Figure 7C). A direct comparison of the activation potential of memory B cell 
subsets healthy and HIV-1 infected donors confirmed that HIV-infection impaired the 
stimulation potential in memory B cell subsets with an activated phenotype, AM, TLM and 
CD21- MZ B cells but not in resting memory cells such as RM and IM B cells and CD21+ MZ 
B cells( Figure 7D). Thus while the stimulation potential of  CD21- naïve B cells is genuinely 
reduced, HIV-1 infection does not augment this deficiency.  
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5.4 Discussion 
HIV-1 infection is accompanied by altered frequencies of B cell subsets with increased levels 
of transitional B cells and plasmablasts in addition to skewed memory B cell compartment 
towards activated and exhausted phenotypes (38, 41, 42, 70, 84, 85). In the present study 
we build on these observations by exploring to what extent perturbations in other B cell 
subsets exist. To do this we performed a detailed phenotypic analysis using multi-
dimensional 16-parameter flow cytometry of peripheral B cells from 21 HIV-1 infected and 29 
healthy donors. The comprehensive data on multiple parameters collected in these analyses 
enabled us to define B cell subset signatures associated with progressing HIV-1 infection 
(Figure 1D). Most importantly our high-content analysis revealed that the complexity of B cell 
subsets is higher than thus far appreciated (Figures 1A and Supplementary Figure 3). As we 
show here, amongst CD10+ cells a memory B cell-like subsets exists that expresses CD27, 
IgG1, IgG3 and IgA but no IgD and only low levels of CD38 as classical memory B cells do 
(Figures 1A and Supplementary Figure 3A and B) suggesting that these cells are closely 
related to the maturation state of memory B cells.  
Increased frequencies of CD21- activated (AM) and exhausted (TLM) memory B cells are 
considered a hallmark of HIV-1 infection (38-40, 42). As we show here for the first time, 
reduction of CD21 expression is not limited to these subsets, as in chronic HIV infection a 
substantial proportion of naïve and MZ B cells also lack CD21 (Figure 1B and C).  Intriguingly 
increased frequencies of CD21- naïve B cells are described in common variable 
immunodeficiency (CVID) and different autoimmune disorders such as systemic lupus 
erythematosus, rheumatoid arthritis and thrombocytopenia but can also be found in healthy 
subjects at low frequencies (58-61). These cells are described to express high levels of 
activation markers such as CD95 and are characterized by decreased responses to B cell 
activation through BCR cross-linking in vitro with diminished calcium flux (58, 59). In contrast 
to their decreased proliferation upon stimulation in vitro, these CD21- naïve B cells have been 
shown to have an increased history of stimulation induced proliferation in vivo (58). The 
CD21- naïve B cells we identified in HIV infection resemble this pattern. They express high 
levels of activation and exhaustion marker CD95 and FcRL4, respectively, are characterized 
by altered chemokine receptor expression patterns with down-regulation of CCR7 and 
CXCR5 and increased levels of CXCR3 and show diminished phosphorylation upon BCR 
cross-linking compared to CD21+ naïve B cells (Figure 3A and B and 7A-C). In healthy 
controls proliferating Ki-67+CD21- naïve B cells are increased (Figure 6D and E). Interestingly, 
in chronic HIV infection CD21+ naïve B cells show increased frequencies of Ki-67-expressing 
cells to comparable levels as CD21- naïve and MZ B cells emphasizing that a fraction of 
classical CD21+ naïve B cells get activated in chronic HIV infection and undergo proliferation. 
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Collectively thus, CD21- naïve B cells in HIV infection show high similarities with the CD21- 
naïve B cell subsets described in autoimmune diseases highlighting that this is a genuinely 
interesting B cell subset that needs to be considered in future studies. In this respect 
resolving whether or not CD21- naïve B cells evolve from classical CD21+ naïve B cells upon 
a base level activation or have individual development paths will be of particular interest.  
CD21- MZ B cells show a similar phenotype as observed for CD21- naïve B cells and are 
therefore likely to be activated and exhausted similar to CD21- naïve B cells and other CD21- 
memory B cell subsets (Figure 3). There are only few reports describing aberrant MZ B cell 
responses associated with a CD21- phenotype. In chronic Hepatitis C virus infection CD21- 
MZ B cell with similar impaired functional consequences as observed in CD21- naïve B cells 
were described (74). The strong association of CD21- MZ B cells with CD4 counts and viral 
load in chronic HIV infection we observed suggests that the activation and exhaustion state 
of these cells is directly linked with virus-induced immune activation (Figure 2). This is 
supported by the fact that human MZ B cells exhibit a memory B cell phenotype and likewise 
frequencies of the CD21- memory B cell subsets AM and TLM are highly associated with 
virus replication and CD4 T cell levels similar to CD21- MZ B cells ((86) and chapter 6).  
Interestingly, we found that in contrast the appearance of CD21- naïve B cells does not 
correlate with viral load, CD4 counts and plasma IgG concentration, possibly suggesting that 
the alterations in the naïve B cells happens early in HIV infection and is not linked with 
disease progression. HIV-1 infection is nevertheless a driving factor of increased CD21- 
naïve B cells as ART successfully restores healthy donor levels (Figure 1C).  
CD21- naïve B cells show reduced levels of receptors for IL-21, a crucial cytokine for GC 
survival, retention and affinity maturation but also for the formation of memory B cells and 
plasmablasts (Figure 3A and B) (87-92). Decreased IL-21R levels thus should render CD21- 
naïve B cells less efficient to undergo GC reaction and thus impact on the development of 
effective antibody responses and might also result in reduced survival signals. Together with 
the down-regulation of CCR7 and CXCR5 which also reduce the migratory capacity, down-
regulation of IL-21R may be a further mechanism of immune tolerance by excluding these 
cells from generating high-affinity antibodies and reduce survival signal from IL-21. In support 
of this, human STAT3-deficiency, the canonical pathway downstream of IL-21R signaling, is 
associated with impaired development of antigen-specific memory B cells and plasmablasts 
(93). However, as our clustering analysis highlights, IL-21R is not downregulated in the entire 
CD21- naïve B cell compartment as subsets exist in chronic HIV-1 infection that expressing 
high levels of IL-21R and thus should have the potential to undergo IL-21 dependent affinity 
maturation (Figure 5A-D).  
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The increase of IL-21R levels we observed in CD21- MZ B cells during chronic HIV infection 
is intriguing (Figure 3C-D and Supplementary figure 5A and B). IL-21 has been reported to 
have divergent effects on MZ B cells and was found to be associated with cell death in mice 
and increased affinity maturation in humans (94-96). Decreased peripheral MZ B cell 
frequencies in STAT-3 deficient humans highlighted the importance of IL-21 for MZ B cell 
homeostasis (95). An increased expression of IL-21R as we observed in HIV infection, 
therefore possibility suggests that these CD21- MZ B cells may have gained improved 
sensitivity to IL-21 which likely impacts on subsequent affinity maturation and class-switch 
recombination in HIV infection. As IL-21 concentrations are decreased in chronic HIV 
infection (97, 98), up-regulation of IL-21R might potentially serve as a compensation to 
receive sufficient signals for survival and activation. Future studies that resolve the causal 
relationship of increased IL-21R expression on the quality of antibody responses and the 
functional properties of the IL-21Rhigh CD21- naïve B cell subsets will thus be of high interest. 
HIV-1 infection is associated with impaired antibody responses against other pathogens and 
vaccines (24-34). Interestingly, a recent study revealed that HIV-infected patients with CD4 
counts less than 350/µl lack IgM responses to Influenza vaccine whereas IgG responses 
could be induced, however at lower magnitude (99, 100). IgG responses may in part stem 
from reactivation of memory B cells, while early IgM responses are elicited de novo and 
therefore suggesting an intrinsic defect of naïve B cells in mounting IgM responses (99, 101). 
Indeed as we show here, a large pool of naïve B cells is anergic and therefore likely to show 
impaired antigen responses (Figure 7A-C).  
Of note, immune responses against bacterial polysaccharides are in most cases dependent 
on marginal zone B cells as well as secreted IgM (102, 103) and splenectomy has been 
linked with higher risk of infections with bacterial pathogens such as Streptococcus 
pneumoniae (102-104). Infections associated with dramatic alterations of the B cell 
compartment such as HIV-1 are known to show reduced responses against polysaccharide-
based vaccines and are associated with increased risk of bacterial co-infections, however, 
the reasons for this defect have thus far been unclear (28, 29, 32, 105-107). The extensive 
emergence of non-responsive CD21- MZ B cells that we demonstrate here may be a 
plausible explanation for these impaired responses.  
To elucidate the phenotypic diversity within CD21- naïve B cells we employed the clustering 
algorithm SPADE combined with hierarchical clustering using the Ward method which 
revealed 10 distinct CD21- naïve B cell clusters in healthy and HIV-1 infected donors (5A-C 
and Supplementary figure 6A and B). While the functional properties of these clusters need 
to be determined, their differential expression profiles raise the possibility that for certain 
clusters also a functional heterogeneity may exist. More closely related clusters may however 
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rather represent CD21- naïve B cell at different developmental stages and thus rather display 
the gradual loss/gain of certain receptor without a directly linked change in functionality. 
Dissection of potential functional differences and developmental pathways will be important 
future avenues of research leading to an improved understanding of the role of CD21- naïve 
B cell in immune responses. Importantly, judging from the receptor expression of the diverse 
CD21- naïve B cell clusters CD21- naïve B cells exist which maintained the capacity to 
migrate towards diverse inflamed tissues and preserved IL-21R to retain responsiveness to 
IL-21 mediated signaling. Of further note, the enriched subsets during chronic HIV-1 infection 
were widely characterized by high levels of CXCR4 and CD19 in combination with low or no 
levels of CCR7.  
Interestingly, poly- and autoreactive BCR have been described to be enriched within CD21- B 
cells in healthy controls and patients with autoimmune diseases (59, 76) and moreover were 
described to be in an anergic state (58, 59, 76). The frequency of polyreactive BCR within 
CD21- naïve B cells in HIV infection needs to be determined. Considering that CD21- B cells 
in HIV-1 infection have strong phenotypic and functional similarities with B cells in 
autoimmune diseases raises the possibility that poly- and autoreactive BCR are also 
prevalent amongst CD21- B cells in HIV infection. If the HIV-associated excessive immune 
activation leads to elevated frequencies of polyreactive CD21- naïve B cells this could lead to 
alterations in immune tolerance checkpoints similar to autoimmune diseases (59, 76). In 
further support of such a scenario, transitional B cells, which are elevated in HIV-1 infection, 
are known to show high frequencies of polyreactive BCR and require peripheral immune 
tolerance mechanism to silence these cells before developing into naïve B cells (57, 108-
110). IL-7 and BAFF, two important factors supporting B cell survival during B cell 
development and maintenance, are elevated in HIV-1 infected individuals (57, 111, 112). IL-7 
in particular supports the egress of transitional B cells from bone marrow (57, 113, 114) and 
both, the increased levels of IL-7 and BAFF are thus likely to support survival of autoreactive 
B cell clones in the periphery (115, 116). 
Of particular relevance in HIV-1 infection, poly- and/or autoreactivity is a common feature of 
many neutralizing antibodies and bnAbs in HIV-1 infection (62, 117-121). For some, e.g., the 
MPER-directed bnAbs 2F5 and 4E10 autoreactivity appears to be in part linked with their 
neutralization activity (63, 118, 122). Polyreactivity has been suggested to aid the 
development of neutralizing antibody responses as it promotes heteroligation and increased 
affinity of HIV-1 envelope specific antibodies (63). However, elicitation of polyreactive bnAbs 
requires a concerted action of immune tolerance mechanisms and may thus be rare (123-
128). Recent reports of co-evolution of viral diversification, autologous antibody response 
and development of bnAbs showed that polyreactivity developed during affinity maturation (8, 
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63) in line with the observation that many memory B cells acquire polyreactivity during GC 
reaction (108, 129). The potential roles of CD21- naïve and CD21- MZ B cells in the elicitation 
of potent HIV-specific antibody responses will thus be important to define specifically as both 
have a lowered responsiveness to stimulation (Figure 7). In support of potential role, a recent 
report from Tipton et al. demonstrates that a large fraction of plasmablasts and IgM+ memory 
B cells in the periphery of SLE patients are derived from so-called activated naïve B cells 
with a phenotype comparable with the CD21- naïve B cells described in our study (60). These 
activated naïve B cells showed increased polyreactivity, a remarkable frequency of SHM and 
the ability to develop into large clones. Whether these activated naïve B cells participate in 
GC reaction or go through extrafollicular pathways has not yet been investigated. 
Nevertheless these observations are highly intriguing, highlighting that activated CD21- naïve 
B cells can undergo evolution towards B cell receptors with higher affinities as demonstrated 
by SHM and their ability to develop into large clusters of antibody-secreting effector cells. To 
explore this potential pathway in HIV-1 infection, dedicated studies will be needed to dissect 
whether CD21- naïve B cells in HIV-1 infection are likewise able to undergo SHM and CSR 
and, develop into effector cells. 
The seeming dichotomy of observations with on the one hand CD21- naïve B cells exhibiting 
reduced response to BCR stimulation and the expansion to large clonal families observed in 
SLE patients remains puzzling (59, 60). The breakdown of immune tolerance checkpoints in 
autoimmune diseases may result in higher frequencies of polyreactive B cells in the 
periphery. Activation of their BCR with their cognate autoantigen may aid there survival and 
allow to at least partially overcome the anergic state. In line with this tonic BCR signals are 
known to be important to support survival of mature B cells (130). In contrast in HIV-1 the 
emergence of CD21- naïve B cells are most likely driven by antigen-independent bystander 
activation which may be less efficient than activation with a cognate antigen. The decisive 
factor whether CD21- naïve B cells overcome their anergic state and induce potent antibody 
responses might be the duration and/or quality and pathway of activation. In addition, T cell 
help in HIV infection is defective and therefore not capable providing sufficient help to 
overcome the anergic state of CD21- naïve and CD21- MZ B cells. In support of a reduced 
capacity to adequately respond to antigen the lower efficacy of vaccines in HIV-infected 
patients can be overcome by administering more series of booster vaccinations  (106, 131).  
In summary, our comprehensive analysis of the B cell compartment in HIV-infection revealed 
a number of signatures associated with chronic immune activation, most importantly anergic 
naïve and MZ B cells that are characterized by down-regulation of CD21 and changed 
chemokine and IL-21R expression pattern which have thus far not been described in HIV-1 
infection. Unraveling the role of  CD21- naïve  and MZ B cells together with other B cell 
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clusters in the development of humoral immune responses will be critical for understanding 
pathogenic changes of the immune system in HIV-1 infection and accordingly tailor 
preventive and therapeutic vaccine approaches.  
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5.5 Methods 
 
Clinical specimen 
Cryopreserved peripheral blood mononuclear cells (PBMC) and plasma of HIV-1 infected 
individuals were available from samples stored in the biobank of the Zurich Primary HIV 
Infection Study (ZPHI). The ZPHI is an ongoing, observational, nonrandomized, single center 
cohort founded in 2002 that specifically enrolls patients with documented acute or recent 
primary HIV-1 infection (ClinicalTrials.gov identifier NCT00537966) (132). The ZPHI is 
approved by the ethics committee of the Kantonale Ethikkommission Zürich and written 
informed consent was obtained from all participants. Longitudinal samples of patients that 
started ART early (during the acute infection stage, n=11) and late (in the chronic infection 
stage, n=10) were analyzed and included samples from the untreated acute and chronic 
stage and after 1 year of ART (Supplementary table 1 and 2). A separate set of patients were 
analyzed during the chronic infection stage for functional disturbance in B cell subsets 
(Figure 6F and 7, Supplementary table 1 and 2). Patient and disease demographics 
(estimated time of infection, CD4 cell count and plasma viral load level at sampling date) 
were available through the ZPHI data bank.   
PBMC and plasma from healthy donors (n=21) were collected in the frame of a separate 
clinical study (PI H. Günthard) that was approved by the ethics committee of the Kantonale 
Ethikkommission Zürich and written informed consent was obtained from all participants.  
PBMC were isolated by density-gradient centrifugation using LymphoPrep (Axis-Shield) from 
whole blood drawn in EDTA vacutainer tubes (BD Biosciences). Until further processing 
PBMC were cryopreserved using 90% inactivated FCS (Thermo Fisher Scientific) and 10% 
DMSO (Sigma Aldrich) and stored in liquid nitrogen. Plasma was heat-inactivated for 1h at 
56°C and stored at -80°C for further analysis. 
 
Flow cytometry 
To monitor B cell populations by flow cytometry PBMC were stained using a 16-parameter 
panel as described (Liechti, T. et al. manuscript in preparation, Chapter 4). Briefly, cells were 
thawed and washed with FACS buffer containing PBS (Thermo Fisher Scientific), 2% heat-
inactivated FCS (Thermo Fisher Scientific), 2mM EDTA (Sigma Aldrich) and 20µg/ml DNase 
(Sigma Aldrich), stained with a cocktail of antibodies directed against surface markers 
encompassing CD3 APC-Cy7 (clone SK7, Biolegend), CD14 APC-Cy7 (clone HCD14, 
Biolegend), CD16 APC-Cy7 (clone 3G8, Biolegend), CD10 BV650 (clone HI10a, BD 
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Pharmingen), CD19 BV786 (clone SJ25C1, BD Pharmingen), CD21 BV711 (clone B-ly4m 
BD Pharmingen), CD27 PE-CF594 (clone M-T271, BD Pharmingen), CD38 AF700 (clone 
HIT2, Biolegend), IgG1 PE (clone HP6001, Southern Biotech), IgG3 FITC (polyclonal sheep 
IgG, AbD Serotec), IgA APC (polyclonal goat IgG, Jackson Immuno), CCR7 BV605 (clone 
G043H7, Biolegend), CXCR3 PE-Cy7 (clone G025H7, Biolegend), CXCR5 BV510 (clone 
RF8B2, BD Pharmingen), IL-21R BV421 (clone 2G1-K12, Biolegend)  and Live/dead near-
infrared dye (Life Technologies). IgD (clone IA6-2, Biolegend) and CXCR4 (clone 12G5, 
Biolegend) were labelled in-house with labeling kits for PE-Cy5 (Innova Biosciences) and 
PE-Cy5.5 (Innova Biosciences), respectively, according to the manufacturer’s instructions. 
Each new batch of labeled antibodies was titrated in parallel with and adjusted to the old 
batch to ascertain comparable staining intensities. Cells were afterwards fixed and 
permeabilized with the FoxP3 staining kit (eBioscience) according to manufacturer’s 
instructions to stain for Ki-67 PerCP-eFluor710 (clone 20Raj1, eBioscience). Data was 
acquired on a BD Fortessa calibrated daily using the CS&T module. Staining intensity QC 
was conducted as recommended (133) and individual stainings with markers that did not fulfil 
requirements excluded when comparative analysis of intensities was performed 
(Supplementary figure 1). To further limit the possibility of influences due to day-to-day 
variability in the flow cytometry analysis, all longitudinally time points of a given patient were 
analyzed at the same day. In addition patients assigned to the early and late ART group 
were included in all experiments to exclude batch effects.   
The staining to analyze IgM, CD95 and FcRL4 expression was performed with the same 
protocol but with a smaller panel including Live/dead near-infrared dye (Life Technologies), 
CD19 BV510 (clone SJ25C1, BD Pharmingen), IgM FITC (polyclonal goat, Caltag), CD95 
BV421 (clone DX2, Biolegend), FcRL4 PE (clone 413D12, Biolegend), IgD APC (clone IA6-2, 
Biolegend), CD21 BV711 (clone B-ly4, BD Pharmingen), CD27 PE-CF594 (clone M-T271, 
BD Pharmingen), IgG PE-Cy7 (clone G18-145, BD Pharmingen), CD10 BV650 (clone HI10a, 
BD Pharmingen) and CD38 AF700 (clone HIT2, Biolegend).   
 
Clustering analysis 
The diversity of CD21- naïve B cells was assessed using the clustering algorithm SPADE 
(spanning-tree progression analysis of density-normalized events) integrated into the 
cytometry analysis platform Cytobank (134). 17 of the 21 analyzed HIV-infected patients 
were included in the clustering analysis. Two patients had to be excluded as no sample from 
the acute time point was available, two patients were excluded due to staining patterns 
resulting in unusual clustering results. As reference 15 healthy controls were included in the 
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analysis. Clustering was done using pre-gated CD21- naïve B cells including all recorded 
events. Target number of expected nodes was set to 200 and down-sampling to 2%. In order 
to analyze total longitudinal changes of CD21- naïve B cells the flow cytometry files of the 
individual time points or the control group were concatenated and integrated into the 
clustering. Clustering was based on the markers CCR7, CXCR3, CXCR5 and IL-21R. CD19 
was not included due its unimodal expression profile. CXCR4 was not included due to 
variability in staining intensity. 
We chose a setting of over-clustering, by allowing for 200 different clusters as this allows to 
build separate clusters of very rare cell populations. As a consequence frequent cell 
populations can separate into different clusters despite sharing phenotypic properties. 
Therefore, clusters created by SPADE were further clustered using hierarchical clustering 
with the Ward method in R and visualized with the hetmap.2 function. For Ward clustering 
and visualization, the SPADE output (z-transformed arcsinh median fluorescence intensities 
of individual clusters) of the concatenated chronic 2 year samples was used due to the fact 
that this measurement encompassed the highest frequency of CD21- naïve B cells and 
therefore all SPADE clusters should contain cell events. Importantly, Ward clustering is 
based on the same markers used for SPADE clustering. CXCR4 and CD19 expression of the 
SPADE clusters was visualized to investigate the expression profile of these two markers on 
SPADE and Ward clusters. Based on the hierarchical tree generated by Ward clustering a 
total of 10 main clusters could be defined. For manual analysis, the SPADE clusters of the 
concatenated chronic 2 year samples were again concatenated according to the Ward 
cluster classification. The cell events of these Ward clusters were further analyzed in FlowJo 
version 10 (Treestar) to assess the unique expression profile of the Ward clusters. 
 
IgG ELISA 
Total immunoglobulin concentrations in heat-inactivated plasma from the HIV-1 infected 
patients (Supplementary table 2) were measured by enzyme-linked immunosorbent assay 
(ELISA) as described previously (135). Briefly, 96 well immunosorbent plates (Thermo Fisher 
Scientific) were coated with polyclonal goat anti-human IgG (2µg/ml; Southern Biotech) in 
sodium carbonate buffer pH8.2 for 2 hours at room temperature. PBS/2% BSA (Sigma 
Aldrich) was used as a blocking reagent for 30 minutes at 37°C. Serial dilutions of the 
plasma samples were applied to the plates and incubated for 2 hours at room temperature. 
Plasma IgG was detected using a biotinylated polyclonal goat anti-human IgG (southern 
Biotech; 2 ng/ml) followed by streptavidin-alkaline phosphatase (Sigma Aldrich, 40ng/ml) 
each diluted in PBS/2% BSA and incubated for 1 hour at room temperature. CDP-Star 
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system (Applied Biosystems) was used as alkaline phosphatase substrate and luminescence 
was measured after 30min with a Dynex luminometer (Magellan Biosciences). Human IgG 
(Sigma Aldrich) was used as a standard to determine the concentration of plasma IgG. 
 
Expression of apoptosis markers 
Cryopreserved PBMC from 10 healthy controls and 10 chronically infected patients were 
analyzed for the frequency of apoptotic cells within the different B cell subsets 
(Supplementary table 2). Cells were stained with antibodies CD19 biotin (clone HIB19, BD 
Pharmingen), CD21 PE (clone B-ly4, BD Pharmingen), CD27 PE-CF594 (clone M-T271, BD 
Pharmingen), IgD PE-Cy7 (clone IA6-2, Biolegend) and Live/Dead near-infrared (Life 
Technologies). CD19 was detected by using BV421-conjugated streptavidin (Biolegend). The 
apoptosis markers cleaved caspase 3 inhibitor FITC-C6-DEVD-FMK (AAT Bioquest) and 
Annexin V APC (BD Pharmingen) stainings were performed according to the manufacturer’s 
protocol. Samples were analyzed either on a FACS Aria III or a BD FACS Verse immediately 
after staining and analyzed with FlowJo version 10. Apoptotic cells were defined as double 
positive for Annexin V and FITC-C6-DEVD-FMK (136).  
 
Phosflow analysis 
PBMC were rested after thawing for 4 hours in RPMI medium without supplements and 
incubated in RPMI containing Live/Dead near-infrared dye (Life Technologies) for 20 minutes 
at room temperature. Cells were washed and split in two wells and resuspended in either 
only RPMI for the unstimulated sample or in RPMI containing 10µg/ml goat anti-human 
IgG/IgA/IgM f(ab)2 (Jackson Immuno). Stimulation was done for 5 minutes including a 2 
minute centrifugation step to remove the medium followed by addition of the fixation and 
permeabilization solution of the Foxp3 staining kit according to manufacturer’s instructions 
(eBiosciences). Cells were fixed and permeabilized for 45 minutes at 4°C and afterwards 
stained with CD3 APC-Cy7 (clone SK7, Biolegend), CD14 APC-Cy7 (clone HCD14, 
Biolegend), CD16 APC-Cy7 (clone 2G8, Biolegend), CD10 PE-Cy5 (clone HI10a, BD 
Pharmingen), CD19 BV510 (clone SJ25C1, BD Pharmingen), CD21 BV711 (clone B-ly4, BD 
Pharmingen), CD27 PE-CF594 (clone M-T271, BD Pharmingen), IgD APC (clone IA6-2, 
Biolegend) and PE-labeled antibody specific for intracellular phosphorylated tyrosine motifs 
(clone PY20, BD Pharmingen) for 30 minutes at room temperature. Cells were extensively 
washed and measured using a BD Fortessa. Analysis was done with with FlowJo 10 
(TreeStar). 
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Statistical analysis 
B cell subset frequencies of HIV-1 infected individuals at different disease stages and healthy 
donors were compared with unpaired one-way ANOVA (Kruskal-Wallis test) and Dunn’s 
multiple testing correction (Figures 1A-C; 4, 5, 6C, Supplementary table 3 and 
Supplementary Figure 8). For comparison of longitudinal phenotypic changes non-parametric 
matched Friedman test and Dunn’s multiple testing correction test was used to compare time 
points within the study groups (Figures 1A-C, 5D, 6B and Supplementary Figure 8). 
Correlation analysis of infected patients and healthy controls was done by Spearman 
correlation (Figure 1A-C). Linear regression was used to analyze correlation of CD21- and 
CD21+ naïve and CD21- and CD21+ MZ B cells with clinical parameters (Figure 2). 
Phenotypic comparisons between CD21- and CD21+ naïve or  CD21- and CD21+ MZ B cell 
subsets within the same patients was done by Wilcoxon matched-pairs signed rank test 
(Figure 3B, 6C-G and 7C) and between healthy donors and HIV-1 infected patients using the 
Mann-Whitney test (Figure 3C-E, 6C-G, 7D). Friedman test and Dunn’s multiple testing 
correction test was used to compare different memory B cell subsets from the same donor in 
Figure 7C. Statistical analysis was done with Prism (GraphPad) and P values less than 0.05 
were considered statistically significant. Heatmaps and hierarchical clustering were 
generated with heatmap.2 function in R version 3.3.1 (https://r-project.org/) and the interface 
R studio. SPADE clustering analysis was performed using Cytobank. 
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5.6 Figure legends 
 
Figure 1: B cell subset changes during HIV infection.  
(A) Frequencies of main B cell subsets, (B) memory B cell subsets and (C) CD21- naïve and 
CD21- MZ B cells from healthy donors (n=29) and HIV-1 infected patients (n=19) at acute 
and chronic (2 years of continuous virus replication) disease stage and after 1 year of ART 
are shown. (D) Spearman correlation of healthy donors (n=29) and chronically infected 
patients (n=21) based on subset frequencies shown in figure 1A-C is depicted. The 
dendrogram is colored according to the cut-off used to define patient clsuters. (E) 
Comparison of clinical parameters from the patient clusters (Healthy, Chronic and 
Intermediate) identified with hierarchical clustering of spearman correlation in Figure 1D was 
performed. Non-parametric unpaired Kruskal-Wallis test was used to compare healthy 
controls and HIV-1 infected patients and comparison of patient clusters. Longitudinal analysis 
of HIV-1 infected patients was done using non-paramtetric paired Friedman’s test. Dunn’s 
multiple comparison test was performed to correct for multiple testing. P<0.05 was 
considered statistically significant. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
Figure 2: Correlation of CD21- naïve and CD21- MZ B cells 
Linear regression analysis of CD21- naïve and MZ B with CD4 counts, viral load and plasma 
IgG concentration in acute (n=19; n for correlation with CD4=11) and chronic HIV-1 infection 
(2 years of continuous virus replication; n=21; n for correlation with CD4=20) is shown. 
Regression coefficient r2 and p-values are indicated. P<0.05 was considered statistically 
significant. 
 
Figure 3: Phenotype of CD21- naïve and CD21- MZ B cells 
(A) Histogram overlays from flow cytometric analysis of CCR7, CXCR3, CXCR4, CXCR5, 
CD19 and IL-21R expression on CD21- and CD21+ naïve (darkred and red, respectively) and 
MZ B cells (darkblue and blue, respectively) from a chronic HIV-1 infected patient. Where 
applied FMO controls (grey) are shown. (B) Comparison of frequencies of CD21- (grey open 
circle) and CD21+ (black circle) naïve and MZ B cells expressing CCR7, CXCR3, CXCR4, 
CXCR5 and IL-21R in healthy controls (n=29) and chronically (2 years of continuous virus 
replication) HIV-1 infected patients (n=21) is depicted. (C) Differences of the same markers 
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between healthy (n=29) and chronically HIV-1 infected patients (n=21) are shown. ND; 
comparison not performed due to irregular staining as depicted in supplementary figure 1 
and described in the methods part. Median fluorescence intensity (MFI) fold change for (D) 
CCR7, CXCR3, CXCR4, CXCR5 and IL-21R and (E) CD19 between CD21- and CD21+ naïve 
or CD21- and CD21+ MZ B cells compared between healthy controls (n=29) and chronically 
HIV-1 infected patients (n=21) are shown. Comparison of CD21- and CD21+ naïve and MZ B 
cells within the same individual was done by Wilcoxon matched-pairs signed rank test. 
Mann-Whitney T test was used to test differences between healthy controls and chronically 
HIV-1 infected patients. P<0.05 was considered statistically significant. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
 
Figure 4: Longitudinal analysis of phenotypic markers on CD21- naïve and CD21- MZ B cells 
Longitudinal analysis of median fluorescence intensities of phenotypic marker expressed on 
CD21- naïve and MZ B cells are shown. HIV-1 infected patients were split in early ART group 
(closed circles; n=11) and late ART group (open circles, n=8). Matched-pair non-parametric 
one-way ANOVA Friedman test was used to compare MFI values within the study groups 
and non-paired non-parametric ANOVA Kruskal-Wallis test was used to compare MFI values 
between study groups. Dunn’s multiple comparison test was performed to correct for multiple 
testing. P<0.05 was considered statistically significant. *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 5: Computational clustering algorithm SPADE reveals heterogeneity of CD21- naïve B 
cells in chronic HIV infection 
(A) SPADE analysis of CD21- naïve B cells is shown from combined data of chronically HIV-
1 infected patients (n=17; chronic 2 years). The marker expression levels of the defined 
cluster are depicted as a gradient with yellow showing highest expression. Dot sizes 
correspond to cell counts of the individual clusters. (B) Expression of markers not used for 
clustering (CXCR4 and CD19) are shown within the SPADE tree. (C) Heatmap with 
expression profile of SPADE clusters ordered using Ward’s hierarchical clustering I shown. 
Similar SPADE clusters are merged in 10 Ward clusters and named 1-10 as shown in the 
heatmap. Dendrogram is colored according to the cut-off used to define Ward clusters. (D) 
Comparison of Ward cluster frequencies between healthy donors (black dots) and the 
different time points acute (blue), chronic 1 year (light red), chronic 2 years (dark red) and 
ART 1 year (grey) of HIV-1 infected patients are depicted. The latter were separated based 
on the study groups in early (closed dots) and late ART group (open circles). Matched-pair 
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non-parametric one-way ANOVA Friedman test was used to compare cluster frequencies 
within the study groups and non-paired non-parametric ANOVA Kruskal-Wallis test was used 
to compare frequencies between study groups and to healthy controls. Dunn’s multiple 
comparison test was used to perform multiple testing corrections. P values are shown. 
P<0.05 was considered statistically significant. *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 6: CD21- naïve CD21- MZ B cells express high levels of IgM and activation markers 
and contain increased frequencies of proliferating and apoptotic cells. 
(A) Example of flow cytometry data for IgM, CD95 and FcRL4 staining on CD21+ and CD21- 
naïve and CD21+ and CD21- MZ B cells of a chronic (2 years of active infection) HIV-1 
infected patient. Overlay of CD21- naïve and CD21- MZ B cells (red) and total B cells are 
shown in the top row. (B) IgM, CD95 and FcRL4 expression dynamics in CD21- and CD21+ 
naïve and CD21- and CD21+ MZ B cells are shown in percent negative and positive events in 
case of IgM and CD95 and FcRL4, respectively. Healthy controls (n=29) and HIV infected 
patients (n=6) are shown. Longitudinal changes in Figure 6B of HIV-1 infected patients were 
performed using matched-pair non-parametric one-way ANOVA Friedman test. To compare 
healthy controls with HIV-1 infected patients non-paired non-parametric ANOVA Kruskal-
Wallis test was used. To correct for multiple testing Dunn’s multiple comparison test was 
performed. (C) Direct comparison of IgM, CD95 and FcRL4 expression on CD21- and CD21+ 
naïve and CD21- and CD21+ MZ B cells in healthy subjects (n=29) and chronic HIV-infected 
patients (n=7) are shown. (D) Flow cytometry dot plots of Ki-67 expression on CD21- and 
CD21+ naïve and CD21- and CD21+ MZ B cells from a chronic (2 years of active infection) 
HIV-1 infected patient are depicted.  (E) Comparison of the intracellular expression of 
proliferation marker Ki-67 in CD21- and CD21+ naïve and CD21- and CD21+ MZ B cells in 
healthy controls (n=29) and chronic HIV-infected patients (n=21) is shown. (F) Example of 
flow cytometry dot plots of FITC labeled caspase 3 inhibitor FITC-C6-DEVD-FMK and 
Annexin V staining from a chronic (2 years of active infection) HIV-1 infected patient to 
determine the frequency of double-positive apoptotic CD21- and CD21+ naïve and CD21- and 
CD21+ MZ B cells. (G) Frequency of apoptotic CD21- and CD21+ naïve and MZ B cells are 
quantified in healthy controls (n=10) and chronic HIV-infected patients (n=10). Comparison of 
CD21- and CD21+ naïve or CD21- and CD21+ MZ B cells in Figure 6C, 6E and 6G were done 
using matched-pair non-parametric Wilcoxon signed rank test and comparison between 
healthy controls and HIV-infected patients by using unpaired non-parametric Mann-Whitney 
test. P<0.05 was considered statistically significant. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. 
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Figure 7: CD21- naïve and CD21- MZ B cells show impaired phosphorylation upon BCR-
dependent stimulation highlighting their anergic state. 
(A) Histogram overlays of flow cytometric phosflow analysis in unstimulated (black) and BCR 
cross-linking stimulated (blue) CD21- and CD21+ naïve and CD21- and CD21+ MZ B cells are 
shown from a healthy control. (B) Tyrosine phosphorylation was analyzed before and upon 
stimulation with anti-IgG/IgA/IgM in healthy subjects (n=10) and chronic HIV-1 infected 
patients (n=10) and visualized as a heatmap for CD21- and CD21+ naïve and CD21- and 
CD21+ MZ B cells and the four memory B cell subsets based on CD21 and CD27 expression, 
namely intermediate (IM; CD21+CD27-), resting (RM; CD21+CD27+), activated (AM; CD21-
CD27+) and tissue-like (TLM; CD21-CD27-) memory B cells. The color gradient indicates the 
log-transformed MFI values with yellow as highest phosphorylated tyrosine levels. (C) Total 
tyrosine phosphorylation MFI between CD21- naïve and CD21- MZ B cells at basal levels and 
upon stimulation are depicted for healthy subjects (n=10; grey dots) and chronic HIV-1 
infected patients (n=10; red dots). Memory B cell subsets are included as a control. (D) 
Direct comparison of total tyrosine phosphorylation MFI of CD21- and CD21+ naïve, CD21- 
and CD21+ MZ B cells and memory B cell subsets upon stimulation between healthy controls 
and chronic HIV-1 infected patients are depicted. Wilcoxon matched-pairs signed rank test 
was used to compare CD21- and CD21+ naïve and CD21- and CD21+ MZ B cells within 
healthy subjects and chronic HIV-1 infected patients. For the comparison between memory B 
cell subsets Kruskal-Wallis one-way ANOVA with Dunn’s multiple testing correction was used. 
To compare phosphorylation levels between healthy subjects and chronic HIV-1 infected 
patients Mann-Whitney T test was applied. P<0.05 was considered statistically significant. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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5.9 Supplementary table and figure legends 
 
Supplementary table 1: Characteristics of the early and late treatment groups 
Summary of the clinical characteristics of the HIV-1 infected patients for the time points 
analyzed are shown. Patients are separated into the study groups based on initiation of ART 
early ART and late ART group. aComparison was done between early ART group (weeks off 
ART) and late ART group (weeks of active replication) to compare the continuous period of 
active replication before chronic 2 year sample was collected. Differences between the study 
groups were calculated with Mann-Whitney test and considered statistically significant with a 
p value <0.05. 
 
Supplementary table 2: Patient characteristics 
Characteristics of the individual patients are shown and in addition the samples used for the 
different assays are depicted. 
 
Supplementary table 3: Comparison of Ward clusters between healthy donors and HIV-1 
infected patients 
Statistical results of comparison of Ward cluster frequencies between healthy controls (n=15) 
and the different time points of HIV-1 infected individuals (n=17) of both study groups as 
shown in figure 5. Non-paired non-parametric ANOVA Kruskal-Wallis test was used to 
compare frequencies of Ward cluster between study groups and healthy controls. Dunn’s 
multiple comparison test was used to perform multiple testing corrections. P values are 
shown. P<0.05 was considered statistically significant. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. 
 
Supplementary figure 1: Quality control of phenotypic markers for each sample.    
Median fluorescence signal intensities for phenotypic markers IL-21R, CCR7, CXCR3, 
CXCR4, CXCR5 and Ki-67 of all samples measured in this study are shown. Samples from 
each experiment are concatenated.  Where applied FMO control is shown. Irregular stainings 
as described in the method part are highlighted by blue and red background.  
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Supplementary figure 2: Gating strategy to identify B cell subsets.  
(A) Gating strategy to define main subsets of B cells (Dump-CD19+), which are transitional 
(CD10+CD38+IgD+; green gate), CD10+ memory (CD10+CD38lowIgD-; green gate), naïve  
(CD10-IgD+CD27-; blue gate), Marginal Zone (MZ) B cells (IgD+CD27+CD38low, blue gate) 
and class-switched B cells (IgD-CD38low, orange gate) and plasmablasts (IgD-CD38high, 
purple gate). Gating is shown with a healthy control sample. (B) Gating of CD21- and CD21+ 
naïve and MZ B cells as well as the definition of memory B cell subsets based on CD21 and 
CD27 expression, which includes intermediate memory (IM; CD21+CD27-), resting memory 
(RM; CD21+CD27+), activated memory (AM; CD21-CD27+) and tissue-like memory (CD21-
CD27-) B cells, are depicted from a healthy control and a chronic HIV-1 infected patient. 
 
Supplementary figure 3: Phenotypic characterization of CD10+ memory B cells. 
(A) Histogram overlay of CD27 expression on CD10-IgD+ B cells (grey) and CD10+ memory 
B cells from a healthy control is shown. (B) Percentage of CD27-expressing CD10+ memory 
B cells in healthy donors (n=29) is depicted. (C) Comparison of frequency of IgA+, IgG1+ and 
IgG3+ cells in CD10+ memory B cells (black dots) and class-switched B cells (CD10-IgD-
CD38low) in healthy donors (n=29) is shown. Mann-Whitney test was used to determine 
differences between class-switched and CD10+ memory B cells. 
 
Supplementary figure 4: Differences between patients with ART initiated during acute or 
chronic phase.  
(A) Comparison of main B cell subsets, (B) memory B cell subsets and (C) CD21- naïve and 
CD21- MZ B cells (C) between acute ART group (n=11; orange squares) and chronic ART 
group (n=10; blue dots) at different time points are shown. Differences were analyzed by 
using unpaired non-parametric Mann-Whitney test. P values are shown. (D) Comparison of 
CD10+ memory B cells between healthy donors (n=29) and early (n=11) and late (n=10) ART 
group is shown. Comparison was done to healthy controls with unpaired non-parametric 
ANOVA Kruskal-Wallis. Dunn’s multiple comparison test was used to perform multiple testing 
corrections. P<0.05 was considered statistically significant. *p<0.05, **p<0.01.  
 
Supplementary figure 5: CD21- naïve and CD21- MZ B cells exhibit a unique expression 
pattern of chemokine receptors, Il-21R and CD19. 
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(A) Flow cytometry dot plots and gating to estimate the frequency of CCR7-, CXCR3-, 
CXCR4-, CXCR5- and IL-21R-expressing CD21- and CD21+ naïve and CD21- and CD21+ MZ 
B cells and the corresponding FMO controls where applied are shown from one healthy 
control as an example. (B) Differences median fluorescence intensity between CD21+ and 
CD21- naïve (upper row) and CD21+ and CD21- MZ B cells (lower row) in healthy controls 
and chronic HIV-infected patients (2 years of active infection) are shown for CCR7, CXCR3, 
CXCR4, CXCR5, IL-21R and CD19. Comparison within patients was done using Wilcoxon 
matched-pairs signed rank test. Mann-Whitney T test was used to test differences between 
healthy controls and chronically HIV-infected patients. P<0.05 was considered statistically 
significant. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
Supplementary figure 6: Backgating of Ward clusters show unique phenotypes of the 
individual Ward clusters. 
(A) Expression levels of CCR7, CXCR3, CXCR4, CXCR5, IL-21R and CD19 on individual 
Ward cluster are shown as z-score of arcsinh transformed MFI values. Z-Scores <0.22 were 
indicates as negative (-) whereas intermediate expression levels were defined as 0.22<z-
score<1 (+). Z-scores >1 are considered as high expression levels (++). (B) FlowJo analysis 
to estimate the homogeneity of marker expression on Ward clusters are shown from the 
combined chronic HIV-1 infected patients (2 years of active replication). The first column 
shows contour plots of marker expression on CD21- naïve B cells and the subsequent 
columns depict the overlay of Ward cluster (red colored) on top of CD21- naïve B cells (grey 
colored). 
 
Supplementary figure 7: Correlation of marker expression on CD21- and CD21+ naïve and 
CD21- and CD21+ MZ B cells and clinical parameters. 
Spearman correlation of expression of CCR7, CXCR3, CXCR4, CXCR5 and IL-21R and in 
addition log-transformed viral load, plasma IgG levels (mg/ml) and CD4 counts are visualized 
with heatmaps for CD21- and CD21+ naïve and CD21- and CD21+ MZ B cells. P-values of 
spearman correlation calculation are shown and considered significant when p<0.05 and 
colored orange. p-values  between 0.05 and 0.06 are colored yellow and highlight possible 
correlation although not meeting the significance requirements whereas non-significant 
values are shown as blue boxes. 
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Supplementary figure 8: Activated and exhausted memory B cells express higher levels of 
activation marker CD95 and FcRL4. 
(A) Flow cytometry dot plots of CD95 and FcRL4 expression on the four memory B cell 
subsets , intermediate (IM), resting (RM), activated (AM) and tissue-like memory (TLM) B 
cells, are shown from a chronic HIV-1 infected patient (2 years of active infection). (B) 
Comparison of CD95 and FcRL-4 expression on memory B cell subsets is shown. Analysis 
was performed on healthy controls (n=29) and different time points of HIV-infected patients 
(n=6). Non-parametric unpaired Kruskal-Wallis one-way ANOVA and Dunn’s multiple 
correction test was used. P<0.05 was considered statistically significant. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
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5.10 Supplementary tables and figures 
 
Supplementary table 1 
Time point Parameter Acute ART group 
(n=11) 
Chronic ART group 
(n=10) 
p-value 
 
Acute 
 
Weeks of infection 
 
5 (3-8) 
 
13 (8-24) 
 
<0.0001 
 Viral load 475000 (2380-12400000) 
(n=11) 
18300 (261-107000) 
(n=8) 
0.0268 
 CD4 counts 724 (436-816) 
(n=5) 
 
540.5 (359-1120) 
(n=6) 
0.5368 
Chronic 1 year Weeks of active 
virus replication 
51 (41-65) 51.5 (31-59) 0.3762 
 Weeks off ART 45 (36-62) Not available 0.6912a 
 Viral load 6650 (0-786000) 23200 (264-103500) 0.3494 
 CD4 counts 663 (457-1094) 477 (270-1099) 0.1145 
 
Chronic 2 years Weeks of active 
virus replication 
112 (101-138) 122.5 (71-139) 0.7171 
 Weeks off ART 109 (94-134) Not available 0.2893a 
 Viral load 14200 (140-122000) 86400 (49-580000) 0.0513 
 CD4 counts 569 (371-945) 263 (163-1429) 
(n=9) 
 
0.0441 
ART 1 year Weeks on ART 53 (33-68) 58.5 (20-72) 0.2273 
 Viral load 0 (0-0) 0 (0-58) 0.0902 
 CD4 counts 798 (460-1363) 579 (278-905) 0.0381 
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Supplementary table 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Early ART group  Late ART group 
Ward 
cluster 
acute ART 
1 year 
Chronic 
1 year 
Chronic 
2 years 
 acute Chronic 
1 year 
Chronic 
2 years 
ART 
1 year 
1 0.4305 0.0006 0.0006 0.0075  0.0037 0.0142 0.0348 0.0152 
2 >0.9999 0.1031 0.0468 0.0468  >0.9999 >0.9999 >0.9999 0.0717 
3 >0.9999 0.5813 0.0256 >0.9999  0.0474 0.0793 0.1662 0.3852 
4 >0.9999 >0.9999 0.9542 >0.9999  >0.9999 0.632 >0.9999 >0.9999 
5 >0.9999 >0.9999 0.1866 0.3437  >0.9999 >0.9999 >0.9999 >0.9999 
6 0.4974 >0.9999 >0.9999 0.27  >0.9999 >0.9999 >0.9999 >0.9999 
7 >0.9999 0.1184 0.0092 >0.9999  0.1375 0.3268 0.2153 0.1002 
8 >0.9999 0.0723 >0.9999 0.0854  >0.9999 >0.9999 >0.9999 >0.9999 
9 >0.9999 >0.9999 >0.9999 0.4415  >0.9999 >0.9999 >0.9999 >0.9999 
10 >0.9999 0.3488 0.0556 >0.9999  0.0207 0.0107 0.0552 0.1629 
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Supplementary figure 1 
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Supplementary figure 2 
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Supplementary figure 3 
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Supplementary figure 4 
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Supplementary figure 5 
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Supplementary figure 6 
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Supplementary figure 7 
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6. Unsupervised high-dimensional flow cytometric analysis of 
memory B cells in healthy and HIV-1 infected individuals 
 
 
Manuscript in preparation. My contributions include study design, generating, analyzing and 
plotting all data. Significant input for computational analysis and statistical analysis as well as 
Figure 2C were provided by Claus Kadelka. I prepared all figures and wrote the manuscript 
which was commented on by the coauthors. 
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6.1 Abstract 
HIV-1 infection induces severe perturbations of the B cell compartment foremost an 
increased activation and exhaustion of memory B cells and plasmablasts that are linked with 
impaired antibody responses against HIV-1 and co-infections. To allow resolution of 
mechanism underlying HIV-1 induced alteration of B cell responses and to identify B cell 
subsets most relevant for the induction of effective, neutralizing antibody responses against 
HIV-1 the phenotypical diversity and dynamics of memory B cells and plasmablasts during 
HIV-1 infection need to be delineated. Here we report on a comprehensive analysis of 
memory B cells and plasmablasts in HIV-1 infected and healthy donors using multicolor flow 
cytometry in combination with computational analysis tools that revealed an unprecedented 
diversity of subsets. Memory B cell subsets with distinct isotypes showed unique distribution 
of activated and exhausted cells and phenotypic differences in healthy and HIV-1 infected 
donors suggesting that class-switch recombination to distinct isotypes are a consequence of 
unique activation circumstances and can lead to divergent phenotypic characteristics. The 
comprehensive memory B cell landscape we established here provides essential support for 
further studies aiming to resolve the functional properties of memory B cell subsets in HIV-1 
infection and specific targeting of subsets by vaccination.  
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6.2 Introduction 
Neutralizing antibodies are a key component of natural immune responses against viral 
pathogens and play a key role in vaccine-induced antiviral immunity (1-4). As memory B cells 
can persist for decades in the periphery, the induction of memory B cells secreting high-
affinity antibodies with the ability to neutralize pathogens and to induce Fc-mediated immune 
responses is a central focus of vaccine development (5-7). In HIV-1 infection, a peculiar 
dichotomy in respect to B cell responses exists. For one, B cell responses are generally 
distorted (8-18). Alteration in B cells subsets are signified by increased numbers of activated 
and exhausted memory B cell subsets that are linked with virus replication and disease 
progression (12, 14-16, 19-22). As a consequence antibody responses to HIV-1 and 
unrelated antigens are diminished in HIV-1 infected individuals (11, 23-30). While there is a 
general agreement on these dysfunctionalities, broadly neutralizing antibodies (bnAbs) that 
potently block HIV-1 infection, develop almost exclusively in viremic individuals after 
prolonged infection (31-33). Thus, while B cell responses are genuinely impaired, bnAbs 
paradoxically appear to require exactly this setting to emerge. Induction of bnAb responses is 
the ultimate goal of HIV-1 vaccine design but despite decades of intensive efforts, current 
candidate vaccines struggle to mount even modestly protective antibodies [reviewed in (25, 
34-37)]. Unraveling the underlying causalities of B cell alterations in HIV-1 infection and the 
requirements for bnAb evolution is thus of high importance (25, 31, 35, 38).  
Memory B cells can be phenotypically and functionally divided into four subsets based on 
CD21 and CD27 expression which are referred to as intermediate (CD21+CD27-; IM), resting 
(CD21+CD27+; RM), activated (CD21-CD27+; AM) and exhausted “tissue-like” (CD21-CD27-; 
TLM) memory B cells (12, 14, 16, 22). In chronic viral diseases such as HIV-1 infection 
activated and exhausted memory B cell subsets increase in frequency (12, 14, 16, 39) and 
exhaustion of memory B cells has been suggested to be a driving force of impaired antibody 
responses against HIV-1 and long-term memory against other pathogens (11, 16, 26, 40). 
While virus load, CD4 loss, immune activation and disease progression have been 
associated with pronounced increase of AM and TLM subsets (12, 14), the majority of  AM 
and TLM B cells are not HIV-1 specific highlighting that these cells emerge as consequence 
of a bystander immune activation (9).  
While the increase in activated and exhausted B cells in HIV-1 infection is well established, 
the dynamics and developmental pathways of the individual subsets have not yet been 
unraveled. It has been long appreciated that memory B cells encompass highly diverse 
subsets beyond the IM, RM, AM and TLM B cells based on the expression of differing 
markers including chemokine receptors, B cell receptor isotypes and activation markers (5). 
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Despite this apparent heterogeneity only few studies have thus far investigated the 
phenotypic diversity of memory B cells at high dimensionality (41-46). A precise definition of 
the memory B cell landscape will however be important to enable verification of the 
differences in functional properties of subsets and their impact on clearing infections (41, 43, 
47).   
The bystander activation of memory B cells is thought to drive terminal differentiation towards 
antibody-secreting plasmablasts (12, 14, 48-53). In line with this frequencies of plasmablasts 
upsurge in HIV-1 infection, and, similar to what has been observed for AM and TLM B cells, 
only a minor fraction of plasmablasts are HIV-specific underlining the participation of 
bystander activation processes (8, 17). Of particular note, the increase in plasmablasts 
correlates with elevated total plasma IgG levels in HIV-1 infection a condition referred to as 
hypergammaglobulinemia (8, 12, 14, 50) 
Phenotypically the highly proliferating plasmablasts are defined by an high expression of 
CD27 and CD38, and a prototypic low CD19 expression paired with the expression of the 
proliferation marker Ki-67 in the vast majority of cells (54, 55). Beyond this canonical 
phenotype phenotypic differences of plasmablasts have been observed in a range of 
infectious and chronic inflammatory diseases (8, 54, 56-59). Alterations of phenotypic and 
functional properties of plasmablast in HIV-1 infection have however thus far not been 
systematically explored. Considering that these cells represent the last stage of the B cell 
response before developing into long-lived antibody secreting plasma cells, a detailed 
phenotypic evaluation of the plasmablast repertoire may provide valuable insights how the 
antibody repertoire is shaped during HIV-1 infection (60). 
In the present study we report on a high-dimensional map of the memory B cell and 
plasmablast landscape in HIV-1 infected individuals and healthy subjects. The phenotypic 
analysis we present here provides novel insights into the diversity of memory B cells and 
plasmablasts and the dynamics of the individual subsets in HIV-1 infection. A detailed 
delineation of the memory B cell compartment as we provide here is key to allow future 
definition of memory B cell subsets associated with the development of potent HIV-1 specific 
antibodies. The latter is of particular importance for vaccination strategies to enable specific 
targeting of these cells to foster the development of bnAbs. By comparing B cell subsets in 
heathy donors and in longitudinal samples of HIV-1 infected individuals during acute and 
chronic infection and after antitretroviral therapy our study highlights which perturbations of 
the B cell response are fully reversibly by ART and which are not. As HIV-1 infected 
individuals under successful ART retain lower responsiveness to diverse vaccines and 
infections (29, 61-67), B cell alterations that persist during ART may provide important cues 
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for future definition of the underlying causes of the reduced humoral immune reactivity in 
HIV-1 infection.  
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6.3 Results 
6.3.1 High-dimensional analysis of the phenotypic diversity of memory B cells and   
plasmablasts in HIV-1 infection   
In the current study we sought to establish a detailed landscape of memory B cell and 
plasmablast alterations in HIV-1 infection as a step towards the delineation of B cell subsets 
that are involved in the induction of bnAbs. Fine-mapping of the B cell repertoire will provide 
further insights into which subsets are afflicted by HIV-1 infection and where the limitations of 
current ART are in reverting B cell functionality to normal levels. A specific focus of our 
phenotypic analysis was on exploring to what extent alterations differ depending on the BCR 
isotype as isotype responses to different antigens are differentially steered (68, 69). The 
latter is of particular interest for bnAb responses. The majority of HIV-1 Env specific and 
neutralizing antibodies including bnAbs are IgG1 (35, 70, 71). A striking exception are 
however MPER reactive bnAbs, of which all three currently isolated developed as IgG3 
isotypes (35, 72). Owing to the high autoreactivity of the MPER bnAbs 2F5 and 4E10 and the 
ensuing need to overcome counter-selection and tolerance mechanisms in order to evolve 
the elicitation of these antibodies is highly restricted (73-78). What the prerequisites in HIV-1 
infection are that allow MPER antibodies to evolve and if this is linked with IgG3 isotype is 
currently not known (79). In a first step towards resolving the underlying casualties we sought 
in the present study to define phenotypic alteration of IgG1, IgG3 and IgA isotypes which are 
the main three isotypes considered relevant in eliciting anti-HIV-1 activities (70, 79, 80). 
To do this we analyzed 12 phenotypic markers on CD19+CD10-IgD- class-switched B cells 
from  three longitudinal time points (during acute infection, after 2 years chronic infection and 
after 1 year of ART;  Supplementary table 1 and 2) from 15 HIV-1 infected individuals that 
participated in the Zurich Primary HIV Infection Study ( ZPHI) and compared these to the B 
cell repertoire of a control group of 15 healthy donors measured at a single time point.  
To obtain a general overview of composition of memory B cells and plasmablasts in healthy 
donors and at the individual stages of HIV-1 infection, we applied t-SNE (Figure 1A. The 
location of pre-gated memory B cell subsets based on CD21 and CD27 expression and 
CD27highCD38high plasmablasts are highlighted by individual colors in the t-SNE map (Figure 
1A). As previously described frequencies of AM B cells, TLM B cells and plasmablasts are 
increased in HIV-1 infection as visualized by an increased density of these populations in the 
t-SNE map of chronically infected patients (14, 22). A global analysis of the individual 
memory B cell subsets reveals unique expression patterns of chemokine receptors, IL-21R 
and the proliferation marker Ki-67 in chronic HIV-1 infection (Figure 1B). We observed a 
down-regulation of CCR7 and CXCR5 during B cell transition from intermediate to tissue-like 
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memory B cells, whereas CXCR4 and IL-21R were upregulated. In addition, CXCR3 levels 
peal at the activated memory B cell stage and revert to lower levels in TLM B cells (Figure 
1B). A similar pattern was observed also for proliferation which was the highest in AM B cells 
among the memory B cell subsets.  The majority of plasmablasts showed Ki-67 expression 
which is in accordance with previous observations (Figure 1B and Supplementary figure 1) 
[reviewed in(54)]. In addition, plasmablasts expressed CXCR3, CXCR4 and IL-21R (Figure 
1B) (81-83).  
 
6.3.2 Distinct properties of IgG1, IgG3 and IgA expressing memory B cells 
We next visualized the expression intensities of the different markers in the t-SNE map 
(Figure 2A). These expression maps revealed an astonishing heterogeneity within the B cell 
subsets highlighting a more complex diversity of the memory B cell compartment than 
anticipated (Figure 2A). Of particular note, the t-SNE map revealed that memory B cell 
subsets as defined by CD21/CD27 expression are differentially distributed among IgA-, IgG1- 
and IgG3-expressing memory B cells. IgG3-expressing memory B cells composed the 
highest proportion of TLM B cells, whereas IgA-expressing memory B cells mainly were 
restricted to the CD27 expressing RM and AM B cells (Figure 2A and Supplementary figure 
2). 
To verify this we manually gated class-switched B cells excluding IgD-CD38high plasmablasts 
and estimated the frequency of IgA-, IgG1- and IgG3-expressing memory B cells (Figure 2B 
and Supplementary figure 3A). In line with what is known from the literature across both HIV-
1 infected and healthy donors, IgA- and IgG1-expressing memory B cells showed similar 
frequencies within total B cells while IgG3-expressing memory B cells are less frequent 
(Supplementary figure 3A) (84). While HIV-1 infection had no effect on total levels of IgA, 
IgG1 and IgG3 expressing memory B cells (Supplementary figure 3B) the distribution of IM, 
RM, AM and TLM B cells amongst the manually gated IgA, IgG1 and IgG3 expressing 
memory B cells was markedly different (Figure 2C-D) confirming the results of the t-SNE 
analysis (Figure 2A and Supplementary figure 2). Based on the results from healthy donors 
peripheral IgA+ memory B cells are in general predominantly RM B cells, IgG3-expressing 
memory B cells contain the highest frequencies of IM and TLM B cells and very low levels of 
RM B cells, while AM B cells include higher levels of IgG1+ and IgG3+ than IgA+ memory B 
cells (Figure 2C and D). In sum these frequency distributions highlight that peripheral IgA-
expressing memory B cells are the least activated and exhausted, followed by IgG1+ B cells 
and IgG3+ B cell subsets which intriguingly is dominated by IM and TLM memory B cells, 
potentially indicating a rapid transition through the activation steps to TLM B cells. We 
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observed a similar frequency distribution amongst HIV-1 infected patients although due to 
the disease-dependent B cell alterations certain distributions shifted (Figure 2C and 2D). Of 
particular note as IgG3 frequencies amongst IM and RM B cells dropped whereas their 
frequency in both AM and TLM B cells increased the frequency of memory B cell subsets 
within IgG3 expressing cells were more similar to IgG1+ B cells in HIV-1 infection than in 
healthy donors. The same pattern of upregulation of AM and TLM frequencies was observed 
for IgA expressing B cells (Figure 2C and D).  
Irrespective of the isotype expressed frequencies of RM and AM B cells in acute infection 
differed the most from healthy donors highlighting that they are among the earliest subsets 
that experience disease-dependent alterations. Although ART as previously described (14, 
22) restored the frequency distribution of IM, AM , RM and TLM B cells close to healthy 
donor levels (Fig 2C and D), elevated levels of AM and TLM B cells and decreased levels of 
RM B cell persist even after 1 year of ART. This was particularly pronounced for IgG1+ 
memory B cells suggesting possibly a more severe perturbation or reduced capacity for 
normalization than IgA- and IgG3-expressing B cells during therapy. This was true for both 
early and late initiation of ART since we could not detect any difference in frequencies of the 
investigated memory B cell subsets between the study groups after 1 year of ART 
(Supplementary figure 4).  
 
6.3.3 Alterations of the memory B cell compartment in chronic HIV-1 infection are 
tightly linked with disease progression 
A known major driver of immune cell activation and exhaustion during HIV-1 infection is viral 
replication and associated bystander effects (12, 14). We thus next performed a 
comprehensive correlation map analysis to explore the interrelationships between the 
different isotype expressing memory B cell subsets and plasmablasts amongst each other 
and with disease parameters (viral load, CD4 counts and plasma IgG levels; (Figure 3) 
during acute and chronic HIV-1 infection. An inverse association between frequencies of the 
activated/exhausted subsets (AM and TLM) and IM and RM B cells is already evident during 
the acute stage across the majority of the different isotype expressing B cell subsets. This is 
remarkable as a direct link with disease parameters was not yet evident for the memory B 
cell subsets during acute infection whereas  increases in plasmablasts already in acute 
infection showed a clear association with viral load levels emphasizing that the differentiation 
to antibody-secreting cells is tightly driven by virus replication and associated immune 
activation (14). In chronic infection association with disease parameters became generally 
evident and that increases in plasmablast, AM and TLM B cells and decreases in IM and RM 
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B cells independent of expressed antibody isotype are driven by viral load (Figure 3). As 
expected from the inverse association of CD4 and viral load (85), CD4 counts negatively 
correlates with the emergence of memory B cell activation and exhaustion (Figure 3). 
Elevated total IgG levels defined as hypergammaglobulinemia are a characteristic of B cell 
response perturbations in chronic HIV infection and considered a result of bystander 
activation of B cells and can thus be viewed as surrogate marker of  immune activation in 
HIV-1 infection (8, 12, 14, 50). In line with this, plasma IgG levels in chronic infection 
correlated with the frequency of plasmablasts, total IgG1+ memory B cells IgG1+ AM and 
IgG3+ AM B cells.  
 
6.3.4 Phenotypic differences of IgG1, IgG3 and IgA expressing memory B cells in 
healthy donors 
The high-dimensional multiparametric flow cytometry analysis we conducted allowed us to 
conduct a comprehensive comparison of phenotypic features of IgA, IgG1 and IgG3 isotype-
expressing memory B cells focusing on IL-21R, the chemokine receptors CCR7, CXCR3, 
CXCR4, CXCR5 and the proliferation marker Ki-67 (Figure 4). We first performed a 
phenotypic characterization of the three types of isotype expressing cells in IM, RM, AM and 
TLM B cells in healthy donors (Figure 4A). IM and RM IgG3+ B cells proved to markedly differ 
from IgA+ and IgG1+ cells, showing significantly lower CCR7 and CXCR5 but higher CXCR3 
and IL-21R expression (Figure 4A). Lower CXCR5 and higher CXCR3 characterized also 
IgG3+ AM and TLM B cells. CXCR4 levels interestingly were only strongly upregulated on 
IgG3+ IM and AM B cells compared to the other isotype expressing cells (Figure 4A). For 
most parameters IgG1+ IM and RM showed an intermediate phenotype between IgA+ and 
IgG3+ memory B cells.  
The distinct expression pattern of IgG3+ B cells could potentially be a result from a more 
activated phenotype compared to other isotype expressing cells as previously suggested 
(86). To probe directly if the isotype subsets differ in their proliferation history we analyzed 
the intracellular expression of the proliferation marker Ki-67 (Figure 4B) (87). Interestingly, 
with the exception of RM cells where all isotype expressing cells were comparable, IgA-
expressing subsets proved to be the most strongly proliferating while IgG1+ and IgG3+ B cell 
subsets showed only low levels of proliferation. Thus, even though the altered receptor 
densities on IgG3 expressing cells suggest a somewhat higher activation this did not result in 
increased proliferation of these cells. The markedly higher proliferation of IgA cells may be 
an indication that these cells originate from different environments than IgG1 and IgG3 
expressing cells (42, 88).  
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6.3.5 Phenotypic differences of IgG1, IgG3 and IgA expressing memory B cells in 
HIV-1 infection  
We next analyzed the dynamics of phenotypic changes on IgA-, IgG1- and IgG3-expressing 
memory B cell subsets in HIV-infection comparing acute, chronic infection and the effect of 
ART to the status in healthy donors (Figure 5). While across all memory B cell subsets 
expression of CCR7, CXCR4, CXCR5, IL-21R and Ki-67 on IgA-, IgG1- and IgG3-expressing 
did not markedly differ (data not shown), we observed a marked upregulation of CXCR3 in 
chronic infection for IgG1 and IgG3 IM and RM B cells and a low level upregulation of 
CXCR3 on all IgA subsets (Figure 5A). Hence, the less activated subsets showed the 
strongest upregulation of CXCR3. Interestingly 1 year of ART does not show lower CXCR3 
expression in IgA, IgG1 and IgG3 IM and RM cells compared to the chronic time point 
(Figure 5A). As our patient cohort included two group of patients, those who started ART 
early during acute infection and those who started late in chronic infection, we next explored 
if the differential effect of ART is linked to the stage of ART initiation (Figure 5B). Indeed, for 
several B cells subsets CXCR3 expression was significantly higher after late treatment 
highlights that CXCR3 expression is not completely normalized upon late ART and therefore 
memory B cells are likely to retain enhanced potential to migrate towards inflamed tissues 
secreting the CXCR3 ligands CXCL9-11 (89).  
 
6.3.6 Rapid change of phenotypic markers in plasmablasts in acute HIV-1 infection  
In a next step we analyzed the phenotypic changes of plasmablasts during HIV infection. In 
contrast to what we had observed for memory B cells the main changes for plasmablasts 
already occurred with acute infection and were signified by a marked downregulation of 
CCR7 and notable, but less pronounced upregulation of CXCR4, CXCR5 and I-21R 
compared to healthy donors (Figure 6A). Interestingly, with the exception of lower CCR7 
expression the changes in these markers reverted to normal levels in chronic infection 
whereas CXCR3 levels were upregulated. In line with the generally high proliferation of 
plasmablasts (Supplementary figure 1) (54), we observed no HIV-1 induced alterations in Ki-
67 expression (Figure 6B). 
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6.3.7 Clustering algorithm defines complex heterogeneity within memory B cell 
subsets 
Considering the complexity of the phenotypic differences we observed in the t-SNE and the 
manual gating analysis we next applied the clustering algorithm SPADE (spanning-tree 
progression analysis of density-normalized events) to group cells with similar expression 
profiles into clusters. The SPADE trees allowed a rapid definition of cluster regions in chronic 
HIV-1 infected patients with expression patterns comparable to plasmablasts and memory B 
cell expressing different isotypes (Supplementary figure 5A). In line with our prior analyses 
memory B cells harbored distinct expression profiles according to their BCR isotype 
(Supplementary figure 5B).  
In order to be able to define rare subsets as separate populations clustering algorithms such 
as SPADE perform over-clustering that resulting in a high number of clusters with similar 
phenotypes (Figure 5A-C). We thus performed a second hierarchical clustering based on 
Ward’s hierarchical clustering method in order to merge similar SPADE clusters 
(Supplementary figure 6) which resulted in the definition of 40 differential clusters among 
memory B cells and plasmablasts (Figure 7A and 8A and Supplementary figure 6). We 
grouped these clusters manually based on their expression of CD21 and CD27 into the 
known IM, RM, AM and TLM B cell subsets and defined plasmablasts based on expression 
of Ki-67, CD27 and CD38 (Figure 7A and 8A). Clusters that were assigned to these specific 
subsets showed overall the known characteristics, e.g. CXCR3 was expressed on the 
majority of clusters defined as AM and TLM B cells whereas CXCR5 expression was mostly 
restricted to IM and RM B cells and TLM B cells were signified by high CXCR4 and IL-21R 
expression (Figure 7A). However, the Ward analysis revealed that each main memory B cell 
subset contained clusters with unusual expression pattern that were not revealed by our prior 
global expression analysis.  While CXCR3 expression is generally low on RM B cells the 
clustering analysis highlighted that nevertheless RM B cell populations with high CXCR3 
expression (Figure 7A; Ward cluster 9, 10, 13, 16 and 28) and no CCR7 expression could be 
observed (Figure 7A; Ward cluster16, 18 and 25) exist. Likewise, despite an overall low 
expression of CCR7 on AM B cells, distinct AM B cell populations express CCR7 at high 
levels (Figure 7A; Ward cluster 5, 8, 14, 15 and 27). Of particular note, comparing the results 
of the Ward and t-SNE analysis we confirmed that these unusual phenotypes can also be 
traced by t-SNE supporting the utility of t-SNE in revealing complex cell population 
heterogeneity (Figure 2A and Supplementary figure 2). 
As certain ward clusters deviated from the global expression profiles of AM and RM B cells 
(Figure 1B) we probed whether manual gating and clustering analysis results in similar 
frequencies of RM and AM B cells to ascertain that both approaches have indeed 
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comparable capabilities to define major B cell subsets. We found that the computational 
clustering analysis assigns slightly lower numbers of RM B cells compared to manual gating 
(median difference of 8.136% ± 5.218%) but both methods retrieve identical numbers of AM 
B cells (Supplementary figure 7) highlighting the validity of both approaches. This was also 
supported when we compared the frequency of CCR7high cells within RM and AM B cells with 
both methods which confirmed that also by Ward analysis RM B cells contain higher 
frequency of CCR7high cells (49.77% ± 10.64%) than AM B cells (31.05% ± 11.86%).  A 
limitation of the global analysis as we conducted it, is that it relies on median fluorescence 
intensity values. The latter is useful to estimate expression levels across larger populations 
but bears the caveat that markers expressed only on a minority of cells are neglected. This 
may have in the analysis of AM B cells lead to an underappreciation of CCR7high cells since 
less than 50% are expressing high levels of CCR7.  
To further verify the validity of the Ward cluster analysis, we manually monitored the 
expression pattern of the individual Ward clusters and found that they formed homogenous 
populations. The manual re-analysis also confirmed that the assignment of the individual 
clusters to memory B cell subsets as defined by CD21/CD27 expression was in the majority 
of Ward clusters accurate and allowed to reveal subpopulations with unique characteristics. 
For example, re-analysis of cluster 9, which belongs to RM B cells allowed verification of the 
unusual high expression of CXCR3 that was not revealed by prior MFI based global 
expression analysis (Figure 7B). Nevertheless, few clusters showed heterogeneous 
CD21/CD27 expression highlighting that other markers are more decisive for the definition of 
these clusters. 
Interestingly the dynamics of individual memory B cell clusters differed during HIV-1 infection. 
While total IM and RM B cell numbers decrease and AM and TLM B cells increase (Chapter 
5, Figure 1B), this was not the case for all individual clusters within these subsets ( Fig 7C).  
For instance, the IM B cell cluster with high expression of IL-21R (Ward cluster 24) was not 
affected whereas the IL-21R- clusters decreased in chronic HIV-1 infection. Likewise, three 
RM B cell clusters (Ward clusters 16, 17 and 28) with comparatively low CCR7 expression 
were not affected by HIV-1 infection. While the majority of AM B cell clusters increased 
during HIV infection and decreased after 1 year of ART, AM Ward cluster 15  which is 
signified by high Ki-67 expression showed rapid reduction during acute phase and 
normalized during later stages of HIV infection (Figure 7A and C).  
Most ward clusters assigned to plasmablasts showed a characteristic low expression of 
CD19 paired with high expression of CD27, CD38 and Ki-67 (Figure 8A) (54, 90). Yet, some 
clusters linked with plasmablasts in our analysis, expressed only two of these canonical 
plasmablasts markers. One intriguing observation was a rare plasmablast population (91) 
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that lacked CD27 expression but maintained high levels of CD38 and Ki-67 (Figure 8A). In 
general the plasmablast clusters showed highly diverse expression patterns of chemokine 
receptors CCR7, CXCR3 and CXCR5. We again confirmed the expression profiles manually 
and verified that all clusters showed homogenous expression patterns as exemplified by 
cluster 32 (Figure 8B).  
Interestingly, we observed non-proliferating plasmablast associated cell clusters expressing 
no or little Ki-67 expression (cluster 33 and 40) which increased levels during HIV infection 
(Figure 8C). Several plasmablast clusters show characteristic dynamics during HIV-1 
infection with increased levels during acute and chronic phase and restored levels after 1 
year of ART (clusters 31, 33, 35, 37, 39, 40) while HIV-1 infection had no or only a marginal 
effect on others (cluster 32, 34, 36, 38). In sum this highlights that also in plasmablasts a 
considerable heterogeneity exists that are differentially affected by HIV-1 infection.  
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6.4 Discussion 
HIV-1 infection is characterized by severe immunomodulatory effects that severely impact on 
B cell responses (9, 10, 12, 14-16, 23, 30). Hallmarks of these alterations are hypergamma-
globulinemia and an accumulation of activated and exhausted memory B cells (12, 14, 17) 
which are functionally linked with a decreased capacity to mount novel antibody responses 
against diverse antigens (11, 23-30).  Despite the reduced capacity to mount effective B cell 
responses with progressing disease, potent HIV-1 specific broadly neutralizing antibodies 
develop preferentially after several years of HIV-1 infection (31-33). Definition if and which 
specific B cell subsets or stimulatory environments foster bnAb evolution is of high interest to 
guide HIV vaccine design. In a step towards this we conducted here a high-dimensional 
analysis of the memory B cell and plasmablast compartment in healthy donors and HIV-
infected patients that is amongst the most comprehensive attempted to date (41-46, 92). 
Most studies that have analyzed the dynamics of memory B cells during HIV-1 infection thus 
far focused solely on the canonical subdivision into intermediate (CD21+CD27-), resting 
(CD21+CD27+), activated (CD21-CD27+) and exhausted tissue-like (CD21-CD27-) memory B 
cells and a selected range of phenotypic characteristics of these four subsets (12, 14, 16, 93). 
With the current study we aimed for a high-dimensional analysis of the memory B cell 
compartment including the assessment of activation markers, BCR isotypes, chemokine 
receptors, proliferation marker and the cytokine receptor IL-21R in a 16-paramter flow 
cytometry analysis. To reveal the complexity of the memory B cell landscape we used a 
combination of manual examination and computational clustering algorithms.   
Our analysis of the memory B cell compartment in HIV-1 infected individuals confirmed all 
previously observed perturbations (Chapter 5; Figure 1B) and the strong association with 
clinical markers of disease progression  (Figure 3) (12, 14) but beyond this revealed a high 
complexity of subsets within the four memory B cell types (Figure 7A-D).  
An important aspect of our study was the differentiation of memory B cells according to the 
BCR isotype. Focusing on IgA, IgG1 and IgG3, which are considered most relevant for HIV-1 
specific neutralizing antibody responses (70, 80), we analyzed the distribution of the isotype 
expressing B cells across the different memory B cell subsets and their phenotypic 
differences. A precise definition of differential regulation of BCR isotypes is of particular 
interest in respect to HIV-1 bnAbs. bnAbs directed against gp120 like gp120 specific 
antibodies in general are predominantly IgG1 whereas the three MPER-specific bnAbs 
isolated thus far emerged as IgG3 (35, 94, 95). Whether epitope specificities steer this 
disparate distribution or specific co-stimulatory events are necessary to induce the 
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generation of the partly autoreactive MPER bnabs is a matter of extensive research efforts 
(25, 35, 36).  
Using the t-SNE algorithm we revealed distinct distributions of IgA-, IgG1- and IgG3-
expressing memory B among IM, RM, AM and TLM B cells in both healthy and HIV-1 
infected donors (Figure 1A and 2C and Supplementary Figure 2). IgG3 and IgA expressing 
memory B cells differed the most in their phenotypic features, with IgG3 expressing cells 
encompassing the highest proportion of activated AM and exhausted TLM B cells whereas 
IgA-expressing memory B cells showed a high frequency of RM B cells (Figure 2B-D). The 
increased frequency of IgG3+ B cells amongst activated and exhausted B cells is intriguing 
and agrees with previous observations (86, 96, 97). The developmental paths of these cells 
remain unclear but a low variable gene mutation rate of a fraction of CD27-IgG3+ B cells 
potentially suggests that some of the cells originate from germinal center- and T cell-
independent responses or represent the first wave of antibody responses (42, 86, 97, 98). 
While antigens and exposure can influence CSR to induce a specific isotype (68), this can 
not be the sole reason for the differential distribution of BCR isotypes cross the memory B 
cell subsets as we observed similar patterns in healthy donors and in HIV-1 infection.   
In line with their activated and exhausted profile, IM and RM IgG3+ B cells showed reduced 
levels of CCR7 and CXCR5 and increased levels of CXCR3 and IL-21R when compared to 
IgA+ and IgG1+ memory B cells  in healthy donors (Figure 4) suggesting that IgG3-
expressing IM and RM  B cells may bear a higher potential to differentiate into AM and TLM 
B cells. HIV-1 infection lead to a generally higher expression of CXCR3 in IM and RM 
memory B cell subsets across all BCR isotypes expressing cells (Figure 5A). This 
emphasizes that HIV induces phenotypic changes within IM, RM, AM and TLM B cells in 
addition to their altered distribution. As up-regulation of CXCR3 is indicative for activation 
processes, the phenotypic analyses highlights that differentially activated subpopulations 
exist within the canonical memory B cells subsets that are solely based on CD21/CD27 
classification (16, 82, 99).  
Activation as based on  CXCR3 expression was fully reversed by early initiation of ART but 
not when ART was initiated late during chronic infection (Figure 5B) supporting  the notion 
that initiation of ART in the acute phase can prevent irreversible B cell alterations (14, 22). 
Whether elevated levels of CXCR3 on B cells subsets amongst are an indication of long 
debated residual virus replication, long-term presentation of viral antigens or a result of slow 
turnover of these cells and/or the CXCR3 receptor remains to be determined (82, 100-102) .  
To obtain a detailed overview of the memory B cell and plasma landscape we re-analyzed all 
data using the clustering algorithm SPADE and Ward hierarchical clustering which revealed 
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30 distinct memory B cell and 10 plasmablast clusters (Figure7A and 8A and  Supplementary 
Figure 5A-D and 6). While these computational approaches highlighted the same gross 
changes we observed in the global analysis, they revealed a higher than previously 
appreciated heterogeneity within the IM, RM, AM and TLM B cells and plasmablasts of 
healthy individuals which were in part differentially affected by HIV-1 infection, highlighting 
the need to improve monitoring and our understanding of the diverse subsets within the B 
cell population  (Figure 7A-C and 8A-C).  Of particular note, some cell clusters within IM, RM 
and TLM B cells were not altered by HIV-1 infection. This included IM B cells expressing high 
levels of IL-21R which did not change in frequency, whereas IL21R- IM B cells decreased 
during HIV infection. Tracing the underlying causalities may be difficult as the general 
function of IM B cells are poorly understood but it is feasible that IL-21R signaling may 
contribute to their survival (103-105).  
The refined analysis of plasmablasts we conducted here confirmed earlier reports that 
highlighted their phenotypical diversity (54). We found similar to the memory B ell landscape 
that HIV-1 infection afflicted plasmablast subsets differentially. Most intriguingly, we found 
that plasmablast subsets show a diversity in CXCR3 expression emphasizing that a fraction 
of plasmablasts are migrating towards inflamed tissues (82, 106). High CCR7 levels on 
certain plasmablast subsets emphasized that they are destined to migrate to/from lymphoid 
tissues. (106). Interestingly, we observed phenotypic changes amongst plasmablast subsets  
predominantly during acute infection where perturbations of the memory B cells were less 
evident possibly indicating that direct action of the cytokine storm early in the acute phase 
may be linked to the modulations of plasmablast rather than preceding alteration of memory 
B cells  (107, 108).  
Overall our high-dimensional analysis provides a detailed map of the memory B cell and 
plasmablast compartments in both healthy individuals and HIV-1 infection that provide a 
basis for further dissection of B cell responses to explore components of the B cell response 
the restrict or promote bnAb evolution.  
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6.5 Methods 
 
Clinical specimen 
Cryopreserved peripheral blood mononuclear cells (PBMC) and plasma of HIV-1 infected 
individuals (n=19) were available from samples stored in the biobank of the Zurich Primary 
HIV Infection Study (ZPHI). The ZPHI is an ongoing, observational, nonrandomized, single 
center cohort founded in 2002 that specifically enrolls patients with documented acute or 
recent primary HIV-1 infection (ClinicalTrials.gov identifier NCT00537966) (109). The ZPHI is 
approved by the ethics committee of the Kantonale Ethikkommission Zürich and written 
informed consent was obtained from all participants. Longitudinal samples of patients that 
started ART early (during the acute infection stage, n=11) and late (in the chronic infection 
stage, n=8), were analyzed. Longitudinal samples encompassed samples from the untreated 
acute and chronic stage (year 1, year 2) and after 1 year of ART (Supplementary table 1 and 
2). Patient and disease demographics (estimated time of infection, CD4 cell count and 
plasma viral load level at sampling date) were available through the ZPHI data bank.   
PBMC and plasma from healthy donors (n= 29; single time points) were collected in the 
frame of a separate clinical study (PI H. Günthard) that was approved by the ethics 
committee of the Kantonale Ethikkommission Zürich and written informed consent was 
obtained from all participants.  
PBMC were isolated by density-gradient centrifugation using LymphoPrep (Axis-Shield) from 
whole blood drawn in EDTA vacutainer tubes (BD Biosciences). Until further processing 
PBMC were cryopreserved using 90% inactivated FCS (Thermo Fisher Scientific) and 10% 
DMSO (Sigma Aldrich) and stored in liquid nitrogen. Plasma  was heat-inactivated for 1h at 
56°C and stored at -80°C for further analysis. 
 
Flow Cytometry 
To monitor B cell populations by flow cytometry PBMC were stained using a 16-parameter 
panel as described (Liechti, T. et al. manuscript in preparation, Chapter 4). Briefly, cells were 
thawed and washed with FACS buffer containing PBS (Thermo Fisher Scientific), 2% heat-
inactivated FCS (Thermo Fisher Scientific), 2mM EDTA (Sigma Aldrich) and 20µg/ml DNase 
(Sigma Aldrich), stained with a cocktail of antibodies directed against surface markers 
encompassing CD3 APC-Cy7 (clone SK7, Biolegend), CD14 APC-Cy7 (clone HCD14, 
Biolegend), CD16 APC-Cy7 (clone 3G8, Biolegend), CD10 BV650 (clone HI10a, BD 
Pharmingen), CD19 BV786 (clone SJ25C1, BD Pharmingen), CD21 BV711 (clone B-ly4m 
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BD Pharmingen), CD27 PE-CF594 (clone M-T271, BD Pharmingen), CD38 AF700 (clone 
HIT2, Biolegend), IgG1 PE (clone HP6001, Southern Biotech), IgG3 FITC (polyclonal sheep 
IgG, AbD Serotec), IgA APC (polyclonal goat IgG, Jackson Immuno), CCR7 BV605 (clone 
G043H7, Biolegend), CXCR3 PE-Cy7 (clone G025H7, Biolegend), CXCR5 BV510 (clone 
RF8B2, BD Pharmingen), IL-21R BV421 (clone 2G1-K12, Biolegend)  and Live/dead near-
infrared dye (Life Technologies). IgD (clone IA6-2, Biolegend) and CXCR4 (clone 12G5, 
Biolegend) were labelled in-house with labeling kits for PE-Cy5 (Innova Biosciences) and 
PE-Cy5.5 (Innova Biosciences), respectively, according to the manufacturer’s instructions. 
Each new batch of labeled antibodies was titrated in parallel with and adjusted to the old 
batch to ascertain comparable staining intensities. Cells were afterwards fixed and 
permeabilized with the FoxP3 staining kit (eBioscience) according to manufacturer’s 
instructions to stain for Ki-67 PerCP-eFluor710 (clone 20Raj1, eBioscience). Data was 
acquired on a BD Fortessa calibrated daily using the CS&T module. Staining intensity QC 
was conducted as recommended (110) and individual stainings with markers that did not fulfil 
requirements excluded when comparative analysis of intensities was performed. To further 
limit the possibility of influences due to day-to day variability in the flow cytometry analysis, all 
longitudinally time points of a given patient were analyzed at the same day. In addition 
patients assigned to the early and late ART group were included in all experiments to 
exclude batch effects. Compensation was done for each experiment individually. Manual 
analysis was done with FlowJo (TreeStar). 
 
Analysis using t-distributed stochastic neighbor embedding (t-SNE) and spanning-tree 
progression analysis of density-normalized events (SPADE) 
Data analysis was performed using Cytobank (Cytobank Inc.), a cloud-based software that 
provides the integrated analysis tools SPADE and t-SNE (111-113). Class-switched 
CD19+CD10-IgD- B cells were pre-gated and analyzed with t-SNE and SPADE using the 
markers IgA, IgG1, IgG3, CD21, CD27, CD38, CCR7, CXCR3, CXCR5, IL-21R and Ki-67. In 
these analyses we included samples from a single time point from healthy controls (n=15) 
and longitudinal time points of HIV-1 infected patients (n=15) (acute infection, chronic 
infection after 2 years and after 1 year of ART 1 year). All measurements from a specific time 
point of HIV-infected individuals and from healthy donors were concatenated to visualize the 
global differences between control group, acute and chronic phase of HIV infection and upon 
1 year of ART. 
T-SNE analysis was performed using identical cell counts from each sample in order to 
guarantee equal contribution from each donor and time-point to the t-SNE based 
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dimensionality reduction. As CXCR4 staining showed some variability this marker was 
excluded from SPADE and t-SNE analysis but information on CXCR4 was made available for 
visual examination, distribution and expression profile of CXCR4 in both analyses. For CD19 
the same approach was used due to marginal differences between the different subsets not 
providing further information on clustering and t-SNE. 
We chose a setting of over-clustering, by allowing for 200 different clusters for SPADE as 
this allows to build separate clusters of very rare cell populations. As a consequence 
frequent cell populations can separate into different clusters despite sharing phenotypic 
properties. Therefore, clusters created by SPADE were further clustered using hierarchical 
clustering with the Ward method in R and visualized with the hetmap.2 function (114). 
SPADE clusters were ordered and grouped by Ward hierarchical clustering method based on 
z-score normalized data of arcsinh transformed median fluorescence intensity values from 
the individual SPADE clusters. By analyzing the hierarchical tree a cut-off was determined to 
optimally distinguish the several phenotypes resulting in 40 distinct Ward-based clusters 
within class-switched B cells. To categorize the expression profile of the individual Ward 
clusters we manually determined the z-score at which cells are positive for a given marker 
and defined negative (-), low expression (+), intermediated expression (++) and high 
expression (+++). 
 
IgG ELISA 
Total immunoglobulin concentrations in heat-inactivated plasma from the HIV-1 infected 
patients were measured by enzyme-linked immunosorbent assay (ELISA) as described 
previously (115). Briefly, 96 well immunosorbent plates (Thermo Fisher Scientific) were 
coated with polyclonal goat anti-human IgG (Southern Biotech) in sodium carbonate buffer 
pH8.2 for 2 hours at room temperature. PBS/2% BSA (Sigma Aldrich) was used as a 
blocking reagent for 30 minutes at 37°C. Serial dilutions of the plasma samples were applied 
to the plates and incubated for 2 hours at room temperature. Plasma IgG was detected using 
a biotinylated polyclonal goat anti-human IgG (southern Biotech; 2 ng/ml) followed by 
streptavidin-alkaline phosphatase (Sigma Aldrich, 40ng/ml) each diluted in PBS/2% BSA and 
incubated for 1 hour at room temperature. CDP-Star system (Applied Biosystems) was used 
as alkaline phosphatase substrate and luminescence was measured after 30min with a 
Dynex luminometer (Magellan Biosciences). Human IgG (Sigma Aldrich) was used as a 
standard to determine the concentration of plasma IgG. 
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Statistical analysis 
Comparison of memory B cell subsets between healthy controls and HIV-1 infected patients 
was done using unpaired non-parametric Kruskal-Wallis one-way ANOVA and comparison 
between different time points of HIV-1 infected patients using paired non-parametric 
Friedman one-way ANOVA. Multiple comparison correction was performed using Dunn’s 
multiple testing correction test. Comparisons in Figure 2C and 5B are done using unpaired 
non-parametric Mann-Whitney test without multiple testing corrections. P-values are 
highlighted as color gradient. Comparisons between the early and late treatment group was 
done with unpaired non-parametric Mann-Whitney test. P<0.05 was considered statistically 
significant. Significance levels are reported as *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
Statistical tests were calculated using Prism version 7 (GraphPad). Correlations (Figure 3) 
were calculated using non-parametric Spearman correlation and visualization was done 
using the corrplot package and heatmaps using the heatmap.2 package for R programming 
language (version 3.3.1, http://cran.r-project.org). Heatmaps for figure 2C were done with 
Matlab (MathWorks). 
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6.6 Figure legends 
 
Figure 1: Dimensionality reduction analysis t-SNE reveal HIV-1 dependent dynamics of 
class-switched B cells. 
(A) t-SNE maps of CD19+CD10-IgD- class-switched B cells from healthy (n=15) and HIV-
infected individuals (n=15) at acute phase, after 2 years of chronic infection and after 1 year 
of ART are shown. The main memory B cell subsets and plasmablasts are overlaid and 
differentially colored.  All events of the corresponding group are concatenated and displayed. 
(B) Median expression intensity (MFI) of phenotypic markers on main memory B cell subsets 
defined based on CD21 and CD27 expression and plasmablasts after 2 years of chronic 
infection are depicted. The MFI of fluorescence minus one (FMO) controls estimated on total 
CD19+ B cells are depicted as grey dashed line where applied. Comparison of memory B cell 
subsets and plasmablasts are done using paired non-parametric Friedman one-way ANOVA 
and multiple comparison correction was performed using Dunn’s multiple testing correction 
test. P<0.05 was considered statistically significant. Significance levels are reported as 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
Figure 2: Frequency analysis of memory B cells expressing distinct isotypes. 
 (A) Expression intensities of phenotypic markers in the t-SNE maps are shown. 
Concatenated samples after 2 years of chronic infection are depicted. (B) Gating strategy to 
define IgA, IgG1 and IgG3 expressing memory B cells (CD19+CD10-IgD-CD38low) and the 
main memory B cell subsets within these isotype-expressing memory B cells based on CD21 
and CD27 expression is shown from a chronic HIV-1 infected patient. (C) Frequency of main 
memory B cell subsets based on CD21/CD27 classification within IgA, IgG1 and IgG3 
expressing memory B cells in healthy subjects (n=29; black dots) and HIV-infected 
individuals (n=17) at acute stage (blue dots), after 2 years of chronic infection (dark red dots) 
and after 1 year of ART (grey dots) are depicted. (D) The p-values from the comparisons of 
the frequencies of main B cell subsets plotted in Figure 2C defined based on CD21/CD27 
expression within the different isotype-expressing memory B cells of healthy controls and 
HIV-1 infected patients at different disease stages and after 1 year of ART are visualized as 
a heatmap. The scale is according to the p-value in which red and blue colored boxes 
indicates when subsets from rows are decreased or increased, respectively, compared to the 
subset in columns. Pairs not compared are colored grey. Unpaired non-parametric Mann-
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Whitney test without multiple testing corrections was used for the comparison. P<0.05 was 
considered statistically significant. 
 
Figure 3: Spearman correlation analysis of several subsets and clinical features in acute and 
chronic HIV-1 disease. 
Analysis with samples from the acute (n=17) and chronic (n=19) phase of HIV-1 infection are 
depicted. The matrices in the top row show the Spearman’s Rank Coefficient. The dot size 
corresponds to the value of the coefficient and the color indicates positive or negative 
correlation if colored red or blue, respectively. Only statistically significant correlations are 
shown. Empty fields indicate insignificant p-values. The bottom row displays the p-values of 
the spearman correlations as a heatmap.  P<0.05 was considered statistically significant. 
 
Figure 4: Phenotypic differences of IgA, IgG1, and IgG3 expressing memory B cell subsets. 
(A) Median expression intensity of CCR7, CXCR3, CXCR4, CXCR5 and IL-21R in healthy 
subjects (n=29; n=14 for CXCR5 and IL-21R) are shown for the main memory B cell subsets 
based on CD21 and CD27 expression within the different isotype-expressing memory B cells. 
(B)  Percentage of Ki-67 expression on the same cell subsets of healthy donors (n=29) are 
depicted. Paired non-parametric Friedman one-way ANOVA was used to compare B cell 
subsets and multiple comparison correction was performed using Dunn’s multiple testing 
correction test. P<0.05 was considered statistically significant. Significance levels are 
reported as *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
Figure 5: HIV-1 infection alters the expression of CXCR3 on memory B cell subsets.  
(A) The expression levels of CXCR3 on memory B cell subsets divided into the different 
isotype-expressing memory B cells are shown for healthy controls (n=29) and HIV-infected 
patients (n=17) at acute and 2 years of chronic disease stage and after 1 year of ART. 
Comparison of memory B cell subsets between healthy controls and HIV-1 infected patients 
was done using unpaired non-parametric Kruskal-Wallis one-way ANOVA and comparison 
between different time points of HIV-1 infected patients using paired non-parametric 
Friedman one-way ANOVA. Multiple comparison correction was performed using Dunn’s 
multiple testing correction test. (B) CXCR3 expression levels after 1 year of ART are shown. 
Patients are divided in subgroups based on their initiation of therapy into early ART (n=11, 
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grey dots) and late ART group (n=8, black circles). Unpaired non-parametric Mann-Whitney 
test was used to compare early and late treatment group. P<0.05 was considered statistically 
significant. Significance levels are reported as *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
Figure 6: Plasmablasts show phenotypic alterations during HIV-1 infection. 
(A) Chemokine receptor and IL-21R expression levels from plasmablasts from healthy 
donors (n=29, n=14 for CXCR5 and IL-21R) and HIV-infected patients (n=17) at different 
disease stages and therapy are shown. The MFI of fluorescence minus one (FMO) controls 
estimated on total CD19+ B cells are depicted as black dotted line where applied. (B) The 
frequency of Ki-67-positive plasmablasts were estimated for the same samples. Comparison 
of markers expressed on plasmablasts between healthy controls and HIV-1 infected patients 
was done using unpaired non-parametric Kruskal-Wallis one-way ANOVA and comparison 
between different time points of HIV-1 infected patients using paired non-parametric 
Friedman one-way ANOVA. Multiple comparison correction was performed using Dunn’s 
multiple testing correction test. P<0.05 was considered statistically significant. Significance 
levels are reported as *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
Figure 7: Memory B cells show high phenotypic diversity individually influenced by HIV-1 
infection. 
(A) Expression profile of Ward clusters based on SPADE/Ward hierarchical clustering of 
class-switched B cells from the concatenated chronic 2 year samples are depicted as a 
heatmap. Expression of phenotypic marker are shown as no expression (-; blue), low 
expression (+; yellow), medium expression (++; orange) and high expression (+++; red). 
Ward clusters are numbered according to Ward cluster identification in supplementary figure 
6. Clusters are ordered manually according to their CD21/CD27 expression classification. (B) 
Manual inspection of Ward clusters was performed as depicted for Ward cluster #9 (red) 
which is overlaid on total class-switched B cells (grey). (C) The frequency of the individual 
Ward clusters in healthy control (n=15) and HIV-infected individuals (n=15) at different 
disease stages and ART are shown. Comparison of Ward clusters between healthy controls 
and HIV-1 infected patients was done using unpaired non-parametric Kruskal-Wallis one-way 
ANOVA and comparison between different time points of HIV-1 infected patients using paired 
non-parametric Friedman one-way ANOVA. Multiple comparison correction was performed 
using Dunn’s multiple testing correction test. P<0.05 was considered statistically significant. 
Significance levels are reported as *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 8: Phenotypic diversity of plasmablasts revealed with clustering analysis 
 (A) Expression profile of Ward cluster resembling plasmablasts is shown of the chronic 
disease stage. Expression of phenotypic marker is shown as no expression (-; blue), low 
expression (+; yellow), medium expression (++; orange) and high expression (+++; red). 
Ward clusters are numbered according to Ward cluster identification in supplementary figure 
6. Clusters are ordered manually according to their expression of Ki-67, CD27 and CD38. (B) 
Manual validation of the individual clusters was done and cluster (#32) is shown as an 
example. Ward clusters (red) are overlaid on top of total class-switched B cells (grey). (C) 
Dynamics of the plasmablast clusters are shown for healthy controls (n=15) and HIV-infected 
patients (n=15) at different disease stages and after 1 year of ART. Comparison of Ward 
clusters resembling plasmablasts between healthy controls and HIV-1 infected patients was 
done using unpaired non-parametric Kruskal-Wallis one-way ANOVA and comparison 
between different time points of HIV-1 infected patients using paired non-parametric 
Friedman one-way ANOVA. Multiple comparison correction was performed using Dunn’s 
multiple testing correction test. P<0.05 was considered statistically significant. Significance 
levels are reported as *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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6.9 Supplementary table and figure legends 
 
Supplementary table 1: Characteristics of the early and late treatment groups 
Summary of the clinical characteristics of the HIV-1 infected patients for the time points 
analyzed are shown. Patients are separated into the study groups based on initiation of ART 
early ART and late ART group. aComparison was done between early ART group (weeks off 
ART) and late ART group (weeks of active replication) to compare the continuous period of 
active replication before chronic 2 year sample was collected. Differences between the study 
groups were calculated with Mann-Whitney test and considered statistically significant with a 
p value <0.05. 
 
Supplementary table 2: Patient characteristics 
Characteristics of the individual patients are shown and in addition the samples used for the 
different assays are depicted. 
 
Supplementary figure 1: The majority of plasmablasts express high levels of the 
proliferation marker Ki-67.  
Left plot shows manual gating of IgD+ B cells (grey) encompassing marginal zone and naïve 
B cells, memory B cells (blue) and plasmablasts (red). Analysis of Ki-67 expression on these 
subsets is shown as overlaid histogram. The FMO control gated on plasmablasts is shown in 
black. 
 
Supplementary figure 2: t-SNE plots with phenotypic marker expression levels 
t-SNE plots from the concatenated samples of healthy donors (n=15) and HIV-1 infected 
patients (n=15) at the acute phase and after 1 year of ART are shown for the phenotypic 
marker IgA, IgG1, IgG3, CD21, CD27, CD38, CCR7, CXCR3, CXCR5, IL-21R, Ki-67 and 
CXCR4. Expression levels of arcsinh-transformed MFI values are shown as a color gradient 
ranging from blue to red color highlighting no to highest expression, respectively.  
 
Supplementary figure 3: Frequency of isotype-expressing memory B cells  
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(A) Frequency of IgA (black dots), IgG1 (blue dots) and IgG3 (dark red dots) expressing B 
cells are shown for healthy controls (n=29) and HIV-1 infected individuals (n=17) at acute 
and 2 years of chronic phase and after 1 year of ART. Comparison of IgA, IgG1 and IgG3 
expressing B cells was done using paired non-parametric Friedman one-way ANOVA. 
Multiple comparison correction was performed using Dunn’s multiple testing correction test. 
(B) Comparison of IgA+, IgG1+ and IgG3+ memory B cells between healthy (n=29) and HIV-1 
infected patients (n=17) at acute and chronic phase and after 1 year of ART was performed. 
Comparison of B cell subsets between healthy controls and HIV-1 infected patients was done 
using unpaired non-parametric Kruskal-Wallis one-way ANOVA and comparison between 
different time points of HIV-1 infected patients using paired non-parametric Friedman one-
way ANOVA. Multiple comparison correction was performed using Dunn’s multiple testing 
correction test. P<0.05 was considered statistically significant. Significance levels are 
reported as *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
Supplementary figure 4: Comparison of memory B cell subsets of early and late ART group. 
Comparison of memory B cell subsets defined by CD21/CD27 expression among IgA, IgG1 
and IgG3 expressing memory B cells between early (n=11; grey dots) and late (n=8; black 
circles) ART group after 1 year of ART is shown. Mann-Whitney test was used. P<0.05 was 
considered statistically significant. 
 
Supplementary figure 5: SPADE clustering analysis to reveal phenotypic diversity of 
memory B cells in healthy donors and HIV-1 infection 
(A) SPADE trees were generated from class-switched B cells (CD19+IgD-CD38low) of healthy 
controls (n=15) and HIV-infected patients (n=15) at acute and chronic stage and after 1 year 
of ART. Shown is the SPADE tree from all 15 HIV-1 infected patients after 2 years of chronic 
infection concatenated. Cluster size corresponds to the frequency of cells in the cluster. 
Regions of the tree consisting of IgA-, IgG1-, IgG3- and other isotype-expressing memory B 
cells and plasmablasts are highlighted as green, red, blue and yellow areas, respectively. B 
cells expressing a different isotype are highlighted in the purple area. The expression 
intensities as arcsinh-transformed MFI values for markers (B) not included (CD19 and 
CXCR4) and (C) used for SPADE clustering are shown. Expression levels are depicted. 
Color range is from blue to yellow indicating low to high expression, respectively.  
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Supplementary figure 6: Ward hierarchical clustering of SPADE clusters 
Heatmap based on expression of phenotypic markers from the individual SPADE clusters is 
shown. Ward hierarchical clustering was done with marker used for SPADE clustering, 
namely CCR7, CXCR4, CXCR5, IL-21R, Ki-67, IgA, IgG1, IgG3, CD21, CD27 and CD38. 
CXCR4 and CD19 were not used for Ward hierarchical clustering but are depicted on the 
heatmap. Expression is based on z-score transformed arcsinh MFI values. Clusters are 
ordered based on Ward hierarchical clustering and the coloring of the dendrogram shows the 
cut-off used to define Ward clusters. Ward clusters are numbered from 1-40 according to the 
ordering based on Ward hierarchical clustering. 
 
Supplementary figure 7: Comparison of the frequency of RM or AM B cells defined based 
on manual and computational analysis.  
(A) The frequencies of RM and AM B cells from HIV-infected patients (n=15) at the chronic 
stage of infection estimated with computational (black dots) and manual gating (red circles) 
are shown. (B) Frequency of total CCR7high cells within RM and AM B cells are compared 
from the same donors. CCR7high cells encompass cells exhibiting the highest expression 
levels of CCR7 (Figure 7A, red boxes) as estimated with the Ward clustering approach. 
Wilcoxon matched-pairs signed rank test was used to compare manual and computational 
analysis. P<0.05 was considered statistically significant. Significance levels are reported as 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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6.10 Supplementary tables and figures 
 
Supplementary table 1 
Time point Parameter Early ART group 
(n=11) 
Late ART group 
(n=8) 
p-value 
 
Acute 
 
Weeks of infection 
 
5 (3-8) 
(n=11) 
 
13.5 (8-24) 
(n=6) 
 
0.0002 
 Viral load 475000 (2380-12400000) 
(n=11) 
1930 (261-107000) 
(n=5) 
0.0275 
 CD4 counts 724 (436-816) 
(n=5) 
 
633.5 (402-1120) 
(n=4) 
0.5368 
Chronic 2 years Weeks of active 
virus replication 
112 (101-138) 125 (104-139) 0.1838 
 Weeks off ART 109 (94-134) Not available 0.2627a 
 Viral load 14200 (140-122000) 86400 (49-580000) 0.1087 
 CD4 counts 569 (371-945) 
 
263 (163-1429) 
(n=7) 
 
0.0992 
ART 1 year Weeks on ART 53 (33-68) 58.5 (20-68) 0.3167 
 Viral load 0 (0-0) 0 (0-58) 0.0578 
 CD4 counts 798 (460-1363) 579 (278-804) 
(n=7) 
0.0154 
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Chapter 7                                                                      HIV-1 gp120-mediated modulation of CD4+ T cell activation 
7. The Orientation of HIV-1 gp120 Binding to CD4 Receptor 
Differentially Modulates CD4+ T cell activation 
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The Orientation of HIV-1 gp120 Binding to the CD4 Receptor
Differentially Modulates CD4+ T Cell Activation
Kathrin Zimmermann,* Thomas Liechti,† Anna Haas,* Manuela Rehr,* Alexandra Trkola,†
Huldrych F. G€unthard,‡ and Annette Oxenius*
Progressive quantitative and qualitative decline of CD4+ T cell responses is one hallmark of HIV-1 infection and likely depends on
several factors, including a possible contribution by the HIV-1 envelope glycoprotein gp120, which binds with high affinity to the
CD4 receptor. Besides virion-associated and cell-expressed gp120, considerable amounts of soluble gp120 are found in plasma or
lymphoid tissue, predominantly in the form of gp120–anti-gp120 immune complexes (ICs). Because the functional consequences of
gp120 binding to CD4+ T cells are controversially discussed, we investigated how gp120 affects TCR-mediated activation of human
CD4+ T cells by agonistic anti-CD3 mAb or by HLA class II–presented peptide Ags. We show that the spatial orientation of gp120–
CD4 receptor binding relative to the site of TCR engagement differentially affects TCR signaling efficiency and hence CD4+ T cell
activation. Whereas spatially and temporally linked CD4 and TCR triggering at a defined site promotes CD4+ T cell activation by
exceeding local thresholds for signaling propagation, CD4 receptor engagement by gp120-containing ICs all around the CD4+
T cell undermine its capacity in supporting proximal TCR signaling. In vitro, gp120 ICs are efficiently captured by CD4+ T cells
and thereby render them hyporesponsive to TCR stimulation. Consistent with these in vitro results we show that CD4+ T cells
isolated from HIV+ individuals are covered with ICs, which at least partially contain gp120, and suggest that IC binding to CD4
receptors might contribute to the progressive decline of CD4+ T cell function during HIV-1 infection. The Journal of Immunol-
ogy, 2015, 194: 637–649.
H ealthy immune systems allow humans to cope lifelongwith multiple persistent virus infections (1, 2). However,HIV-1 infection causes progressive deterioration of the
immune system that ultimately leads to death due to opportunistic
infections. Systemic immune activation as well as the continuous
decline of a functional CD4+ T cell response are main contributors
to disease progression (3–5). The capacity of HIV-1 to progres-
sively debilitate the immune system is multifaceted and incom-
pletely understood. For example, the rapid evolution of HIV-1
owing to its high mutation rate (6–8), as well as its potential to
establish viral reservoirs in resting memory CD4+ T cells (9, 10),
helps HIV-1 to evade functional immune responses. Furthermore,
the HIV-1 surface envelope gp120 renders CD4+ T cells prime
targets for infection (11, 12) via the high-affinity gp120–CD4
receptor interaction (13) and thereby enables HIV-1 uniquely
among persistent viruses to directly interfere with CD4+ T cells,
which are known to take a central position in adaptive immunity.
Interestingly, the extent of qualitative (14) and quantitative (5, 15)
defects within the CD4+ T cell population in HIV-1–infected
individuals is disproportionally high in comparison with the levels
of infectious virus and productively infected cells (16, 17), argu-
ing against the fact that CD4+ T cell–directed viral cytopathicity is
the major contributor to disease progression. However, HIV-1
replication, which is fundamental to disease progression, is not
only associated with virion-associated envelope glycoprotein but
also with soluble gp120 and gp160 due to shedding from the virus
or from infected cells (18, 19). Consequently, soluble gp120 is
present in the plasma (20–22) or lymphoid tissues of HIV+
patients (23, 24), and together with the appearance of dysfunc-
tional CD4+ T cells, it is conceivable that binding of soluble gp120
to CD4+ T cells may be a central parameter in HIV-1 pathogenesis
that could at least partially explain the high proportion of dys-
functional CD4+ T cells.
CD4 receptors play a crucial role in enhancing sensitivity of
TCR-triggered T cell activation by interacting with MHC class II
(MHC II) molecules on APCs (25, 26) and by their noncovalent
interaction with the src family tyrosine kinase p56lck whose acti-
vation initiates TCR signaling progression (26–29). In line with
this, a plethora of in vitro studies provide experimental proof that
gp120 binding to the CD4 receptor interferes with TCR-induced
CD4+ T cell activation (30–47). However, the effect of nonin-
fectious gp120–CD4 receptor interaction on CD4+ T cell activa-
tion is still a contradictory issue in the literature, and the gp120
levels measured in plasma of HIV+ patients may be below those
that have functional effects on cells in vitro (48). On the one hand,
gp120 interaction with CD4 receptors was suggested to enhance
the activation of CD4+ T cells in terms of increased calcium
signaling and IL-2R expression (44), transiently enhanced p56lck
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activity (46, 47), activation of the transcription factors AP-1 (45),
and elevated proliferation (49). On the other hand, gp120 binding
to CD4+ T cells was shown to reduce their activation mediated
through TCR stimulation (30–43). Mechanisms to explain gp120-
induced negative effects on CD4+ T cell activation are manifold:
gp120-mediated cross-linking of CD4 receptors was suggested to
induce CD4 receptor endocytosis (33, 35, 36, 41, 46), to prevent
peptide–MHC II–CD4 receptor interaction (37, 50) through in-
terference of gp120 with the MHC II binding site on the CD4
receptor (51), to abolish proximal TCR signaling (32, 34, 38, 40,
52), or to redistribute p56lck away from TCRs or from the im-
munological synapse (IS) (39, 53).
Based on these controversial reports and the possibility that
gp120 binding to the CD4 receptor interferes with CD4+ T cell
function, we investigated in detail whether and how non–virion-
associated gp120 modulates TCR-induced CD4+ T cell activation.
With the aim to mimic the in vivo situation as close as possible,
we performed our in vitro experiments with primary CD4+ T cells
and gp120–anti-gp120 immune complexes (ICs), as these are the
predominant in vivo form of non–virion-associated gp120 (54,
55). To assess the impact of gp120–anti-gp120 ICs on CD4+ T cell
activation, we stimulated cells either with agonistic anti-human
CD3 mAb or with HLA class II–presented peptide Ags.
Our mechanistic study revealed that gp120–anti-gp120 ICs were
rapidly and quantitatively transferred from APCs to CD4+ T cells.
Importantly, following this process, IC-engaged CD4 receptors
proved to substantially prevent subsequent TCR-mediated acti-
vation of CD4+ T cells. In contrast, CD4 and TCR cross-linking
induced in vitro by immobilized gp120 and anti-human CD3 mAb
on a planar substrate in close proximity promoted full CD4+ T cell
activation. Thus, the microanatomical environment of how gp120
cross-links CD4 receptors appears to be crucial for the ensuing
effect on CD4+ T cell activation. Our data thereby offer an ex-
planation for the contradictory results of previous in vitro studies,
reporting either enhanced or reduced CD4+ T cell activation upon
gp120–CD4 receptor interaction. Furthermore, we demonstrate
that CD4+ T cells from HIV-1 patients are covered with ICs that at
least partly contain gp120, as also reported in Refs. 54–59, and
therefore suggest that gp120-containing ICs impair CD4+ T cell
activation and hence represent a crucial driving force of HIV-1
pathogenesis.
Materials and Methods
Ethics
Patients were enrolled in the Swiss HIV Cohort Study (60) or the Zurich
Primary HIV Infection Study at the Division of Infectious Diseases and
Hospital Epidemiology, University Hospital Zurich (http://clinicaltrials.
gov, ID no. 5 NCT00537966) (61). Approval and written informed con-
sent from patients were obtained according to the guidelines of the Ethics
Committee of the University Hospital Zurich.
Cell preparation
Citrate-phosphate-dextrose anticoagulated buffy coats of healthy human
adults were purchased from the Swiss Red Cross (Blutspende Z€urich,
Schlieren, Switzerland), and EDTA anti-coagulated blood was obtained
from HIV+ and HIV2 individuals from the University Hospital Zurich
(Zurich, Switzerland). Viral load in HIV-1+ blood was determined at the
Institute for Medical Virology at the University of Zurich (see Table I for
detailed information). PBMCs were isolated by density centrifugation
on lymphocyte separation media. Cells were washed in PBS and resus-
pended in RPMI 1640 supplemented with 10% FBS, 100 U/ml penicillin,
100 mg/ml streptomycin, and 2 mM L-glutamine (all reagents from PAA
Laboratories, Pasching, Austria), which is referred to as RPMI 10
throughout. When PBMCs were not directly used for experiments, they
were cryopreserved in RPMI 1640 supplemented with 20% FBS and 10%
DMSO (Sigma-Aldrich Chemie, Buchs, Switzerland). Cell viability was
determined by 0.4% trypan blue exclusion (Invitrogen, Basel, Switzerland)
and assessed to be .90%. CD4+ T cells and CD14+ monocytes were
isolated from PBMCs using anti-CD4 and anti-CD14 microbeads (Miltenyi
Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s
instructions.
Plasma samples
Plasma samples from HIV-1 patients (see Table II for detailed information)
were heat inactivated at 56˚C for 60 min and stored at 280˚C until pro-
cessing. Plasma viral loads (copies/ml), IgG anti-gp120 (JR-FL) titer, as
well as IgG anti-gp120–CD4 binding site (CD4BS) titer were determined
as described previously (62).
CFSE labeling
For CFSE labeling, CD4+ T cells were incubated at a concentration of 53 106
cells/ml in PBS supplemented with 10% FBS and 5 mM CFSE (Molecular
Probes/Life Technologies Europe, Zug, Switzerland) for 11 min at 37˚C.
Afterward, cells were washed twice with cold RPMI 10 to quench residual CFSE
and finally resuspended with RPMI 10 at an appropriate cell concentration.
IC preparation
ICs were prepared by incubating mammalian cell–derived recombinant
HIV-1 gp120 JR-FL (endotoxin level , 1 endotoxin units/mg; Progenics
Pharmaceuticals, Tarrytown, NY) or gp120 LAI together with non-CD4BS
anti-gp120 mAbs [clone 2G12 (63) and clone 1-79 (64)] or with CD4BS
anti-gp120 mAbs [clone b6 (65) and b12 (66)] at a molar gp120/anti-gp120
mAb ratio of ∼4:5 (final concentration of gp120 [f.c.gp120] 5 mg/ml) to
prepare gp120–anti-gp120 IC and gp120–anti-gp120–CD4BS control IC,
respectively. Gp120 LAI and anti-gp120 Abs 2G12, 1-79, b6, and b12 were
provided by A. Trkola. For the generation of gp120 containing ICs with
plasma from HIV-1+ donors, plasma from HIV-12 and HIV-1+ donors and
recombinant HIV-1 gp120 JR-FL were both diluted 1:100 and incubated
for at least 2 h.
In vitro CD4+ T cell stimulation assay with plate-immobilized
stimuli
CD4+ T cells (2 3 106/ml) were activated with plate-immobilized stimuli
in a final volume of 100 ml RPMI 10. Plate immobilization of stimuli was
done by incubating anti-human CD3 mAb (clone OKT3), anti-human
CD28 mAb (clone CD28.2 or clone CD28.6), anti-human CD4 mAb
(clone SK3; all from eBioscience, Vienna, Austria) recombinant gp120 JR-
FL/LAI/CAAN (provided by A. Trkola) or ICs/control ICs (prepared as
described previously) in a total volume of 100 ml PBS on F-bottom 96-well
plates (Nunc Maxisorp; Sigma-Aldrich Chemie) for at least 18 h. Anti-
human CD3 mAbs (50 ng/well) were used alone to induce subthreshold
T cell activation or in combination with 0.8 mg/well gp120 or 1 mg/well
anti-human CD28 mAb/CD4 mAb. To induce full T cell activation by the
TCR alone, 1 mg anti-human CD3 mAb was coated on each well. For the
stimulation of mouse CD4+ T cells, anti-mouse CD3ε mAb and anti-mouse
CD28 mAb (both from BioLegend, Lucerna Chem AG, Lucerne, Swit-
zerland) were used at similar concentrations as human-specific Abs. For
internal assay controls, CD4+ T cells were left unstimulated or mitogeni-
cally stimulated with PMA (50 ng/ml) in combination with ionomycin
(500 ng/ml, both from Sigma-Aldrich Chemie). When indicated, the gp120
binding site on the CD4 receptor was blocked by preincubation of the
CD4+ T cells with anti-human CD4 mAbs (10 mg/ml, clone SK3) for 1 h at
37˚C or actin polymerization was blocked by preincubation of the CD4+
T cells with cytochalasin D (50 mM, Sigma-Aldrich Chemie) for 30 min at
37˚C prior to stimulation. For intracellular analysis of IL-2 expression,
brefeldin A (10 mg/ml, Sigma-Aldrich Chemie) was added during the final
4 h of stimulation. Expression of CD40L, CD69, IL-2, IFN-g, and TNF-a
was analyzed after 6 h, and expression of CD25 and CD38 as well as
proliferation by CFSE dilution after 5 d of stimulation at 37˚C was as
described below under “Flow cytometric analysis.”
In vitro CD4+ T cell stimulation assay with autologous
monocytes
CD4+ T cells (2 3 105) were stimulated with autologous CD14+ mono-
cytes (1 3 105) in round-bottom 96-well cell culture plates in a final
volume of 100 ml RPMI 10. Monocytes were loaded by sequential incu-
bation of anti-human CD3 mAb (0.5–10 ng/ml, clone OKT3) for 30 min at
4˚C or with CMV lysate (1:50, Virion, R€uschlikon, Switzerland) overnight
at 37˚C followed by incubation with ICs/control ICs (f.c.gp120 of 5 mg/ml) or
gp120 containing ICs generated with plasma from HIV-12 and HIV-1+
donors (final dilution factor 100–400) (as described for IC preparation) for
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30 min at 4˚C. Expression of CD69 was analyzed after 6 h, and ex-
pression of CD25 and CD38 as well as proliferation by CFSE dilution
after 5 d of stimulation at 37˚C was as described below under “Flow
cytometric analysis.”
Western blot analysis of phospho–linker for activation of
T cells expression in CD4+ T cells
For the analysis of levels of phosphorylated and unphosphorylated linker for
activation of T cells (LAT), cells were cultured in RPMI 1640 supplemented
with 10% human serum (type AB), 100 U/ml penicillin, 100 mg/ml
streptomycin, and 2 mM L-glutamine (all reagents from PAA Laborato-
ries). CD4+ T cells were preactivated for 2 d with plate-immobilized anti-
human CD3 mAb (50 ng/well) in combination with anti-human CD28
mAb (1 mg/well), rested for 3 d in fresh medium, and ultimately stimulated
with plate-immobilized stimuli as described above under “In vitro CD4+
T cell stimulation assay with plate-immobilized stimuli.” Cells (6 3 105)
were lysed in 30 ml cell lysis buffer (Cell Signaling Technologies/
BioConcept, Allschwil, Switzerland) in the presence of phosphatase in-
hibitor tablets (Thermo Fisher Scientific, Reinach, Switzerland). Proteins
were separated on a 10% SDS polyacrylamide gel and transferred to
0.2-mm pore size nitrocellulose transfer membranes (Schleicher and
Schuel, Dassel, Germany). The amount of phosphorylated LAT was
determined by polyclonal anti–phospho-LAT Ab (Tyr171, 1:1000) fol-
lowed by HRP-conjugated goat anti-rabbit Ab (1:5000, Jackson Immu-
noResearch Laboratories, Suffolk, U.K.) using Amersham ECL technology
(GE Healthcare, Glattbrugg, Switzerland). To measure the level of non-
phosphorylated LAT protein, the membrane was reprobed after stripping
with a polyclonal anti-LAT Ab (Cell Signaling Technology). Signal
intensities were quantified by ImageJ (National Institutes of Health,
Rockville, MD). After background subtraction, the signal intensity of
phosphorylated LAT was normalized to the amount of nonphosphorylated
LAT, and fold increase of normalized levels versus the unstimulated
controls was calculated.
Microtubule organizing center polarization analysis of CD4+
T cells in the context of plate and cellular stimulation by
immunofluorescence confocal microscopy
For analysis of microtubule organizing center (MTOC) polarization in the
context of plate stimulation, CD4+ T cells were incubated for 2 h on 12-mm
round coverslips (Karl Hecht Assistent, Altnau, Switzerland) that have pre-
viously been coated for at least 18 h with anti-human CD3 mAb (50 ng/ml)
in combination with ICs/control ICs (f.c.gp120 of 5 mg/ml) diluted in PBS
containing 0.0025% poly-L-lysine (Sigma-Aldrich Chemie). MTOC po-
larization analysis in the context of cellular stimulation was performed as
described above under “In vitro CD4+ T cell stimulation assay with au-
tologous monocytes” except that stimulation was performed for 2 h only
and cells were adhered onto poly-L-lysine (0.0025%) coated coverslips.
After stimulation, cells were fixed with PBS containing 4% paraformal-
dehyde for 15 min at room temperature, followed by permeabilization
(20% lysing solution [BD Biosciences, Allschwil, Switzerland] and 0.05%
Tween 20 [National Diagnostics, Chemie Brunschwig, Basel, Switzer-
land]) for 10 min at room temperature. MTOC structures were visualized
by staining with an anti–tubulin-b mAb (clone 9F3, Cell Signaling
Technology/Bioconcept, Allschwil, Switzerland) overnight at 4˚C in a hu-
mid chamber and Cy3-conjugated anti-rabbit ab (Jackson Immuno-
Research Laboratories) for 30 min at room temperature.
Analysis of IC localization by flow cytometry or
immunofluorescence confocal microscopy
For the analysis of IC localization by immunofluorescence confocal mi-
croscopy, CD14+ monocytes were loaded with ICs/control ICs (as described
above under “In vitro CD4+ T cell stimulation assay with autologous
monocytes”) and cocultured for 30, 60, or 120 min with CD4+ T cells on
poly-L-lysine (0.0025%; Sigma Aldrich Chemie)–coated coverslips. When
indicated, CD4+ T cells were preincubated with anti-human CD4 mAbs
(10 mg/ml, clone SK3; eBioscience) for 1 h at 37˚C. ICs were visualized by
staining with a Cy3-conjugated anti-human IgG Ab (Jackson Immuno-
Research Laboratories) for 30 min at room temperature. For the analysis of
IC localization by flow cytometry, CD4+ T cells were cocultured with IC/
control IC–loaded CD14+ monocytes or directly with gp120 containing ICs
generated with plasma from HIV-12 and HIV-1+ donors (final dilution of
1:100). After 6 h, IC localization was investigated by staining with an
FITC-conjugated anti-human IgG (H+L) (Jackson ImmunoResearch Lab-
oratories) as described below under “Flow cytometric analysis.”
Immunofluorescence confocal microscopy
After staining, cells were fixed with PBS containing 4% paraformaldehyde
for 15 min at room temperature and briefly rinsed with distilled H2O before
mounting in VectaShield (Vector Laboratories, Burlingame, CA) contain-
ing 0.1% DAPI (Sigma-Aldrich Chemie) for visualization of nuclear DNA.
Confocal immunofluorescence microscopy was performed with an inverted
confocal microscope (Axiovert 200, Carl Zeiss) equipped with an oil-phase
contrast objective (363 oil objective, Plan Neofluar, 1.25 numerical ap-
erture, Carl Zeiss) and a CSU-X1 spinning-disk confocal unit (Yokogawa)
and a solid-state laser unit with four laser lines (405, 488, 561, an 647 nm;
Toptica). Data analysis was done with Volocity 5.0.3 (Improvision, Cov-
entry, U.K.). Quantification of IC staining was done by evaluation of the
integrated signal density by ImageJ (National Institutes of Health), with
values being normalized to cell size. Analysis of MTOC polarization was
done by visual scoring as described in Fig. 6B, 6E.
Flow cytometric analysis
Cells were surface stained with fluorochrome-conjugated anti-CD3 (clone
UHCT-1), anti-CD4 (clone SK3), anti-CD8 (clone SK1), anti-CD14 (clone
61D3), anti-CD25 (clone BC96), anti-CD38 (clone HIT-2a), anti-CD40L
(clone TRAP1), anti-CD69 (clone FN50), or anti-human IgG (H+L)
(Jackson ImmunoResearch Laboratories) for 30 min at 4˚C. Gp120 binding
on CD4+ T cells was assessed by FITC (Sigma-Aldrich Chemie)-
conjugated gp120 staining for 30 min at 4˚C. For the analysis of in-
tracellular IL-2 expression, surface staining was followed by a per-
meabilization step of 10 min at room temperature (20% lysing solution and
0.05% Tween 20) and staining with anti–IL-2 (clone MQ1-17H12), anti–
IFN-g (clone B27), and anti–TNF-a (clone 6401.1111) for 30 min at room
temperature. Abs were from BioLegend, Lucerna Chem, or BD Bio-
sciences unless specified otherwise. When staining was performed in
whole blood (Fig. 7A–C), RBCs were lysed with lysing solution directly
after staining for 10 min at room temperature. For compensation, a com-
bination of anti-mouse Igk/negative control compensation particles (BD
Biosciences) or PBMCs were used. Cells were resuspended in PBS con-
taining 1% paraformaldehyde before acquisition. Acquisition was done on
an LSR II flow cytometer (BD Biosciences) using FACSDiva software.
Samples were acquired on the day of the analysis and usually 1–3 3 105
cells of interest were acquired. Doublets were excluded using side and
forward scatter area and width parameters, and negative biological or
fluorescence minus one controls were used to set gates. Data analysis was
done with FlowJo software (Tree Star, San Carlos, CA). Cells were se-
quentially gated on lymphocytes, singlets, and CD3+CD4+ cells unless
mentioned otherwise in the figure legend.
FACS
PBMCs were surface stained using anti-CD3 (clone UHCT-1), anti-CD4
(clone RPA-T4), anti-CD8 (clone SK1), and anti-CD14 (clone 61D3) for
30 min at 4˚C. Abs were from BioLegend, Lucerna Chem, or BD Bio-
Table I. Characteristics of HIV-12infected individuals
Patient ID Gender
Time Period of
HIV-1 Infection
CD4+ T Cell
Count/ml
Plasma
Viral Load
(Copies/ml)
1 M ,5 y 20 290,000
2 M ,5 y 114 50,200
3 M ,5 y 359 257,443
4 M ,5 y 579 38,987
5 M .10 y 314 22,558
6 M .10 y 209 27,208
Table II. Characteristics of plasma samples from HIV-1 patients
Patient ID
IgG Anti-gp120
(JR-FL) Titer
IgG Anti–gp120-
CD4BS Titer
Plasma
Viral Load
(Copies/ml)
1_1 15,107 6682 22,510
1_2 14,166 4926 283,140
1_3 7,342 5590 53,500
2_1 16.54 1a 29,700
2_2 8.23 1a 32,800
aValues , 1 indicate undetectable levels of anti–gp120-CD4BS Ab titers.
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sciences. Cells were isolated on a FACSAria (BD Biosciences) using
FACSDiva software.
Statistical analysis
Data were analyzed and plotted with GraphPad Prism (GraphPad Software,
La Jolla, CA) and results are illustrated as means 6 SEM. Statistical
analysis was performed as specified in the figure legend. A p value ,0.05
was considered statistically significant. In the figure legends, n values in-
dicate individual donors unless specified otherwise.
Results
Plate-immobilized gp120 enhances TCR-induced activation of
CD4+ T cells
CD4 receptors play an essential role in TCR-mediated activation of
CD4+ T cells through their intracellular association with the
T cell–specific kinase p56lck (26–29). Because gp120 binds with
high affinity to the CD4 receptor (13), a potential modulating
capacity of TCR-driven CD4+ T cell activation is attributed to
gp120. Based on the importance of CD4+ T cells as central players
of the adaptive immune system and the high availability of soluble
gp120 in the plasma or lymphoid tissue of HIV-1 patients (20–24),
we set out to investigate how non–virion-associated gp120 affects
TCR-induced CD4+ T cell activation. In a first in vitro assay, CD4+
T cells from healthy donors were stimulated with plate-immobilized
recombinant gp120 in combination with low amounts (50 ng/well)
of agonistic anti-human CD3 mAb, which we previously deter-
mined to induce only marginal CD4+ T cell activation by itself. In
combination, however, simultaneous CD4 receptor/TCR cross-
linking by plate-immobilized gp120/anti-human CD3 mAb signifi-
cantly enhanced CD4+ T cell activation compared with gp120 and
anti-CD3 stimulation alone to a similar level as CD28-induced
costimulation. Activation was determined by the expression of
early T cell activation markers CD69 and CD40L within 6 h
(Fig. 1A–D) and levels of proliferation were measured by CFSE
dilution after 5 d (Fig. 1E, 1F). Importantly, CD4 receptor cross-
linking by gp120 in the absence of concomitant TCR stimulation
did not have any activating capacity on CD4+ T cells (Fig. 1A, 1B).
Of note, a low level of CD4+ T cell activation is not only enhanced
by R5-tropic HIV-1 envelope glycoprotein gp120 strain JR-FL but
also by gp120 originating from the R5-tropic strain CAAN, the X4-
tropic strain LAI, as well as by anti-CD4 mAbs (Fig. 1C), sup-
porting the fact that TCR-induced CD4+ T cell activation is en-
hanced by concomitant CD4 receptor cross-linking rather than
a gp120 intrinsic property. Ligation of CD4 receptors supports TCR
signaling in a quantitative manner that allows the expression of
activation markers and proliferation; however, cytokine expression
in T cells critically depends on a qualitative, distinct costimulatory
signal such as induced by the ligation by CD28 (67, 68). In line with
a selective role of CD4 receptors in reinforcing proximal TCR
signaling, IL-2, INF-g, and TNF-a production was not robustly
induced by gp120-mediated CD4 receptor cross-linking in contrast
to CD28 costimulatory conditions (Fig. 1G, 1H). These data suggest
that CD4 receptor cross-linking quantitatively supports TCR-
induced signaling, yielding a high level of CD4+ T cell activation
when signals are provided in close temporal and spatial proximity.
Gp120-mediated increase of CD4+ T cell activation depends
on gp120 binding to the CD4 receptor
The capacity of gp120 to selectively enhance TCR-induced acti-
vation of human (Fig. 1) and not mouse CD4+ T cells (Fig. 2A),
whose CD4 receptor does not bind gp120 (69), indicates that
gp120–CD4 receptor interaction is crucial for gp120-mediated
enhancement of CD4+ T cell activation and also excludes the
possibility that impurities of the gp120 preparation influenced the
observed CD4+ T cell activation. To substantiate the prerequisite
of gp120–CD4 receptor interaction in promoting CD4+ T cell
activation, we used in a next step Abs that specifically blocked
the gp120 binding site on the CD4 receptor (70). As expected,
gp120 binding to CD4+ T cells was reduced to background levels
in the presence of the CD4 receptor blocking Ab (clone SK3)
(Fig. 2B, 2C), and such blocking of the gp120 binding site on the
CD4 receptor selectively abrogated anti-CD3/gp120– but not anti-
CD3/anti-CD28–induced activation of CD4+ T cells (Fig. 2D).
Furthermore, CD8+CD4+ T cells, which are present in the blood at
low frequencies (71), were efficiently activated by gp120 in the
presence of low amounts of anti-human CD3 mAb, whereas this
was not the case for CD8+CD42 T cells (Fig. 2E).
The CD4 receptor–associated p56lck is crucial for proximal TCR
signaling (26, 27, 72) by initiating a sequential cascade of tyrosine
phosphorylation on signaling molecules, as for example on LAT,
which is the nucleating site for multiprotein signaling complexes
(73). We found that simultaneous CD4 receptor/TCR cross-linking
by plate-immobilized gp120 and low amounts of plate-immobilized
anti-human CD3 mAb induced slightly elevated levels of phos-
phorylated LAT, similar as with CD28 costimulatory conditions, in
relationship to CD4+ T cells that received weak TCR stimulation
alone (Fig. 2F, 2G).
These experiments support the notion that gp120 binding to the
CD4 receptor not only represents the first step of viral entry, but it
also has the potential to significantly increase CD4+ T cell acti-
vation by quantitatively supporting proximal TCR signaling.
Gp120–anti-gp120 ICs activate CD4+ T cells in a comparable
manner to monomeric gp120
Because gp120 (20–24) as well as anti-gp120 Abs (74–76) are
present in HIV-1 patients, gp120–anti-gp120 ICs are likely to be
generated and abundant in vivo (54, 55). We therefore generated
such gp120–anti-gp120 ICs by coincubating recombinant gp120
with two different human IgG anti-gp120 mAb at a molar gp120/
anti-gp120 mAb ratio of ∼4:5. As schematically shown in Fig. 3A,
either two different anti-gp120 mAbs that block the CD4BS
[clones b6 (65) and b12 (66, 77)] or anti-gp120 mAbs that spare
the CD4 binding site (non-CD4BS) [clones 2G12 (63) and 1-79
(64)] were used for the formation of gp120–anti-gp120–CD4BS
control IC (left) or gp120–anti-gp120 IC (right), which are
henceforth referred to as control IC or IC, respectively. Conse-
quently, the control IC, which contains anti-gp120 Abs that target
the CD4BS, does not allow any interaction with the CD4 receptor
and is not expected to have any functional effect on CD4+ T cells.
Our results clearly showed that similarly to non–virion-associated
gp120 alone, plate-immobilized IC significantly enhanced CD4+
T cell activation induced by weak TCR stimulation as measured
by CD69 expression (Fig. 3B, 3C) after 6 h. In contrast, the
control IC failed to do so (Fig. 3B, 3C). Additionally, proliferation
of CD4+ T cells determined by CFSE dilution as well as the ex-
pression of late T cell activation markers CD25 and CD38 were
significantly increased in the presence of IC compared with the
control IC in combination with low level of TCR stimulation
(Fig. 3D, 3E) after 5 d. Thus, gp120 within the context of ICs
enhances a low level of TCR-driven CD4+ T cell activation in
a CD4 receptor–dependent manner similar to gp120 alone.
Fast transfer of monocyte-bound gp120–anti-gp120 IC to the
CD4 receptor of CD4+ T cells
In a next step, we set out to investigate whether the activating
potential of gp120 can be translated to a more physiological sit-
uation. To mimic a condition in which ICs made of gp120 and anti-
gp120 Abs interact with CD4 receptors during TCR-induced CD4+
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T cell stimulation by APCs, CD4+ T cells from healthy donors
were stimulated with autologous monocytes that had been previ-
ously incubated with gp120 containing ICs as well as anti-human
CD3 mAb. Initially, flow cytometric determination of IC locali-
zation was performed by the analysis of human IgG binding after
6 h of coculture on CD4+ T cells or CD14+ monocytes. Control
ICs were predominantly found on the CD14+ monocytes whereas
the IC was almost exclusively found on CD4+ T cells (Fig. 4A). A
similar localization pattern of control IC and IC was confirmed by
the analysis of human IgG localization after 2 h by confocal mi-
croscopy (Fig. 4B). These experiments showed that only the IC
and not the control IC was efficiently transferred to the CD4+
T cells from monocytes on which they were initially localized.
The cell–cell transfer of ICs proved to be very fast and efficient, as
already after 60 min most ICs were localized on CD4+ T cells
(Fig. 4C). Furthermore, the transfer of ICs to CD4+ T cells was
abrogated in the presence of an anti-human CD4 mAb, which
blocks the gp120 binding site on the CD4 receptor (Fig. 4D, 4E).
TCR-induced CD4+ T cell activation is impaired in the presence
of CD4 receptor cross-linking by gp120–anti-gp120 IC
We next investigated whether ICs, which were transferred from
monocytes to CD4 receptors on CD4+ T cells, would also reinforce
responsiveness toward TCR stimulation induced by anti-human
CD3 mAb–coated monocytes, as this was the case when the TCR
and CD4 receptor were cross-linked in close proximity at a de-
fined site, as for example upon immobilization of the stimuli on
a plate (Figs. 1–3).
Toward this end, CD4+ T cells were stimulated with monocytes
that had been previously loaded with ICs that contain gp120 in
FIGURE 1. Plate-immobilized gp120 increases TCR-induced activation of CD4+ T cells. CD4+ T cells from healthy donors were stimulated for 6 h (A–D,
G, and H) or 5 d (E and F) with subactivating amounts of plate-immobilized anti-human CD3 mAb in the presence or absence of gp120 (JR-FL, CAAN, and
LAI as indicated). Gp120 JR-FL was used unless mentioned otherwise. As control, CD4+ T cells were similarly stimulated with anti-human CD3 mAb in
combination with anti-human CD28 mAb, with gp120 alone, or they were left untreated. (A) Dot plot of one representative experiment showing CD69
expression on CD4+ T cells. (B) Bar graph depicting average expression levels of CD69 on CD4+ T cells (n = 20, bars represent mean 6 SEM, ****p ,
0.0001 one-tailed paired t test). (C) Bar graph depicting average expression levels of CD69 on CD4+ T cells (n = 20 for gp120 JR-FL, n = 6 for gp120
CAAN and LAI, n = 3 for anti-CD4 mAb; bars represent mean 6 SEM; **p , 0.01, ****p , 0.0001 one-tailed paired t test). (D) Bar graph illustrates the
expression of CD40L on CD4+ T cells (n = 6, bars represent mean 6 SEM; **p , 0.01 one-tailed paired t test). (E) Bar graph represents the average
frequency of CFSElowCD4+ T cells (n = 9, bars represent mean6 SEM; ***p, 0.001 one-tailed paired t test). (F) Representative flow cytometry histogram
depicts CFSE dilution profile of CD4+ T cells. (G) Representative flow cytometry histogram depicts TNF-a expression in CD4+ T cells. (H) Bar graph
illustrates the expression of TNF-a, IFN-g, and IL-2 on CD4+ T cells (n = 3, bars represent mean 6 SEM).
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combination with anti-human CD3 mAb. Gp120 within ICs either
allows an interaction with the CD4 receptor (IC) or does not allow
any interaction with the CD4 receptor (control IC). Interestingly,
ICs that were transferred to CD4+ T cells, and consequently not
only cross-linked CD4 receptors at the site of TCR engagement but
on the whole CD4+ T cell surface, impaired CD4+ T cell activation
induced by anti-human CD3 mAb–loaded monocytes in comparison
with control conditions with control IC–loaded monocytes. The
reduction was manifested by the expression of CD69 after 6 h
(Fig. 5B, 5C) or CD25 and CD38 expression as well as prolifer-
ation measured by CFSE dilution after 5 d (Fig. 5D, 5E). Im-
portantly, the inhibitory effect of IC on TCR-induced CD4+ T cell
activation was not limited to polyclonal activation induced by
anti-human CD3 mAb but also held true for CMV-specific CD4+
T cell activation induced by HLA class II–bound CMV peptides
on monocytes, as the levels of CD25 and CD38 expression as well
as proliferation of CMV-specific CD4+ T cells were significantly
reduced in the presence of IC compared with control IC (Fig. 5F).
The fact that IC-coated CD4+ T cells were still susceptible to
mitogenic stimulation with PMA and ionomycin (Fig. 5G) implies
that IC interferes with a proximal TCR signaling event rather than
rendering CD4+ T cells completely incompetent to respond to
activating stimuli in general.
Thus far, our data indicate that the way of CD4 receptor cross-
linking by gp120 dictates in which way TCR-driven CD4+ T cell is
FIGURE 2. Plate-immobilized gp120 enhances TCR-mediated activa-
tion of CD4+ T cells in a significant manner. (A) Representative flow
cytometry histogram illustrates CD69 expression on mouse CD4+ T cells
after stimulation with plate-immobilized anti-mouse CD3 mAb alone or in
combination with gp120 or anti-mouse CD28 mAb for 6 h. CD4+ T cells
isolated from HIV-12 human donors were preincubated with anti-human
CD4 mAb (clone SK3) to block the gp120 binding site on the CD4 re-
ceptor (B–D). (B) Representative flow cytometry histogram showing gp120
binding on CD4+ T cells with and without anti-human CD4 mAb. (C) Bar
graph depicting mean fluorescence intensity (MFI) signal in arbitrary units
(AU) of gp120 on CD4+ T cells with and without anti-human CD4 mAb (n
= 3, bars represent mean 6 SEM; **p , 0.01 one-tailed paired t test). (D)
Bar graph depicting the relative decrease in activation induced by stimu-
lation with plate-immobilized anti-human CD3 mAb plus gp120 or anti-
human CD3+ plus anti-human CD28 in the presence versus absence of
anti-human CD4 mAb (measured by CD69 expression after 6 h) (n = 9,
bars represent mean 6 SEM; ***p , 0.001 one-tailed paired t test). (E)
Bar graph summarizes the expression of CD69 on human CD8+CD42 (n =
3) or CD8+CD4+ (n = 2) T cells stimulated with plate-immobilized anti-
human CD3 with and without gp120 for 6 h (cells were sequentially gated
on lymphocytes, singlets, CD3+, and CD8+CD42/CD8+CD4+ cells, bars
represent mean 6 SEM; **p , 0.01 one-tailed unpaired t test). CD4+
T cells isolated from HIV-12 human donors were stimulated for 2–10 min
with plate-immobilized anti-human CD3 alone or in combination with
gp120/anti-human CD28 or they were left unstimulated (F and G). (F)
Corresponding representative immunoblot showing the levels of phos-
phorylated and unphosphorylated LAT. (G) Bar graph indicates the average
fold increase of phospho-LAT/LAT levels (n = 3, bars represent mean 6
SEM; ns, p = 0.0524 one-tailed paired t test).
FIGURE 3. Plate-immobilized gp120–anti-gp120 ICs augment TCR-in-
duced CD4+ T cell activation in a CD4 receptor–dependent manner. (A)
Schematic representation of gp120–anti-gp120–CD4BS control IC (ctrl IC;
left) and gp120–anti-gp120 IC (IC; right) consisting of gp120 in combination
with either two CD4BS anti-gp120 mAbs (clone b6 and b12) or non-CD4BS
anti-gp120 mAbs (clone 2G12 and 1-79) at a molar gp120/Ab ratio of ∼4:5.
CD4+ T cells were stimulated for 6 h (B and C) or for 5 d (D and E) with
plate-immobilized control IC or IC in the presence of anti-human CD3 mAb.
(B) Representative flow cytometry histogram showing CD69 expression on
CD4+ T cells. (C) Bar graph depicting CD69 expression on CD4+ T cells
(n = 4, bars represent mean6 SEM; **p, 0.01 one-tailed paired t test). (D)
Representative CFSE dilution profile and flow cytometry histogram showing
CD25 and CD38 expression on CD4+ T cells. (E) Bar graphs showing
percentage of CFSElow, CD25+, and CD38+CD4+ T cells (n = 5, bars rep-
resent mean 6 SEM; *p , 0.05, **p , 0.01 one-tailed paired t test).
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affected. Whereas simultaneous TCR/CD4 receptor cross-linking
confined to a specific site leads to enhanced CD4+ T cell activa-
tion, CD4 receptor cross-linking by IC not only at the site of TCR
engagement manifested impaired responsiveness toward TCR-
induced CD4+ T cell activation. We next aimed at elucidating
how the manner of CD4 receptor cross-linking with respect to
TCR engagement determines whether TCR signaling leads to
enhanced or reduced CD4+ T cell activation.
CD4 receptor cross-linking by gp120–anti-gp120 IC interferes
with clustering of signaling complexes at the site of TCR
engagement
TCR triggering induces a clustering of signaling complexes beyond
the engaged TCRs that upon sustained signaling gives rise to the
formation of IS (78–81). Such accumulation of surface and sig-
naling molecules depends on dynamic reorganization of the actin-
and tubulin-based T cell cytoskeleton (82–86), which is also re-
flected by the repositioning of the MTOC toward the site of
stimulation (87, 88). CD4 receptors are essential in proximal TCR
signaling (26–29) by recruiting p56lck to the establishing IS (89,
90). Because many TCR signaling molecules (e.g., the CD4 re-
ceptor) are indirectly or directly linked to the cytoskeleton (91–
93), this opens the possibility that gp120 binding to the CD4 re-
ceptor interferes with IS formation. Accordingly, when cytoskel-
eton dynamics were abrogated by disrupting actin polymerization
by cytochalasin D (94), TCR signaling induced by concomitant
CD4/TCR cross-linking at a defined site did not promote full
CD4+ T cell activation, whereas a functional, dynamic cytoskel-
eton supported the accumulation of signaling complexes under-
neath the engaged TCRs such that local signaling strength resulted
in full CD4+ T cell activation (Fig. 6A). Importantly, TCR- and
CD4-independent stimulation by PMA and ionomycin was not
dependent on a functional, dynamic actin cytoskeleton (Fig. 6A).
We therefore speculated that spatially and temporally linked en-
gagement of TCR and CD4 (as in the case of plate-immobilized anti-
human CD3 mAb and gp120) would favor IS formation. However,
when CD4 receptors are cross-linked over the entire surface of the
CD4+ T cell upon capturing ICs from monocytes, we suggest that the
cytoskeletal dynamics that are required for IS formation might be
impeded in such IC-decorated CD4+ T cells. To test this hypothesis,
we investigated MTOC positioning toward the growing synapse as
a marker for IS formation (87, 88) by staining for b-tubulin. Fig. 6B
shows representative confocal z-stack images of CD4+ T cells
stimulated by plate-immobilized anti-human CD3 mAb and gp120.
The left lane shows a CD4+ T cell in which the MTOC is oriented
toward the stimuli (referred to as polarized), whereas the right lane
depicts a CD4+ T cell in which the MTOC is not polarized. Fig. 6E
shows representative immunofluorescence images of CD4+ T cells
that were stimulated by anti-human CD3 mAb–loaded monocytes.
On the top, a situation is shown in which the MTOCs of both APC-
engaging CD4+ T cells point toward the site of cell–cell contact
(filled arrow, polarized), whereas the MTOC of the APC-engaging
CD4+ T cell shown in the bottom image points away from the cell–
cell contact (open arrow, not polarized). In line with the increased
CD4+ T cell activation induced by plate-immobilized anti-human
CD3 mAb and gp120 or IC (Figs. 1–3), MTOC polarization to-
ward the site of TCR stimulation site was increased in the presence
of IC (Fig. 6C, bottom, 6D) in contrast to the control IC (Fig. 6C,
top, 6D). Note that MTOC polarization was defined as MTOC being
localized in the cell hemisphere close to the planar surface. Because
MTOC position is random in resting, unstimulated CD4+ T cells, it
will by chance point toward the site of stimulation (i.e., the planar
surface) in ∼50% of the cells (data not shown).
In striking contrast to the results with the plate-immobilized sti-
muli, reduced TCR-induced CD4+ T cell activation in the presence
of IC on monocytes (Fig. 5) was associated with impaired MTOC
polarization toward the CD4+ T cell–APC interface, whereas
the presence of the control IC allowed efficient polarization of
MTOCs toward the site of TCR engagement (Fig. 6F, 6G).
These data indicate that the manner of gp120/CD4 receptor
cross-linking relative to the site of TCR engagement is crucial in
the decision whether MTOCs can polarize to the site of engaged
TCRs in a way that IS formation and hence CD4+ T cell activation
are supported.
CD4+ T cells from HIV-1 patients are covered with ICs
Based on the fact that gp120 is present in plasma from HIV-1
patients (20–22) and that HIV-1 infection is associated with ro-
FIGURE 4. Gp120–anti-gp120 ICs are transferred from monocytes to
CD4+ T cells in a CD4 receptor–dependent manner. (A) CD4+ T cells were
cocultured for 6 h with control IC or IC-loaded CD14+ monocytes. Bar
graph represents percentage of CD4+ T cells (open bar) and CD14+
monocytes (filled bar) that stain for human IgG as measure for control IC
and IC (as determined by flow cytometry). CFSE-labeled CD4+ T cells
were cocultured for 2 h (B, D, and E) or various time points (C) with
control IC or IC-loaded CD14+ monocytes. CD4+ T cells were pre-
incubated with an anti-human CD4 mAb (clone SK3) to block the gp120
binding site on the CD4 receptor when specified. n, number of individual
cells. (B) Representative confocal image showing anti-human IgG for vi-
sualization of IC (white) on CFSE-labeled CD4+ T cells (green) and CD14+
monocytes; nuclear DNA is visualized by DAPI staining (blue). Scale bars,
5 mm. (C) Bar graph represents quantification of fluorescence intensity of
anti-human IgG (in arbitrary units [AU]/mm2) as measure of IC on CD4+
T cells after 0 (input, n = 17), 30 (n = 25), 60 (n = 12), and 120 (n = 24)
min of coculture with IC-loaded monocytes (bars represent mean 6 SEM;
***p , 0.001 one-tailed unpaired t test). (D) Representative confocal image
of anti-human IgG staining (white) with and without anti-CD4. Scale bars,
5 mm. (E) Bar graph represents quantification of fluorescence intensity of
anti-human IgG (in AU/mm2) as measure for IC on CD4+ T cells in the
presence (n = 24) and absence (n = 22) of anti-CD4 (bars represent
mean 6 SEM; ***p , 0.001 one-tailed unpaired t test).
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bust Ab titers specific for HIV-1 surface structures (74–76, 95),
gp120–anti-gp120 ICs are suggested to be the predominant form
of gp120 in vivo (54, 55). Such complexes might either circulate
or more likely be bound by FcR or complement receptor–
expressing host cells. Based on the observation that monocyte-
bound ICs were efficiently transferred to CD4+ T cells in our
in vitro experiments (Fig. 4), we hypothesized that circulating
CD4+ T cells from HIV-1 patients might be decorated with gp120-
containing ICs. In line with this, we found that CD4+ T cells
isolated from blood of HIV-1 patients (Table I) exhibited
elevated anti-human IgG staining compared with CD4+ T cells
isolated from blood of healthy controls (Fig. 7A–C), indicative
of the presence of ICs on their surface. Because this difference
was absent on CD8+ T cells (Fig. 7B), we speculated that the
FIGURE 5. Gp120–anti-gp120 IC binding to the CD4 receptor impairs TCR-induced activation of CD4+ T cells. (A) Schematic illustration of CD4+
T cells stimulated with autologous monocytes that were loaded with anti-human CD3 mAb alone (no IC; left) or in combination with gp120–anti-gp120–
CD4BS ctrl IC (ctrl IC; middle), as well as gp120–anti–gp120 IC (IC; right). ICs consist of gp120 JR-FL unless indicated otherwise in combination with
either two CD4BS anti-gp120 mAbs (clone b6 and b12) or non-CD4BS anti-gp120 mAbs (clones 2G12 and 1-79) at a molar gp120/Ab ratio of ∼4:5. CD4+
T cells were stimulated for 6 h (A–C and G) or for 5 d (D–F) with control IC or IC-loaded autologous monocytes in the presence of anti-human CD3 mAb or
for 5 d (D and E) with control IC or IC-loaded autologous monocytes that were previously loaded with CMV lysate (F). (B) Flow cytometry dot plots of one
representative experiment showing CD69 expression on CD4+ T cells. (C) Bar graphs shows relative percentage of CD69+ of CD4+ T cells normalized to
anti-CD3 mAb/control IC after 6 h using ICs that contain gp120 JR-FL (left: n = 9, bars represent mean6 SEM; ****p, 0.0001 one-tailed paired t test) or
gp120 LAI (right: bars represent mean 6 SEM; ***p , 0.001 one-tailed paired t test). (D) Representative CFSE dilution profile and flow cytometry
histogram showing CD25 and CD38 expression on CD4+ T cells. (E) Bar graphs showing relative percentage of CFSElow, CD25+, and CD38+ of CD4+
T cells normalized to anti-CD3 mAb/control IC (n = 3, bars represent mean 6 SEM; **p , 0.01 one-tailed paired t test). (F) Bar graphs showing relative
percentage of CFSElow, CD25+, and CD38+ of CD4+ T cells normalized to CMV/control IC (n = 7, bars represent mean 6 SEM; *p , 0.05, **p , 0.01
one-tailed paired t test). (G) Flow cytometry dot plot showing CD69 expression on CD4+ T cells stimulated for 6 h with PMA plus ionomycin in the
presence of control IC (left) or IC (right).
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increased IgG signal on CD4+ T cells, at least partially, originates
from gp120-containing ICs. These ICs on the surface of CD4+
T cells from HIV+ donors might indeed contain gp120 (as also
suggested in Ref. 59), because staining with two human anti-
gp120 mAbs in combination with an anti-human IgG Ab yiel-
ded increased IgG staining on CD4+ T cells from HIV+ donors
compared with IgG levels without the addition of the two human
anti-gp120 mAbs (Fig. 7C).
The repertoire of anti-gp120 Abs in the plasma from HIV-1
patients supports the formation of gp120–anti-gp120 ICs that
bind to CD4+ T cells and constrain subsequent TCR-induced
activation
Finally, we addressed the question whether the repertoire of
polyclonal anti-gp120 Abs present in the plasma of HIV-1 patients
would support the formation of gp120–anti-gp120 ICs that would
interfere with TCR-mediated CD4+ T cell activation. Toward this
end, plasma from HIV-1 patients (Table II) was incubated with
soluble gp120 to allow generation of gp120–anti-gp120 ICs, fol-
lowed by adsorption to CD4+ T cells from healthy donors.
Staining for anti-human IgG revealed that even in plasma from
HIV+ donors with high titers of anti-gp120 Abs targeting the
CD4BS, such ICs could be detected on CD4+ T cells, whereas
plasma from healthy controls did not lead to the formation of ICs,
which specifically bound to CD4+ T cells (Fig. 7D). When such
gp120 ICs composed of polyclonal Abs from HIV+ patients, in
combination with anti-human CD3 mAb, were loaded on CD14+
monocytes, the activation of autologous CD4+ T cells was sig-
nificantly impaired, as shown by the analysis of CD69 expression
after 6 h (Fig. 7E).
Discussion
An exceptional peculiarity of HIV-1 is that its envelope surface
glycoprotein has a very high affinity for the CD4 receptor (13),
enabling HIV-1 and/or gp120 to directly interact and potentially
interfere with CD4+ T cell function. Such direct interference with
the function of central regulators of the immune system is unique
among human persistent viruses and represents a crucial factor in
undermining HIV-specific and heterologous immune control. CD4
receptor binding by the HIV-1 envelope mediates not only viral
infection (11, 12), but it can also amplify TCR-induced signaling
by recruiting p56lck to the engaged TCRs (26–29, 89, 90), at-
tributing the noninfectious interaction between gp120 and the
CD4 receptor a potential role in modulating CD4+ T cell responses
FIGURE 6. Gp120–anti-gp120 ICs interfere with the orientation of the MTOCs toward the site of TCR engagement. (A) Bar graphs depict the expression
of CD69 on CD4+ T cells stimulated for 6 h with plate-immobilized anti-CD3 plus gp120 or PMA plus ionomycin in the presence (filled bars) or absence
(open bars) of cytochalasin D (n = 3) (bars represent mean 6 SEM, **p, 0.01 one-tailed paired t test). CD4+ T cells were stimulated for 30 min with anti-
human CD3 mAb in the presence of control IC or IC immobilized on coverslips showing nuclei by DAPI staining (blue) and MTOCs by b-tubulin staining
(white) (B–D). (B) Exemplary z-stacks of immunofluorescence images depicting two CD4+ T cells with differential MTOC polarization (left, polarized;
right, not polarized), whereas MTOC polarization is referred to as MTOC positioning toward the site of TCR engagement. (C) Representative immuno-
fluorescence images of CD4+ T cells in z-stack close to the coverslip in the presence of control IC (top) or IC (bottom). (D) Bar graph summarizing MTOC
polarization to the stimuli (white) and random polarization (black) in the presence of control IC (n = 166) and IC (n = 180) (n indicates number of individual
cells, ***p , 0.001, x2 approximation). (E–G) CD4+ T cells were stimulated for 2 h with monocytes loaded with anti-human CD3 mAb in the presence of
control IC or IC showing nuclei by DAPI staining (blue), MTOC by b-tubulin staining (white), and CFSE-labeled CD4+ T cells (green). (E) Exemplary
immunofluorescence images showing MTOCs that are polarized (filled arrow) or not polarized (empty arrow) to the site of cell–cell contact or not. (F)
Representative immunofluorescence images of CD4+ T cells in the presence of control IC (top) or IC (bottom). (G) Bar graph summarizing MTOC po-
larization toward the site of cell–cell contact (white) and random polarization (black) of CD4+ T cells in the presence of control IC (n = 15) or IC (n = 14)-
loaded monocytes (n indicates number of individual cell–cell interactions, ***p , 0.001 Fisher exact test), Scale bar, 5 mm.
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(30–47). Several studies demonstrated the presence of soluble
gp120 in the plasma or lymphoid tissue of HIV-1 patients (20–24),
but its effect on TCR-induced CD4+ T cell activation is still
a contentious issue in the literature.
Our data clearly show that the spatial orientation of CD4 receptor
cross-linking by gp120 relative to the site of TCR engagement
substantially affects TCR-mediated activation of CD4+ T cells.
Namely, simultaneous provision of plate-immobilized agonistic
anti-human CD3 mAb together with gp120 promotes CD4+ T cell
activation, indicating that concomitant cross-linking of CD4
receptors and TCRs at a confined site augments the signaling of
the engaged TCRs, whose cross-linking alone would not allow
optimal signal propagation required for inducing full T cell acti-
vation. Gp120 provided in a simultaneous manner with TCR
stimulation does not increase CD4+ T cell activation in a gp120-
intrinsic manner, because CD4 cross-linking by Abs similarly
enhances stimulation of CD4+ T cells in the presence of low levels
of agonistic anti-CD3 mAbs, indicating that any CD4 cross-
linking modality would promote CD4+ T cell activation when
provided in a temporally and spatially linked manner. Conversely,
ICs adsorbed to CD4 receptors all around CD4+ T cells led to
substantial impairment of CD4+ T cell activation upon interaction
with APCs providing TCR engagement either by agonistic anti-
human CD3 mAb or antigenic HLA class II–peptide complexes.
We suggest that the basis for gp120-mediated interference with
TCR-induced CD4+ T cell activation relies on the fact that CD4
receptors not only interact with the TCR–CD3 complex and p56lck
but also with elements of the cytoskeleton (91), and consequently
substantially interfere with the cytoskeletal-dependent rearrange-
ment of signaling molecules toward the site of TCR stimulation,
which ultimately regulates CD4+ T cell activation (82–86). This
reasoning is supported by the observation that cross-linking of
TCR–CD4 receptors in close proximity at a confined site only
supports CD4+ T cell activation when the dynamics of the cyto-
skeleton are highly dynamic but not when actin polymerization is
blocked by cytochalasin D. MTOC orientation toward the site of
TCR engagement is one hallmark of a functional IS (87, 96), and
our results clearly demonstrate that MTOC positioning is prefer-
entially oriented toward plate-coimmobilized anti-human CD3
mAb and gp120. This indicates that cross-linking of CD4–TCR in
close proximity allows cytoskeleton-directed accumulation of
signaling molecules toward the site of engagement, thereby sup-
porting full CD4+ T cell activation.
In contrast, IC binding to CD4 receptors of CD4+ T cells likely
restricts cytoskeletal rearrangement by impairing lateral mobility
of CD4 receptors and their cytoskeleton-associated framework. In
line with this, we demonstrate that cross-linking of CD4 receptors
by ICs not just at the site of TCR engagement hinders the accu-
mulation of signaling units beyond the engaged TCRs, reflected
by impaired MTOC orientation toward the site of TCR stimulation
and hence compromised T cell activation. These results attribute
gp120 a role in interfering with CD4+ T cell activation at the level
of IS formation, which is in line with a previous report that
describes defective recruitment of p56lck to the IS upon CD4 re-
ceptor engagement prior to TCR engagement (39).
Although many studies agree on a role of gp120 in negatively
impacting CD4+ T cell activation (30–41, 46, 50, 52, 53), the un-
derlying mechanism was so far not clearly elucidated. Gp120
binding to CD4 receptors was described to induce their downreg-
ulation and consequently impairing CD4–TCR complex assembly
required for CD4+ T cell activation (33, 35, 36, 41, 46). Our results
did not confirm CD4 receptor downregulation upon exposure to ICs
within the time of analysis (data not shown). Furthermore, our data
cannot confirm that gp120 prevents CD4+ T cell activation by in-
terfering with MHC II–CD4 receptor interaction required for opti-
mal CD4+ T cell activation (37, 50), because we observed the
inhibitory effect of gp120 on CD4+ T cells activated upon MHC II–
independent TCR engagement by anti-human CD3 mAb. Gp120
binding was suggested to interfere with proximal TCR signaling
(32, 34, 38, 40, 52, 97), being possibly a direct consequence of
impaired IS formation and consequent TCR signaling propagation,
as demonstrated by our results. Moreover, we exclude that ICs
manifest reduced CD4+ T cell activation due to TCRs being steri-
cally hindered from contacting their activating ligands on the APC,
because both the control IC and IC were localized comparably at
the site of cell–cell contact, and only the latter ones affected CD4+
T cell activation.
FIGURE 7. CD4+ T cells from HIV-1+ patients are covered with ICs.
Anti-human IgG staining in combination with or without preincubation
with human anti-gp120 mAb (clones 2G12 and 1-79) mAbs was performed
on CD4+ T cells in blood from HIV-1+ and HIV-12 donors (A–C). (A)
Representative FACS histogram showing anti-human IgG staining. (B) Bar
graph depicting mean fluorescence intensity (MFI) in arbitrary units (AU)
of human IgG on cells isolated from HIV-1+ (n = 6) and HIV-12 donors (n =
6, **p , 0.01 two-tailed unpaired t test). (C) Representative FACS histo-
gram showing human gp120/IgG staining and human IgG staining. (D)
CD4+ T cells from HIV-12 donors were incubated with plasma from HIV-
12 (n = 5) or HIV-1+ donors with and without gp120 (n = 5). Bar graph
showing MFI of IgG in AU as measure for IC (**p, 0.01 one-tailed paired
t test). (E) CD4+ T cells were stimulated with monocytes loaded with anti-
human CD3 mAb in combination with plasma from HIV-12 and HIV-1+
donors with and without gp120. Bar graphs represent the relative decrease
in activation (measured by CD69 expression after 6 h) induced by anti-
human CD3 mAb in combination with plasma from HIV-12 donors (n = 7),
HIV-1+ donors (n = 16), or HIV-1+ donors plus gp120 (n = 16) compared
with activation induced by anti-CD3 alone (n indicates number of plasma
samples from five different donors in several independent experiments,
*p , 0.05 one-tailed paired t test).
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HIV-1 replication is one major driving force of progressive
immunodeficiency (3). One constituent of HIV-1, namely gp120,
has the capacity to directly modulate CD4+ T cell function, as
shown previously (30–47) and in the present study. This effect has
mostly been shown in vitro using relatively high concentrations of
gp120, which leads to the question whether these effects might
similarly operate in an in vivo scenario. Gp120 can be shed from
the virion or from infected cells (18, 19) and is detectable in the
plasma of HIV-1 patients, albeit there is some uncertainty about
the actual gp120 concentrations (48). Levels in the plasma,
however, might be much lower compared with those in lymphoid
tissues where gp120 is thought to accumulate (23, 24). Thus, it is
conceivable that gp120 availability in vivo might be sufficient to
affect CD4+ T cell function. The robust Ab response against the
envelope surface structure of HIV-1 (74–76, 95, 98) results in the
formation of gp120–anti-gp120 ICs, which are the most abundant
form of gp120 in vivo (54, 56). Consistent with this notion, we and
others (54–58) have demonstrated that CD4+ T cells isolated from
the blood of HIV-1 patients are covered with ICs, based on increased
IgG deposition on CD4+ T cells compared with healthy controls.
Because no increase of IgG binding was observed on CD8+ T cells,
we speculate that the increased IgG signal on CD4+ T cells, at least
partially, originates from gp120-containing ICs. Experimental proof
is provided by us and others (59) by disclosing surface staining of
gp120 on a substantial proportion of CD4+ T cells.
ICs that had been loaded on monocytes were rapidly and
quantitatively transferred to CD4+ T cells in our in vitro experi-
ments. We suggest that this transfer is due to the different relative
binding affinities of ICs to CD4+ T cells or monocytes rather than
on an active mechanism. Because the binding affinities between
the IC and the Fc receptors on monocytes is weak compared with
the high-affinity CD4–gp120 interaction (13), we speculate that
ICs are captured by CD4+ T cells from the monocytes in a sto-
chastic process in which the ICs eventually localize on the cells to
which they exhibit increased binding affinity. This transfer was
dependent on the CD4 receptor and consequently did not occur for
the control IC or in the presence of a CD4 receptor–blocking Ab,
and therefore we excluded that ICs bound to the CD4+ T cells in
an unspecific manner. Accordingly, we suggest that ICs trapped on
host cells via Fc or complement receptors as well as soluble
gp120–anti-gp120 ICs might be effectively adsorbed on innocent
bystander CD4+ T cells. This could provoke unresponsiveness to
subsequent TCR-induced activation and thereby add to CD4+
T cell dysfunction during HIV-1 infection. Importantly, gp120–
anti-gp120 ICs generated by the addition of gp120 to plasma from
HIV-1 patients showed that the repertoire of in vivo circulating
polyclonal gp120-specific Abs have the potential to generate
gp120–anti-gp120 ICs that can be adsorbed by CD4+ T cells. Abs
that target the evolutionary conserved CD4BS (99–102) might
prevent gp120-containing ICs from binding to CD4 receptors and
hence could block gp120-related functional impairment of CD4+
T cells similar to our control IC. Our data suggest, however, that
the presence of high CD4BS Ab titers in polyclonal plasma from
HIV-1+ donors does not prevent gp120–anti-gp120 IC formation
upon gp120 addition and that the thereby generated gp120-
containing ICs bind to CD4+ T cells and negatively affect anti-
human CD3 mAb-induced CD4+ T cell activation. This might be
explained by the effective ratio of CD4BS versus non-CD4BS
anti-gp120 Abs in the circulation, with a low ratio still allowing
the formation of gp120-containing IC capable of binding to CD4
receptors. Of note, plasma in which anti-gp120 Ab titers were
below the detection limit did not support the formation of gp120-
containing ICs on CD4+ T cells upon addition of gp120 (data not
shown).
It should be considered in further studies whether gp120–anti-
gp120 IC-coated CD4+ T cells not only contribute to CD4+ T cell
dysfunction by means of impairing their TCR-induced activation
but also by enhancing Ab-dependent cellular phagocytosis or Ab-
dependent cellular cytotoxicity.
Overall, we demonstrate a central role of gp120–CD4 receptor
interaction in impairing CD4+ T cell function and consequently
potential hindrance of establishing functional immune responses
as one factor in the developing progressive immunodeficiency
during HIV-1 infection.
The level of unresponsiveness toward TCR-induced stimulation
likely depends on the extent of IC deposition on CD4+ T cells.
Although it is conceivable that the amounts of ICs we used in our
in vitro assays might be at the upper limit or even higher compared
with the average load of ICs detected on CD4+ T cells isolated ex
vivo in peripheral blood, the levels of gp120 and gp120-containing
ICs are higher in lymphoid tissues (23, 24), and consequently we
would assume that the levels of ICs on CD4+ T cells might also be
higher in these anatomic compartments. Beyond dispute, immune
dysfunction that occurs in HIV-1–infected hosts is likely to be
caused by multiple additional factors. Only very few studies
compared the activation potential of CD4+ T cells isolated from
HIV-1 patients to CD4+ T cells isolated from healthy controls, and
a few of them indicated decreased in vitro lymphocyte proliferation/
activation of CD4+ T cells (56, 103, 104). Daniel et al. (56) revealed
that this could be attributed to the presence of gp120-containing ICs
on the surface of CD4+ T cells. Along these lines, we demonstrate
that HIV-1 gp120 directly influences CD4+ T cell activation,
whereby the geometry of CD4 receptor cross-linking by gp120
dictates the functional outcome of TCR-mediated CD4+ T cell ac-
tivation by differentially affecting IS formation. Although spatially
and temporally linked engagement of CD4 receptors and TCR
promote CD4+ T cell activation, dispersed CD4 receptor engage-
ment in relation to TCR triggering signals results in the opposite
outcome, namely reduced propagation of TCR signaling and hence
CD4+ T cell activation. Our data thereby provide an explanation for
the conflicting reports on gp120–CD4 receptor interaction on TCR-
induced CD4+ T cell activation and suggest a relevant role for the
HIV-1–derived gp120 protein in mediating general downmodulation
of CD4+ T cell responsiveness in HIV-1–infected individuals aside
the prolonged, nonphysiological activation of immune cells occur-
ring in the context of HIV-1 infection (4, 105).
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Abstract
The humoral immune response plays a critical role in controlling infection, and the rapid adaptation to a broad range of
pathogens depends on a highly diverse antibody repertoire. The advent of high-throughput sequencing technologies in the
past decade has enabled insights into this immense diversity. However, not only the variable, but also the constant region
of antibodies determines their in vivo activity. Antibody isotypes differ in effector functions and are thought to play a
defining role in elicitation of immune responses, both in natural infection and in vaccination. We have developed an
Illumina MiSeq high-throughput sequencing protocol that allows determination of the human IgG subtype alongside
sequencing full-length antibody variable heavy chain regions. We thereby took advantage of the Illumina procedure
containing two additional short reads as identifiers. By performing paired-end sequencing of the variable regions and
customizing one of the identifier sequences to distinguish IgG subtypes, IgG transcripts with linked information of variable
regions and IgG subtype can be retrieved. We applied our new method to the analysis of the IgG variable region repertoire
from PBMC of an HIV-1 infected individual confirmed to have serum antibody reactivity to the Membrane Proximal External
Region (MPER) of gp41. We found that IgG3 subtype frequencies in the memory B cell compartment increased after halted
treatment and coincided with increased plasma antibody reactivity against the MPER domain. The sequencing strategy we
developed is not restricted to analysis of IgG. It can be adopted for any Ig subtyping and beyond that for any research
question where phasing of distant regions on the same amplicon is needed.
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Introduction
In the past decade, the development of high-throughput
sequencing technologies (Next Generation Sequencing, NGS)
has largely influenced research possibilities in immunology.
Sequencing of whole antibody repertoires has become feasible
and affordable, offering new approaches to quantitatively study
immune responses [1,2]. For example, the search for potent
neutralizing antibodies against human immunodeficiency virus
type 1 (HIV-1) and ways to elicit them by vaccination has in recent
years funneled extensive research that increasingly relies on NGS
of the IgG variable region, which enables high-resolution profiling
of antibody repertoires and the evolution of neutralizing antibodies
over time [3–8].
For immune effector functions, not only the variable part of an
antibody is important, but also the different isotypes of the
constant region. Antibodies of the same epitope specificity can
therefore elicit different effector functions depending on the
isotype. Antibody-dependent cell-mediated cytotoxicity (ADCC)
for instance is most active with isotype IgG1 followed by IgG3 and
IgA. Subtypes of IgG differentially protect mice from bacterial
infection [9] and are associated with chikungunya virus clearance
and long-term clinical protection [10]. An intriguing example of
the potential importance of IgG subtypes for immune reaction and
antibody elicitation is the membrane-proximal external region
(MPER) of gp41 of HIV-1. All of the broadly neutralizing anti-
MPER antibodies identified thus far, 4E10 and 2F5 [11] and the
recently identified 10E8 [12], were originally isolated as IgG3.
However, in the case of 4E10, the in vitro neutralization potency
is higher for IgG1 and absent for IgM [13]. It was suggested that
this is related to the longer hinge region and greater flexibility of
the IgG3 subtype [14,15]. Of note, in the recent RV144 trial [16],
the first phase III trial of an HIV-1 vaccine that reported some
efficacy, anti-gp120-specific isotype selection was skewed towards
IgG3 [17] and anti-HIV-1 IgG3 antibodies correlated with
antiviral function [18]. These examples highlight the importance
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of evaluating antibody specificity alongside subtype information
when studying immune responses and developing vaccines.
The Illumina MiSeq platform is rapidly becoming the dominant
sequencing system for antibody repertoires due to low error rates,
long read lengths, and declining costs [2]. State of the art
sequencing with Illumina technology currently allows for read
lengths of 26300 nucleotides on the widely used MiSeq platform.
This is sufficient to sequence an antibody variable region from
both ends with an overlap allowing combination of both reads to a
full-length variable region. However, the available read length
might not be enough for antibodies with a long heavy chain
complementary determining region 3 (HCDR3) to also include
determinants of the antibody subtype in the sequences, as they are
located too far downstream in the constant region. In order to
overcome this limitation, we use one of the indexing reads the
Illumina technology applies not in its intended function as a
sample identifier, but instead as a short extra read that identifies
the IgG subtype. This way, we can retrieve full-length variable
regions including the IgG subtype. Of note, in the same
sequencing runs light chains and other desired heavy chain
isotypes can be sequenced. The second Illumina index read is not
modified and used as designed to allow analysis of multiple
samples in a single run.
Methods
Primers
For the heavy chain, forward primers binding to the leader
sequences and reverse primers in the constant region were used
[6,19]. For the kappa light chain, primers binding in the leader
region [19] and in the constant region were used. Lambda light
chains were amplified with primers binding in the leader/variable
[19] and in the joining region [20]. Our customized protocol uses
sequencing adaptors and index sequences based on the Illumina
(San Diego, CA) TruSeq HT setup. Four random nucleotides were
inserted between the sequencing adaptor and the specific primer
to increase diversity and help cluster identification on the Illumina
MiSeq flow cell. The sequences of all primers are listed in Table 1.
Primers were ordered HPL-purified from Microsynth AG
(Balgach, Switzerland).
Clinical specimen
PBMC from healthy donors were purified from buffy coat
obtained from the Zurich Blood Transfusion Service (www.zhbsd.
ch). Cryopreserved PBMC from an HIV-1 infected individual,
patient ZA159, who developed strong MPER specific antibody
responses during disease progression (Liechti et al, in preparation),
were obtained through the Zurich primary HIV infection (ZPHI)
study [21]. BioSample accession numbers for the human subjects
are SAMN02911274 to SAMN02911277.
Ethics statement
Cryopreserved PBMC were obtained from an adult participant
enrolled in the Zurich Primary HIV-infection (ZPHI) study
(http://clinicaltrials.gov, ID 5 NCT00537966) [21]. The study
was approved by the ethics committee of the canton of Zurich and
written informed consent was obtained from all participating
individuals. Buffy coats from healthy donors were obtained from
the Zurich Blood Transfusion Service (www.zhbsd.ch) under a
protocol approved by the ethics committee of the canton of
Zurich.
PCR amplification
Total RNA was extracted from 10 * 106 PBMC (healthy donor)
or 2 * 106 PBMC (patient) using the RNeasy Mini Kit (Qiagen).
cDNA was synthesized in a total volume of 40 ul using 400 U
SuperscriptIII, 1 ug Oligo(dT)15 primer, 2 ul dNTP mix (10 mM
each nucleotide), 2 ul 0.1 M DTT and 1–10 ug RNA. Reverse
transcription was performed at 65uC for five minutes, 50uC for 60
minutes and 70uC for 15 minutes. cDNA was stored at 220uC. Ig
heavy, kappa and lambda genes were amplified in separate
reactions. All PCR reactions were performed in volumes of 50 ul
using 0.5 ul Phusion High-Fidelity DNA Polymerase (New
England Biolabs), 1 ul dNTPs (10 mM each nucleotide) and 5 ul
cDNA template. The first PCR reaction was performed with the
forward primer mix (0.05–0.15 uM each primer) and 0.5 uM gene
specific reverse primer. The temperature protocol was adapted
from [22] and consisted of once 98uC for 60 s; 4 cycles of 98uC
10 s, 45uC 30 s, 72uC 30 s; 4 cycles of 98uC 10 s, 50uC 30 s, 72uC
30 s; 17 cycles of 98uC 10 s, 68uC 30 s, 72uC 30 s; once 72uC
10 min.
The second PCR was performed with the forward index
adaptor primers (TS-D501 to TS-D508, depending on the number
of indices needed) and two custom reverse primers for either the
IgG heavy chains (TS7IgG(int)) or the light chains and heavy
chains of other isotypes (TS7icIgGcSeq). The temperature
protocol was once 98uC for 60 s; 4 cycles of 98uC 10 s, 55uC
30 s, 72uC 30 s; 4 cycles of 98uC 10 s, 60uC 30 s, 72uC 30 s; 17
cycles of 98uC 10 s, 72uC 30 s; once 72uC 10 min. The four
different healthy donor preparations differed in their amplification
strategies: prep 4 was amplified as described above, preps 1 and 2
were amplified with 1 ul cDNA template, prep 3 with 5 ul cDNA
template. Preps 1, 2 and 3 were then amplified for 12, 25 and 12
cycles in the second PCR, respectively. Samples from sorted cells
were amplified for 40 cycles in the first PCR.
The amplicons were purified using the QIAquick Gel Extrac-
tion Kit (Qiagen). Samples were quantitated using Quant-iT
PicoGreen (Invitrogen, Carlsbad, CA), normalized to a concen-
tration of 4 nM (based on an average length of about 525
nucleotides for light chains and 595 nucleotides for heavy chains)
and pooled equimolar for sequencing.
Sequencing strategy
In Illumina high-throughput sequencing technology, the DNA
insert to be sequenced is flanked on both sides by a primer binding
site, a short index and an adapter for binding to the flow cell.
Conventional use allows for paired-end sequencing (forward read
1 and reverse read 2) and dual multiplexing (index read 1 and
index read 2) by four independent sequencing reactions. On the
MiSeq system, custom primers for read 1, read 2 and for the index
read 1 can be used optionally. The priming of index read 2 cannot
be customized. Further, the number of cycles can be individually
chosen for all four reads, as long as the sum is not more than 25
cycles higher than the capacity of the kit used (available kits range
from 50–600 cycles). We used these features of the MiSeq system
to sequence the variable region of immunoglobulins in a paired-
end fashion, determined the subtype of IgGs via a 12 nucleotide
long identifier read and multiplexed samples by an 8 nucleotide
long index read (Figure 1).
The constant region of subtype IgG1 differs from IgG2/3/4 at
position 47 (AAG (K) vs. AGG (R), Figure 2). IgG1/3 and IgG2/4
differ at position 57 (TCT (S) vs. TCC (S)). By sequencing this
stretch of the constant region and defining the corresponding
sequences as indices, subtypes IgG1, 2/4 and 3 can be
differentiated. It is not possible to distinguish IgG2 and 4 at this
position; however, they can be separated based on the first triplet
IgG Sequencing with Subtype Information
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Table 1. List of PCR and sequencing primers.
IGH forward Seq5N4-VH1LA CTTTCCCTACACGACGCTCTTCCGATCTNNNNATGGACTGGACCTGGAGGAT
Seq5N4-VH1LB CTTTCCCTACACGACGCTCTTCCGATCTNNNNATGGACTGGACCTGGAGCAT
Seq5N4-VH1LC CTTTCCCTACACGACGCTCTTCCGATCTNNNNATGGACTGGACCTGGAGAAT
Seq5N4-VH1LD CTTTCCCTACACGACGCTCTTCCGATCTNNNNGGTTCCTCTTTGTGGTGGC
Seq5N4-VH1LE CTTTCCCTACACGACGCTCTTCCGATCTNNNNATGGACTGGACCTGGAGGGT
Seq5N4-VH1LF CTTTCCCTACACGACGCTCTTCCGATCTNNNNATGGACTGGATTTGGAGGAT
Seq5N4-VH1LG CTTTCCCTACACGACGCTCTTCCGATCTNNNNAGGTTCCTCTTTGTGGTGGCAG
Seq5N4-VH3LA CTTTCCCTACACGACGCTCTTCCGATCTNNNNTAAAAGGTGTCCAGTGT
Seq5N4-VH3LB CTTTCCCTACACGACGCTCTTCCGATCTNNNNTAAGAGGTGTCCAGTGT
Seq5N4-VH3LC CTTTCCCTACACGACGCTCTTCCGATCTNNNNTAGAAGGTGTCCAGTGT
Seq5N4-VH3LD CTTTCCCTACACGACGCTCTTCCGATCTNNNNGCTATTTTTAAAGGTGTCCAGTGT
Seq5N4-VH3LE CTTTCCCTACACGACGCTCTTCCGATCTNNNNTACAAGGTGTCCAGTGT
Seq5N4-VH3LF CTTTCCCTACACGACGCTCTTCCGATCTNNNNTTAAAGCTGTCCAGTGT
Seq5N4-VH4LA CTTTCCCTACACGACGCTCTTCCGATCTNNNNATGAAACACCTGTGGTTCTTCC
Seq5N4-VH4LB CTTTCCCTACACGACGCTCTTCCGATCTNNNNATGAAACACCTGTGGTTCTT
Seq5N4-VH4LC CTTTCCCTACACGACGCTCTTCCGATCTNNNNATGAAGCACCTGTGGTTCTT
Seq5N4-VH4LD CTTTCCCTACACGACGCTCTTCCGATCTNNNNATGAAACATCTGTGGTTCTT
Seq5N4-VH5LA CTTTCCCTACACGACGCTCTTCCGATCTNNNNTTCTCCAAGGAGTCTGT
Seq5N4-VH5LB CTTTCCCTACACGACGCTCTTCCGATCTNNNNCCTCCACAGTGAGAGTCTG
Seq5N4-VH6LA CTTTCCCTACACGACGCTCTTCCGATCTNNNNATGTCTGTCTCCTTCCTCATC
Seq5N4-VH7LA CTTTCCCTACACGACGCTCTTCCGATCTNNNNGGCAGCAGCAACAGGTGCCCA
IGL forward Seq5N4-VL1 CTTTCCCTACACGACGCTCTTCCGATCTNNNNGGTCCTGGGCCCAGTCTGTGCTG
Seq5N4-VL2 CTTTCCCTACACGACGCTCTTCCGATCTNNNNGGTCCTGGGCCCAGTCTGCCCTG
Seq5N4-VL3 CTTTCCCTACACGACGCTCTTCCGATCTNNNNGCTCTGTGACCTCCTATGAGCTG
Seq5N4-VL45 CTTTCCCTACACGACGCTCTTCCGATCTNNNNGGTCTCTCTCSCAGCyTGTGCTG
Seq5N4-VL6 CTTTCCCTACACGACGCTCTTCCGATCTNNNNGTTCTTGGGCCAATTTTATGCTG
Seq5N4-VL7 CTTTCCCTACACGACGCTCTTCCGATCTNNNNGGTCCAATTCyCAGGCTGTGGTG
Seq5N4-VL8 CTTTCCCTACACGACGCTCTTCCGATCTNNNNGAGTGGATTCTCAGACTGTGGTG
IGK forward Seq5N4-VK12 CTTTCCCTACACGACGCTCTTCCGATCTNNNNATGAGGSTCCCyGCTCAGCTGCTGG
Seq5N4-VK3 CTTTCCCTACACGACGCTCTTCCGATCTNNNNCTCTTCCTCCTGCTACTCTGGCTCCCAG
Seq5N4-VK4 CTTTCCCTACACGACGCTCTTCCGATCTNNNNATTTCTCTGTTGCTCTGGATCTCTG
IGG reverse TS7IgG(int) CAAGCAGAAGACGGCATACGAGATccGTTCGGGGAAGTAGTCCTTGAC
IGL reverse IgGcSeqhuVL1-rev GGGAAGACCGATGGGCCCTTGGTNNNNTAGGACGGTSASCTTGGTCC
IgGcSeqhuVL7-rev GGGAAGACCGATGGGCCCTTGGTNNNNGAGGACGGTCAGCTGGGTGC
IGK reverse IgGcSeqhuVKC-rev GGGAAGACCGATGGGCCCTTGGTNNNNAGATGGTGCAGCCACAGTTC
IGM reverse IgGcSeqhuIgM-rev GGGAAGACCGATGGGCCCTTGGTNNNNGGTTGGGGCGGATGCACTCC
IGA reverse IgGcSeqIgA-rev GGGAAGACCGATGGGCCCTTGGTNNNNTTGGGGCTGGTCGGGGATGC
indexing forward TS-D501 AATGATACGGCGACCACCGAGATCTACACTATAGCCTACACTCTTTCCCTA
CACGACGCTCTTCCGATCT
TS-D502 AATGATACGGCGACCACCGAGATCTACACATAGAGGCACACTCTTTCCCTA
CACGACGCTCTTCCGATCT
TS-D503 AATGATACGGCGACCACCGAGATCTACACCCTATCCTACACTCTTTCCCTA
CACGACGCTCTTCCGATCT
TS-D504 AATGATACGGCGACCACCGAGATCTACACGGCTCTGAACACTCTTTCCCTA
CACGACGCTCTTCCGATCT
TS-D505 AATGATACGGCGACCACCGAGATCTACACAGGCGAAGACACTCTTTCCCTA
CACGACGCTCTTCCGATCT
TS-D506 AATGATACGGCGACCACCGAGATCTACACTAATCTTAACACTCTTTCCCTA
CACGACGCTCTTCCGATCT
TS-D507 AATGATACGGCGACCACCGAGATCTACACCAGGACGTACACTCTTTCCCTA
CACGACGCTCTTCCGATCT
TS-D508 AATGATACGGCGACCACCGAGATCTACACGTACTGACACACTCTTTCCCTA
CACGACGCTCTTCCGATCT
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of the constant region (GCC (A) vs. GCT (A), Figure 2). This way,
all four IgG subtypes can be called unequivocally. To make
sequencing of light chains and heavy chain isotypes IgM and IgA
possible in the same run, the 59 end of the IgG constant region
(nucleotides 7–45) was added into the respective reverse primers so
that the same read 2 custom primer could be used for sequencing
of IgG, IgA, IgM and kappa (k) and lambda (l) light chains. A
separate index (klMA), which is complementary to the IgG1 index
to increase base variability during sequencing, was used for those
chains.
Illumina MiSeq sequencing
Pooled samples were denatured with NaOH according to the
protocol (Illumina), diluted with hybridization buffer HT1 to a
final dilution of 10 pM, spiked with 5% of PhiX control library
and loaded into a 500 cycle version 2 reagent cartridge. Custom
primers IgGcSeq and IgGcInd for the read 2 and the indexing
read, respectively, were diluted to 0.5 uM in hybridization buffer
HT1 and 600 ul loaded into well 19 (index read 1, IgGcInd) and
well 20 (read 2, IgGcSeq) of the reagent cartridge. The sample
sheet was adapted manually to allow any sequence (N12) as custom
index 1. Sequencing was performed for 2 * 250 cycles. The
workflow was set to ‘‘GenerateFASTQ’’. The raw sequencing data
have been uploaded to zenodo (doi:10.5281/zenodo.10863).
Data analysis
In order to obtain fastq files also for the index reads,
‘‘CreateFastqForIndexReads’’ in the MiSeqReporter.exe.config
file was set to 1 (true). Reads were first de-multiplexed by Illumina
MiSeq Reporter (version 2.4.60) based on index 2 that
distinguishes the different samples. Secondly, reads were assigned
to the different subtypes using a python script (available here
https://gist.github.com/ozagordi/11180835) as follows: IgG1,
IgG3 and light chains or heavy chains of other isotypes (klMA)
were identified by their index 1; IgG2 and IgG4 were additionally
discriminated based on the fourth nucleotide of the second read
(IgG2 if ‘G’, IgG4 if ‘A’, read 2 is reverse complementary). For the
IgG subtype indices a perfect match was required, for the klMA
klMA indexing
reverse
TS7icIgGcSeq CAAGCAGAAGACGGCATACGAGATTCTCCACGAGAAGGAGGAGGGTGCCA
GGGGGAAGACCGATGGGCCCTTGGT
custom sequencing IgGcSeq CCAGGGGGAAGACCGATGGGCCCTTGGT
IgGcInd CCATCGGTCTTCCCCCTGGCRCCCTSCTCC
doi:10.1371/journal.pone.0111726.t001
Table 1. Cont.
Figure 1. Amplification of Ig variable regions and high-throughput sequencing with subtype information. Antibody heavy and light
chain genes are shown schematically with leader regions in purple, variable (V-) regions in blue and constant (C-) regions in green. Ig heavy, kappa
and lambda light chain genes were amplified in separate reactions with family specific primers (represented by arrows) binding to leader and
constant region. Primer names are indicated exemplarily below the arrows and a complete list of all primers used can be found in Table 1.
Sequencing adaptors essential for the Illumina platform (flow cell binding sites P5 and P7, the index 2 region i5 and the read 1 sequencing primer
binding site Rd1 SP, illustrated in orange) were added by primer extension during a second PCR reaction, except for the IgG reverse primer
TS7IgG(int) which contained an adaptor and was used for both amplifications. Purified libraries were then sequenced using standard Illumina MiSeq
primers for read 1 and index 2, and customized primers for index 1 and read 2 (sequencing primers are shown in red and regions sequenced with red
dashed arrows).
doi:10.1371/journal.pone.0111726.g001
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index one mismatch was allowed. Reads not matching above
criteria were classified as undetermined. Forward and reverse
reads of a corresponding pair were stitched together using
PANDAseq [23] with a minimal overlap of 10 nucleotides and
analyzed by IMGT/HighV-QUEST [24]. Subtype frequencies
were calculated as the percentage of completely indexed and full-
length Ig variable region rearrangements.
Staining and cell sorting
Healthy donor PBMC were thawed, washed and split into four
samples. Staining for IgG subtypes was performed in PBS/1%
FCS at 4uC in the dark for 15 minutes using the following
antibodies and dyes: anti-CD19 V500 (BD Horizon), anti-CD3
APC-Cy7 (BioLegend), anti-CD14 APC-Cy7 (BioLegend), LIVE/
DEAD Near-IR Dead Cell Stain (Molecular Probes), anti-CD16
APC-Cy7 (BioLegend), anti-IgD PE-Cy5 (BioLegend, labeled in-
house) and either anti-IgG1 PE, anti-IgG2 PE, anti-IgG3 PE or
anti-IgG4 PE (all from SouthernBiotech). Cells were washed twice,
re-suspended in PBS/1% FCS and cells gated for CD3/14/16/
Dead- CD19+ IgD- and positive for one of the IgG subtypes were
sorted on a FACSAriaIII (Becton Dickinson). Sorted cells were
frozen at 280uC as dry pellets prior to analysis.
Results
Validation of high-throughput immunoglobulin variable
region sequencing with subtype identification
We developed a high-throughput method for the Illumina
MiSeq system to sequence the full variable region of immuno-
globulins in a paired-end fashion and identify at the same time the
subtype of IgGs via a 12 nucleotide long custom index read
(Figure 1). In order to test our sequencing strategy, we sequenced
IgG heavy and light chains from PBMC from a healthy donor and
an HIV-1 infected individual (ZA159 week 213, see below). The
healthy donor sample was amplified in four separate reactions
using different PCR conditions and cDNA input (see methods) to
confirm the robustness of the IgG subtype assignment. We focused
on assigning IgG subtypes and therefore did not sequence light
chains for preparations 1–3. Sequencing of the five samples
yielded a total of 10’249’237 passing filter reads.
19.3% (1’981’155) of the paired-end reads could not be
demultiplexed to one of the five samples and were categorized
as undetermined in regard of sample (Table 2). However, most of
these undetermined reads (193819101, 13.5% of total reads) had an
index identical to the TruSeq Universal primer and were
confirmed to be mostly PhiX control reads (data not shown).
The high number of undetermined reads therefore results from
high PhiX concentrations and not from problems associated with
sample preparation or library generation.
IgG subtype assignment based on index read 1 and the first
triplet of the constant region sequenced in read 2 resulted in 6
categories (IgG1, IgG2, IgG3, IgG4, klMA, undetermined reads)
for each sample (Table 2, column ‘‘Subtype assigned read pairs’’).
Of all read pairs demultiplexed to a sample, 97.5% (8’063’436)
were successfully assigned to one of the IgG subtypes or the light
chains.
To assemble full-length variable region sequences, correspond-
ing paired end reads were combined with PANDAseq [23]. The
overlap of reads peaked at about 100 nucleotides for heavy chains
and at about 100 and 150 nucleotides for kappa and lambda light
chains, respectively. 96.7% of all the read pairs overlapped
(Table 2, column ‘‘Sequences after PANDAseq’’). Sequences were
subjected to IMGT analysis. On average, 98% of both heavy and
Figure 2. Determinants of IgG subtype in the constant region. IgG1 to IgG4 CH1 regions were obtained from IMGT/GENE-DB [34]. Only the
first 107 nucleotides of the constant region are shown. Some alleles identical in this section have been omitted. Binding sites of the IgG reverse
primer (TS7IgG(int)) used for library preparation and the custom sequencing and indexing primers (IgGcSeq and IgGcInd, respectively) are
represented by dashed arrows on top. The full index 1 and the start of read 2 are indicated. Regions used for subtype assignment are shaded.
doi:10.1371/journal.pone.0111726.g002
IgG Sequencing with Subtype Information
PLOS ONE | www.plosone.org 5 November 2014 | Volume 9 | Issue 11 | e111726
199
light chain sequences could be assigned to antibody variable
regions. The median heavy chain variable region length in our
dataset was approximately 360 nucleotides. In total, 796039242
subtype-assigned variable region sequences were obtained (Ta-
ble 2, column ‘‘Rearranged variable regions’’), showing that our
strategy efficiently sequences full-length variable regions with
linked subtype information.
The IgG subtype frequencies were found to be very consistent
among the four preparations of healthy donor and therefore
independent of PCR amplification strategies and cDNA input
(Table 2, Figure 3A, average frequency 6 std. deviation (%) for
IgG1 equals 56.160.2, IgG2 39.560.3, IgG3 4.060.1, IgG4
0.560.1). These values correspond well to IgG subtype frequen-
cies previously reported [25–27].
Validation of Ig subtype distribution analysis by NGS and
FACS sorting
To confirm the correct calling of the IgG subtype, PBMC of a
healthy donor were FACS sorted into the four different IgG
subtype populations. Purity after sorting was .99% for CD19+
IgG1, IgG2 and IgG3 positive cells (approximately 17000, 7000
and 4500 cells were sorted, respectively). IgG4 positive cells were
not further analyzed due to the low yield (total of 82 cells sorted)
and lack of possibility to assess post-sort purity by FACS. After
high-throughput sequencing of these populations in a separated
run and analysis by the same pipeline as described above, we
found subtype frequencies of 92.8% IgG1, 97.5% IgG2 and 98.7%
IgG3 for the IgG1, IgG2 and IgG3 sorted populations, respec-
Table 2. Read numbers and subtype frequencies.
Sample Subtype
Subtype assigned
read pairs
Sequences
after PANDAseq
Rearranged
variable regions
IgG subtypes
per sample
Healthy donor prep 1 IgG1 529’390 515’758 505’942 56.3%
IgG2 369’741 360’472 354’751 39.5%
IgG3 36’604 35’620 34’920 3.9%
IgG4 3’785 3’645 3’572 0.4%
klMA nd nd nd na
Undet(b) 11’577 na na na
Healthy donor prep 2 IgG1 692’673 674’590 660’899 55.9%
IgG2 488’483 475’851 467’958 39.6%
IgG3 50’454 48’880 47’773 4.0%
IgG4 6’191 5’968 5’859 0.5%
klMA nd nd nd na
Undet(b) 18’326 na na na
Healthy donor prep 3 IgG1 641’364 623’522 611’013 55.9%
IgG2 453’471 441’108 433’565 39.7%
IgG3 46’361 44’911 43’848 4.0%
IgG4 5’386 5’155 5’030 0.5%
klMA nd nd nd na
Undet(b) 18’149 na na na
Healthy donor prep 4 IgG1 699’378 679’819 665’267 56.3%
IgG2 481’592 468’433 460’214 39.0%
IgG3 52’028 50’328 49’024 4.2%
IgG4 7’199 6’900 6’695 0.6%
klMA 1’317’918 1’257’301 1’210’698 na
Undet(b) 84’941 na na na
ZA159 (week 213) IgG1 677’787 659’884 646’977 65.8%
IgG2 183’718 178’800 175’718 17.9%
IgG3 163’839 158’878 155’704 15.8%
IgG4 4’487 4’366 4’211 0.4%
klMA 1’151’587 1’097’762 1’053’604 na
Undet(b) 71’653 na na na
Undet (a) 1’981’155 na na na
Total reads 10’249’237 7’797’951 7’603’242
a) Undetermined in regard of sample.
b) Undetermined in regard of subtype.
nd =not done.
na = not applicable.
doi:10.1371/journal.pone.0111726.t002
IgG Sequencing with Subtype Information
PLOS ONE | www.plosone.org 6 November 2014 | Volume 9 | Issue 11 | e111726
200
tively, highlighting the high specificity of our sequencing strategy
(Figure 3 BCD).
IgG subtype dynamics in an HIV-1 infected patient
To get an insight if our method is applicable to monitor IgG
subtype dynamics during infections, we selected an HIV-1 infected
patient with pronounced IgG3-mediated anti-MPER plasma
antibody response (Liechti et al. in preparation). Patient ZA159
was enrolled in the Zurich primary HIV infection study and has
been followed from the acute phase of HIV-1 infection onwards
[21]. The patient was on anti-retroviral treatment until week 92
post infection. Samples for NGS analysis were selected from three
time points with differential IgG3-mediated MPER plasma titers:
the first sample was taken 94 weeks post infection where no IgG3
MPER reactivity was apparent. Plasma from the second time
point, approximately 181 weeks post infection, showed interme-
diate IgG3 MPER reactivity and the third, approximately 213
weeks post infection, had highest IgG3 MPER reactivity.
In addition to the wk213 sample already sequenced in the first
run, frozen PBMC from the other two time points were sequenced
in a second run and 732’390 and 669’244 heavy chain reads were
obtained for those samples from week 94 and 181, respectively (see
Table S1 for reads statistics). Assigning these reads to the IgG
subtypes and comparing subtype frequencies to those from the
healthy donor showed higher IgG1 and decreased IgG2 frequen-
cies for the HIV-1 infected individual at all time points measured
(Figure 3A). Of note, during viral rebound after anti-retroviral
treatment cessation, IgG3 frequencies (measured by NGS) in the
memory B cell compartment increased markedly (Figure 3E),
which coincided with the increase in plasma IgG3 MPER
reactivity.
Discussion
Repertoire analysis of antibody variable genes by NGS has
become an important tool that allows unprecedented insight into
antibody development pathways and holds particular promise for
tailored vaccine design. Here, we describe a strategy for high-
throughput sequencing of antibody heavy chains including
determination of the IgG subtype. To achieve this, we adapted
the Illumina MiSeq standard protocol by employing a mixed
strategy of index reads and customized primers. Sequencing with
custom primers and indices has been done previously [28,29], but
to our knowledge our strategy of using an index read as a ‘‘third
read’’ is novel. Different samples can still be multiplexed in the
same run as the second index read remains available.
As we demonstrate here, our method determines IgG subtypes
very reliably. We could successfully assign 97.5% of the reads in
the demultiplexed samples to a subtype, although our identifier is
12 nucleotides long and the assignment criteria have to be very
strict. Consistently, over 96% of both heavy and light chain
sequences could be assigned to rearranged variable regions,
demonstrating that our sequences are full-length antibody variable
regions.
As the Hamming distances between the subtype identifiers are
only single nucleotides, we do not allow mismatches in the subtype
indices, except one mismatch in calling the klMA category. There
remains a risk of misidentification of the subtype by a PCR or
sequencing error, artifact recombination [30] or a mutation in the
constant region. If further exclusion of misidentification by
sequencing errors in the indices should become warranted for
specific research questions, our analysis could be adapted to first
collapse identical variable regions and then use the consensus of
their index reads to determine the subtype. While this approach
would decrease potential misidentifications, a full repertoire
analysis of the variable domains would be required. Although this
was beyond the scope of our current study, we consider this a
useful and valuable modification of our analysis for future projects.
Yet, despite the increased accuracy of this approach, pre-existing
mutations in the constant region will not be detected and
dismissed. Another possibility to empower subtype identification
would be full-length sequencing of the CH1, as the difference
between subtypes over the whole CH1 would increase to 6–15
nucleotides. However, the required read lengths are currently
limiting for Illumina technology, as additional sequencing of the
CH1 domain further downstream of our index would be necessary
[27]. Even if this became possible, splitting up the available read
length in several smaller reads might still be preferable, as per base
sequencing quality decreases with increasing read length.
Figure 3. IgG subtypes are reliably identified. A) IgG subtype
frequencies of four preparations of PBMC from one healthy donor were
determined by sequencing. Different PCR protocols (prep 1 to prep 4)
as described in the methods section have been applied to amplify
antibody transcripts. Read numbers for the different preparations are
listed in Table 2. B–D) PBMC of a healthy control were sorted by FACS
into individual IgG subtype populations and sequenced. 292219006,
290449153 and 198899353 reads were obtained for sorted IgG1 positive
cells (B), IgG2 positive cells (C) and IgG3 positive cells (D), respectively,
and assigned to the IgG subtypes. E) IgG subtype frequencies of time
points week 94, week 181 and week 213 (Table 2, Table S1) for patient
ZA159. The average frequencies from the healthy control preparations
1–4 are shown as a comparison. Subtype frequencies in all panels were
calculated as the percentage of all completely indexed and full-length
variable region rearrangements.
doi:10.1371/journal.pone.0111726.g003
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Although the purity of sorted subtype populations was higher
measured by FACS than the IgG subtype frequency in the sorted
samples determined by our sequencing approach, we argue that
the sequencing approach serves as a quality control for the sorting
and not the other way round, as even in the most controlled set up,
FACS sorting will suffer from residual cross-reactivity from the
staining antibodies.
No bias or cross-reactivity is expected in sequencing as this
method is independent of immunoglobulin surface expression and,
importantly, all subtypes are amplified with the same primer. A
common primer is a key advantage compared to individual
primers for each subtype. It is, however, important to note that our
method, as it is presented here, is only semi-quantitative as we
focused solely on subclass determination. If needed, a quantitative
analysis would require a full repertoire analysis to avoid counting
the same variable region multiple times. Since oversampling
should be proportional for all the subtypes, distribution of subtype
frequencies as shown here should not be affected.
Our method has the potential of widespread application and
particularly in the antibody field the chance to fill a gap in
information. So far, antibody subtypes have either only been
determined in bulk in plasma samples where the information could
not be linked to variable region sequences, or on the level of
antibodies cloned out of single cells, where the potential for high-
throughput applications is limited.
As recent data have highlighted, information on IgG subtype
profiles could be very useful to study elicitation and dynamics of
IgG antibodies of different subtypes, and could provide informa-
tion on the quality of infection- and vaccine-induced B cell
responses [18,31,32].
Our method can easily be adapted for IgA subtype discrimi-
nation. It can also be applied in other cases where priming of three
reads is necessary or sequence information of a distant site is
needed, e.g. in haplotype analysis used in genetics. Overall, our
method combines the strength of antibody repertoire analyses by
NGS with subtype information of the obtained sequences,
enabling in-depth analysis of immune responses following infec-
tions or vaccinations.
Supporting Information
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9.  Discussion 
HIV-1 infection induces a dramatic polyclonal immune activation of B cells that resulting in 
elevated frequency of antibody-secreting cells in the periphery and as a consequence thereof 
hypergammaglobulinemia develops (Lane, Masur et al. 1983; Schnittman, Lane et al. 1986; 
De Milito, Nilsson et al. 2004; Buckner, Moir et al. 2013). The perturbations in the B cell 
repertoire afflicted by HIV-1 are widespread. Recent bone marrow egressing transitional B 
cells are increased likely as direct consequence of the reduced CD4+ T cell and concomitant 
elevated plasma IL-7 levels in HIV-1 infection (Malaspina, Moir et al. 2006; Malaspina, Moir 
et al. 2007). Memory B cells show a skewed differentiation profile shifting frequencies away 
from resting memory (RM) B cells, the dominating memory B cell subset in healthy 
individuals, to activated (AM) and exhausted tissue-like (TLM) memory B cells which both are 
characterized by down-regulation of CD21 and additionally of CD27 for TLM B cells (Moir, Ho 
et al. 2008; Moir and Fauci 2013).  
IgG-expressing TLM B cells show increased proliferation history in vivo compared to RM and 
AM B cells highlighting that TLM B cells emerge as a consequence of activation (Meffre, 
Louie et al. 2016). Nevertheless TLM B cells contain less diversified variable genes of the B 
cell receptor (BCR) and reduced responsiveness to BCR-mediated stimulation highlighting 
that this subset is exhausted and excluded from further development into high-affinity B cell 
clones (Moir, Ho et al. 2008; Meffre, Louie et al. 2016). In addition TLM B cells are 
characterized by increased expression of inhibitory receptors such as CD22, FcRL4 and 
SIGLEC-6 known to dampen BCR-mediated activation (Moir, Ho et al. 2008; Kardava, Moir 
et al. 2011). Comparison of gp120 CD4 binding site-specific antibodies derived from RM and 
TLM B cells of HIV-1 infected individuals showed that RM B cells contained higher 
frequencies of clones with the potential to neutralize HIV-1 supporting that TLM B cells are 
impaired in developing high-affinity antibody responses (Meffre, Louie et al. 2016). In 
addition to the alterations observed in the B cell compartment HIV-1 induces CD4+ T cell 
depletion and profound remodeling of lymphoid structures characterized by massive B cell 
proliferation, follicle hyperplasia, involution and fibrosis further impairing B cell responses 
(Grossman, Meier-Schellersheim et al. 2006; Brenchley and Douek 2008; Lederman and 
Margolis 2008; Levesque, Moody et al. 2009). As a consequence HIV-1 infection is 
accompanied by impaired B cell responses against co-infections and vaccines (Kroon, 
Vandissel et al. 1994; Kroon, van Dissel et al. 1997; Malaspina, Moir et al. 2005; Bussmann, 
Reiche et al. 2010; Cagigi, Nilsson et al. 2010; Tebas, Frank et al. 2010; Chang, Crane et al. 
2013).  
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Despite this apparent impairment in mounting novel antibody responses, HIV-1 specific 
neutralizing antibodies continue to develop throughout the disease course (Wei, Decker et al. 
2003; Tomaras and Haynes 2009; Overbaugh and Morris 2012; Liao, Lynch et al. 2013). In a 
fraction of individuals exceptionally potent and broadly neutralizing antibodies (bnAbs) 
develop after several years of untreated HIV-1 infection (Simek, Rida et al. 2009; Doria-Rose, 
Klein et al. 2010; Rusert, Kouyos et al. 2016). The length of the infection and antigen loads 
have been shown to be driving factors of bnAb development (Gray, Moore et al. 2007; Sather, 
Armann et al. 2009; Moore, Williamson et al. 2015; Rusert, Kouyos et al. 2016). Hence, the 
very factors that drive the distortion of the B cell response are linked to successful bnAb 
elicitation. Which components of the B cell response are required to mount bnAb responses 
is a subject of intense research efforts to guide bnAb elicitation by vaccines [ reviewed in 
(Haynes, Moody et al. 2011; Haynes, Kelsoe et al. 2012; Mascola and Haynes 2013)]. 
A number of bnAbs have been isolated over the years and intensively characterized to 
understand how they gain such neutralization breadth and potency (Haynes and Montefiori 
2006; Haynes, Moody et al. 2011; Burton, Poignard et al. 2012; Haynes, Kelsoe et al. 2012; 
Burton and Hangartner 2016). Interestingly, many bnAbs show unusual features such as 
high rates of somatic hypermutation (SHM) of the variable and framework regions, long third 
complementary determining regions of the heavy chain (CDRH3) and polyreactivity 
[reviewed in (Mascola and Haynes 2013; West, Scharf et al. 2014)]. In sum these results 
suggest that functional B cell subsets exist that maintained the ability to undergo extensive 
maturation and selection despite the profound B cell alterations in HIV-1 infection [reviewed 
in (Haynes, Kelsoe et al. 2012; Mascola and Haynes 2013)].  
Although B cell alterations in HIV-1 infection have been intensively studied, we still lack a 
high-dimensional analysis of the B cell compartment in HIV-1 infected individuals that has 
sufficient depth to fine-map phenotypic differences within B cell subsets.. Such information 
would be crucial to define immune signatures associated with either the lack or the induction 
of potent immune responses against HIV-1 or co-infections and vaccines. The potential of 
multi-dimensional flow cytometry has been highlighted by the recent reports defining 
protective T cell responses associated with clinical outcome of HIV-1 infection and vaccine 
efficacy (Aghaeepour, Chattopadhyay et al. 2012; Lin, Finak et al. 2015). The aim of this 
thesis was to study the B cell compartment in HIV-1 infection using multidimensional flow 
cytometry in combination with unsupervised computational analysis tools to elucidate B cell 
subset alterations in HIV-1 infection. 
In the first part of this thesis the development of a multicolor flow cytometry panel to dissect 
B cell subsets is described. The panel includes markers to distinguish the main B cell 
subsets according to their developmental stage (transitional B cells, naïve B cells, marginal 
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zone (MZ) B cells, memory B cells and plasmablasts) based on the expression of CD10, 
CD19, CD27, CD38 and IgD. A central goal of our analysis was to distinguish memory B cell 
subsets further based on the expression of different BCR isotypes (IgA, IgG1 and IgG3), 
CD21 and CD27. The CD21/CD27 expression pattern allows to distinguish intermediate (IM; 
CD21+CD27-), resting (RM; CD21+CD27+), activated (AM; CD21-CD27+) and tissue-like (TLM; 
CD21-CD27-) memory B cells (Kardava, Moir et al. 2014; Meffre, Louie et al. 2016).  
Since chemokine receptors define the migratory potential of immune cells, we assessed 
expression of CCR7, CXCR3, CXCR4 and CXCR5 with our panel. CCR7 and CXCR5 are 
important for B cells to enter the T cell area and B cell follicle, respectively [reviewed in 
(Griffith, Sokol et al. 2014)]. CXCR4 can attract B cells to several sites but is mainly known 
for its function of migration towards and homeostasis of the cellular compartment in the bone 
marrow (Sugiyama, Kohara et al. 2006; Chu and Berek 2013). In addition CXCR4 has been 
shown to be important for GC reaction, lymph node entry and migration to inflammatory sites 
(Okada, Ngo et al. 2002; Dotan, Werner et al. 2010; Victora, Schwickert et al. 2010; Werner, 
Guzner-Gur et al. 2013). The ligands of CXCR3, namely CXCL9-11, are expressed at 
inflammatory sites and attract CXCR3-bearing immune cells to sites of active inflammation 
[reviewed in (Groom and Luster 2011; Griffith, Sokol et al. 2014)]. By monitoring expression 
of these chemokine receptors, our panel provides insight on the possible target destinations 
of B cell subsets.  
The cytokine IL-21 plays a crucial role in germinal center reaction and plasmablast 
differentiation (Ettinger, Sims et al. 2005; Ettinger, Kuchen et al. 2008; Avery, Deenick et al. 
2010; Linterman, Beaton et al. 2010; Zotos, Coquet et al. 2010; Crotty 2011; Deenick, Avery 
et al. 2013; Spolski and Leonard 2014; Tangye 2015). We thus included an analysis of IL-
21R expression on B cell subsets to obtain insights on their responsiveness to IL-21 (Ettinger, 
Sims et al. 2005; Ettinger, Kuchen et al. 2008; Linterman, Beaton et al. 2010; Zotos, Coquet 
et al. 2010).  As a further parameter we monitored intracellular staining of Ki-67, a classical 
proliferation marker, that allows the determination of proliferating and therefore recently 
activated B cells [reviewed in (Scholzen and Gerdes 2000; Harwood and Batista 2010)].  
To analyze all markers on the same cell subset a 16 color flow cytometry panel was 
developed following recent guidelines (Perfetto, Chattopadhyay et al. 2004; Mahnke and 
Roederer 2007). We used a progressive approach increasing from a 11 to a 16 colors panel 
to obtain a panel with sufficient resolution that allows to define the desired B cell subsets and 
their phenotypic characteristics (Chapter 4; Figure 1 and online table 6). Nevertheless, 
several iterations in changing fluorochrome combinations were necessary in order to attain 
sufficient staining resolution despite fluorescence spill-over.   
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In chapter 5, we applied the final 16 color B cell panel to study the B cell repertoire in 21 
patients enrolled in the Zurich Primary HIV Infection (ZPHI) cohort study longitudinally. We 
included samples from the acute and chronic infection phase and after 1 year of highly active 
antiretroviral therapy (ART). The patients were stratified into two groups based on the 
initiation of ART. The “early treatment group” initiated ART during the acute phase and 
stopped ART after ≥ 1 year and then progressed.  Patients in the “late ART treatment” group 
initiated ART in the chronic phase. B cell populations at the different longitudinal time points 
of HIV-1 infection were then compared to data from 29 healthy individuals. 
In a first step flow cytometry data were analyzed manually by defining main B cell 
populations and comparing their frequencies at different disease and treatment stages in 
comparison with healthy individuals. The analysis confirmed previously described increased 
levels of transitional B cells and plasmablasts as well as the skewing of the memory B cell 
compartment towards AM and TLM B cells with reduced levels of RM B cells in viremic 
patients (Chapter 5; Figure 1A and B) (Lane, Masur et al. 1983; Malaspina, Moir et al. 2006; 
Moir, Ho et al. 2008; Buckner, Moir et al. 2013).  
Activation of memory B cells results in loss of CD21 expression as a consequence of 
transcriptional down-regulation of CD21 and potentially CD21 shedding (Moir, Malaspina et 
al. 2001; Masilamani, Kassahn et al. 2003). Based on these prior findings CD21 has become 
a canonical marker to discriminate activated and exhausted from resting memory B cells. In 
the current study I explored CD21 expression on naïve (IgD+CD27-) and MZ (IgD+CD27+) B 
cells. Surprisingly, HIV-1 infection lead to increased frequencies of CD21neg naïve and 
CD21neg MZ B cells which reverted to normal levels upon initiation of ART (Chapter 5; Figure 
1C). CD21neg naïve B cells have been described in the context of autoimmune diseases and 
reported to show an exhausted phenotype, lower responsiveness to BCR-mediated 
stimulation and increased frequencies of autoreactive clones (Rakhmanov, Keller et al. 2009; 
Isnardi, Ng et al. 2010; Tipton, Fucile et al. 2015; Flint, Gibson et al. 2016). Furthermore 
CD21neg naïve B cells in autoimmune disease have altered chemokine receptor expression 
profiles that matched the expression pattern observed in CD21neg naïve and MZ cells 
described in our study and were signified by reduced levels of CCR7 and CXCR5 an 
elevated expression of CXCR3 (Chapter 5; Figure 3B). Based on the chemokine expression 
patterns it is likely that these altered subsets shift their migratory pattern from entering lymph 
nodes and B cell follicles to reach sites of inflammation (Griffith, Sokol et al. 2014; Moir and 
Fauci 2014).  
I used spanning-tree progression analysis of density-normalized events (SPADE), a recently 
developed clustering algorithm to cluster multidimensional single cell data, to explore diverse 
phenotypes within CD21neg naïve B cells in HIV-1-infected patients (Chapter 5; Figure 5A) 
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(Qiu, Simonds et al. 2011). CD21neg MZ B cell frequencies in the cryo-preserved PBMC 
samples that were available for these studies were not sufficient for yield reliable results in 
the SPADE analysis and were therefore not included. We found that CXCR3-expressing 
CD21neg naïve B cells express high levels of CXCR4 and CD19 and low levels of CCR7, a 
signature associated with activation and exhaustion (cluster #3 and #5; Chapter 5; Figure 5C) 
(Moir, Ho et al. 2008; Rakhmanov, Keller et al. 2009; Isnardi, Ng et al. 2010; Tipton, Fucile et 
al. 2015). In contrast, within subsets expressing CCR7 only few cells show high levels of 
CXCR3, CD19 and CXCR4 and therefore resemble conventional naïve B cells (Chapter 5; 
Figure 5C). CXCR5- and IL-21R are expressed on diverse subsets with no clear pattern of 
co-expressing markers (Chapter 5; Figure 5C). Most strikingly, the cluster analysis revealed 
that several phenotypically divergent CD21neg naïve B cell subsets can be defined and that 
the expression signature of some CD21neg naïve B cell subsets are more associated with 
exhaustion whereas other signatures are similar to the quiescent state observed in 
conventional naïve B cells. Therefore the transition of subsets within CD21neg naïve B cells to 
a distinct phenotype could be associated with differentiation, functional changes or activation 
and exhaustion. It will be interesting to dissect in forthcoming studies, if and how these 
subpopulations differ in their function, developmental or activation stage.  
CD21neg naïve B cells described in autoimmune diseases and CVID are characterized by 
impaired responsiveness to stimulation and increased apoptosis (Rakhmanov, Keller et al. 
2009; Isnardi, Ng et al. 2010). In addition these cells express high levels of the activation and 
exhaustion markers CD95 and FcRL4, respectively (Rakhmanov, Keller et al. 2009). The 
phenotypic analysis I performed in my thesis showed strong similarities between CD21neg 
naïve and CD21neg MZ B cells in healthy and HIV-1-infected individuals and the naïve 
CD21neg B cells subset described in autoimmune diseases and CVID. I thus investigated the 
functional properties of these subsets in healthy and HIV-1 infected individuals. Indeed, 
CD21neg naïve and CD21neg MZ B cells up-regulate CD95 and FcRL4 in healthy and 
chronically HIV-1 infected individuals and HIV-1 infection results in further up-regulation of 
these markers (Chapter 5; Figure 6A-C) (Moir, Ho et al. 2008; Sciaranghella, Tong et al. 
2012). CD95 is highly up-regulated in activated GC B cells and the CD95/CD95L-axis plays 
an important role in B cell homeostasis and elimination of autoreactive B cells in GC of mice 
(Hao, Duncan et al. 2008). Therefore CD95 is likely to be essential for the elimination of 
activated low-affinity B cells which do not receive sufficient T cell help during GC reaction. In 
line with this, CD21neg naïve and CD21neg MZ B cells showed increased frequencies of 
apoptotic cells compared to CD21pos cells both in healthy and chronically HIV-1 infected 
individuals which could be a result of CD95/CD95L-dependent mechanisms (Chapter 5; 
Figure 6E and F) (Medina, Segundo et al. 1997; Sciaranghella, Tong et al. 2012).  
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In order to investigate the responsiveness of CD21neg naïve B cells to BCR-mediated 
stimulation in healthy and chronically HIV-1 infected individuals I used a flow cytometry-
based method to determine to magnitude of phosphorylated tyrosine motifs since 
phosphorylation is an early and crucial event in B cell activation (Harwood and Batista 2010; 
Schulz, Danna et al. 2012). Elevated basal phosphorylation levels in CD21neg naïve and 
CD21neg MZ B cells were observed in chronically HIV-1-infected individuals while in healthy 
subjects only CD21neg MZ showed significantly elevated phosphorylation compared to 
CD21pos MZ B cells (Chapter 5; Figure 7C). Upon BCR cross-linking phosphorylation levels 
were higher in CD21pos naïve and CD21pos MZ B cells compared to their CD21neg cells 
highlighting that the responsiveness of CD21neg naïve and CD21neg MZ B cells to BCR-
mediated stimulation is impaired. Interestingly though, no difference between CD21pos and 
CD21neg MZ B cells could be observed in healthy individuals (Chapter 5; Figure 7C). 
Collectively our data suggest that CD21neg naïve and CD21neg MZ B cells are impaired in 
their responsiveness to BCR-mediated stimulation. However the elevated phosphorylation 
levels ex vivo observed in healthy and HIV-1 infected individuals support that CD21neg naïve 
and MZ B cells resemble an activated phenotype. Our functional analysis support the notion 
that CD21neg naïve and CD21neg MZ B cells that emerge during HIV-1 infection show highly 
similar phenotypical and functional properties with CD21neg naïve B cells observed in 
autoimmune diseases and common variable immunodeficiency (CVID).  
HIV-1 infection results in loss of memory B cells and diminished B cell responses to co-
infections and vaccines (Ballet, Sulcebe et al. 1987; Kroon, Vandissel et al. 1994; Kroon, van 
Dissel et al. 1997; Malaspina, Moir et al. 2005; Titanji, De Milito et al. 2006; Chang, Crane et 
al. 2013; Crum-Cianflone and Wallace 2014; Mena, Garcia-Basteiro et al. 2015). Since the 
results presented in this study highlight that a high proportion of naïve and MZ B cells show 
loss of CD21 and are characterized by an activated and exhausted phenotype during chronic 
HIV-1 infection these cells are likely to be impaired in reacting to these pathogens. MZ B 
cells are known to be important for polysaccharide-directed responses and therefore the 
reduced efficacy of pneumococcal vaccines could be a consequence of the impaired MZ B 
cell compartment (Kroon, Vandissel et al. 1994; Kruetzmann, Rosado et al. 2003; Weill, 
Weller et al. 2009; Crum-Cianflone and Wallace 2014).  
Autoreactive B cell clones are enriched within CD21neg naïve B cells in autoimmune diseases 
and CVID (Rakhmanov, Keller et al. 2009; Isnardi, Ng et al. 2010). The phenotypical and 
functional similarities of CD21neg naïve B cells in HIV-1 infection, autoimmune diseases and 
CVID raise the possibility that these cells may harbor a similar potential to express 
polyreactive BCR irrespective of the disease setting. It would thus be of importance to proof 
experimentally if this indeed is the case for CD21neg naïve B cells in HIV-1 infection in 
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forthcoming studies. It has long been known that HIV-1 infected patients show increased 
frequencies of autoreactive B cells (Kobie, Alcena et al. 2012). In addition, the bnAbs 2F5 
and 4E10 targeting the membrane proximal region (MPER) of gp41 as well as several other 
gp120 targeting bnAbs are known to be polyreactive (Muster, Steindl et al. 1993; Buchacher, 
Predl et al. 1994; Zwick, Labrijn et al. 2001; Haynes, Fleming et al. 2005; Yang, Holl et al. 
2013). For 2F5 and 4E10 it has been shown that their polyreactivity contributes to their 
activity (Haynes, Fleming et al. 2005; Alam, McAdams et al. 2007; Dennison, Anasti et al. 
2011; Yang, Holl et al. 2013; Verkoczy, Kelsoe et al. 2014).  While adding to their HIV 
inhibitory potential, the polyreactivity of MPER directed bnAbs is an impediment for their 
elicitation as immune tolerance mechanism need to be overcome (Verkoczy, Diaz et al. 2010; 
Verkoczy, Chen et al. 2011).  
Polyreactivity was suggested beneficial in inducing HIV-1 specific antibodies as it may 
provide enhanced affinity binding to the virus surface which harbors only low amounts of the 
actual target protein the HIV envelope trimer (Mouquet, Scheid et al. 2010). In favor of this 
possibility two recent studies showed that autoreactive anergic naïve B cells can enter the 
GC and are selected for mutations reducing polyreactivity but maintaining and increasing 
affinity to the foreign antigen (Sabouri, Schofield et al. 2014). This could be observed in two 
monoclonal antibodies elicited during vaccinia immunization, however the loss of 
polyreactivity was in one antibody accompanied by reduced affinity to the foreign antigen 
highlighting the contribution of polyreactivity to the affinity (Reed, Jackson et al. 2016). 
Autoreactive naïve B cells are excluded from GC in healthy individuals, however in SLE 
these cells showed increased entry into GC with the potential to result in the elicitation of 
autoantibodies (Cappione, Anolik et al. 2005). Whether the same mechanisms occur in HIV-1 
is not known. However, if HIV-1 infection results in the emergence of polyreactive anergic 
naïve B cells as observed in autoimmune diseases and CVID the co-operation between 
antigen-specificity and polyreactivity of naïve B cells might indeed contribute to the induction 
of HIV-specific antibody responses through synergistic activation signals. Noteworthy, the 
search for germline Ig sequences with the ability to bind HIV-1 envelope proteins has been 
largely unsuccessful highlighting the potential or co-operative mechanisms including 
polyreactivity to facilitate the induction of HIV-1 Env antibody responses (Hoot, McGuire et al. 
2013; McGuire, Hoot et al. 2013). A particular interest of future studies will be the 
investigation whether CD21neg naïve B cells contain increased frequencies of 
polyreactive/autoreactive clones and whether the emergence of these cells is exploited by 
the immune system to induce HIV-specific antibodies.  
In chapter 6 of my thesis I studied the complexity of the memory B cell and plasmablast 
compartment as recent studies highlight that peripheral and tissue-resident class-switched B 
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cells are phenotypically more diverse than anticipated (Nair, Newell et al. 2016). My studies 
focused on the same longitudinally HIV-1 patient cohort described in chapter 5 that was 
followed through periods of acute, Chronic infection and ART and healthy donors. To derive 
a comprehensive map of the memory B cell and plasmablast repertoire I assessed 
expression of 16 markers by flow cytometry as described in chapter 4. This was followed by 
a thorough analysis of the flow cytometry data using conventional manual gating, and several 
computational approaches.  
Non-linear dimensionality reduction analysis using t-Distributed Stochastic Neighbor 
Embedding (t-SNE) algorithm allowed a projection of individual cells in two dimensions 
where similar cells are mapped closer together and most dissimilar cells are projected with 
the maximum distance (Chapter 6; Figure 1A and 2A and Supplementary figure 2) (Amir, 
Davis et al. 2013). The t-SNE analysis revealed that in healthy individuals the distribution of 
IM, RM, AM and TLM B cells differs within B cells expressing different isotypes with IgG3+ 
memory B cells showing the highest frequency of AM and TLM B cells whereas IgA+ memory 
B cells contained the highest frequency of RM B cells (Chapter 6; Figure 2C and D). IgG1+ 
memory B cells showed an intermediate distribution of memory B cell subsets. The skewed 
distribution of memory B cell subsets was also evident in HIV-1 infected individuals. However, 
as HIV-1 infection results in accumulation of AM and TLM B cells some of the patterns were 
less pronounced (Chapter 6; Figure 2C and D) (Moir, Ho et al. 2008; Kardava, Moir et al. 
2014). I further observed that IgG3+ resting memory B cells have a phenotype associated 
with progression towards activated and exhausted memory B cells as characterized by 
reduced levels of CCR7 and CXCR5 and elevated levels of CXCR3 and IL-21R compared to 
IgA+ and IgG1+ RM B cells (Chapter 6; Figure 1B and 4A). Collectively these results highlight 
that IgG3+ memory B cells show a phenotypic signature associated with activation that is 
already apparent in resting memory B cells and is paired with a skewed accumulation of 
IgG3+ AM and TLM B cells. It will be of importance to resolve the underlying causes of this 
skewed distribution and memory B cell subsets and activated immune signature amongst 
IgG3+ memory B cells to understand the developmental paths of these cells. Higher 
frequencies of IgG3+ memory B cells have been observed among CD27- naïve B cells and 
are characterized by a low mutation rate which lead to the hypothesis that these cells are 
derived from T cell-independent immune responses or have left GC reaction early as a part 
of the early antibody response (Fecteau, Cote et al. 2006; Berkowska, Driessen et al. 2011). 
This scenario is however challenged by a recent study showing that the majority of CD27-
IgG3+ memory B cells have undergone somatic hypermutation (SHM) suggesting that IgG3+ 
memory B cells do originate from GC-dependent responses (Budeus, Schweigle de Reynoso 
et al. 2015). Preferentially induced IgG3 responses were observed for certain epitopes of 
malaria-derived antigens emphasizing that IgG3 CSR might be guided by the physical 
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properties of the epitope (Tongren, Drakeley et al. 2006). In addition, IgG3 responses against 
malaria antigens are elevated in endemic regions suggesting that repeated antigen 
challenging can skew responses towards IgG3 (Tongren, Drakeley et al. 2006). Therefore 
IgG3 responses can potentially be shaped by persisting antigens and the properties of the 
antigen. Interestingly, the three isolated bnAbs specific for the MPER region were originally 
IgG3 whereas most gp120-specific bnAbs were isolated as IgG1 highlighting that HIV-1 
contains epitopes which might be associated with preferential induction of IgG3 bnAbs 
(Buchacher, Predl et al. 1994; Haynes, Kelsoe et al. 2012; Huang, Ofek et al. 2012).  
Our analysis highlights that HIV-1 infection results in increased CXCR3 expression on IM 
and RM memory B cells irrespective of the isotype expressed (Chapter 6; Figure 5A). We 
observed no disease-dependent alterations of CXCR3 of AM and TLM B cells likely as these 
cells are already activated and generally have up-regulated levels of CXCR3. Of particular 
note we found that only early ART successfully reduced CXCR3 levels, which stayed 
significantly elevated when ART was initiated during the chronic infection stage (Chapter 6; 
Figure 5B). This observation is a further addition to reports that show that despite effective 
ART activation and exhaustion of immune cells persist which potentially may be due to low 
levels HIV-1 replication in lymph nodes  (Hatano, Jain et al. 2013; Pallikkuth, Sharkey et al. 
2015; Banga, Procopio et al. 2016; Cobos Jimenez, Wit et al. 2016; Fromentin, Bakeman et 
al. 2016; Lorenzo-Redondo, Fryer et al. 2016). Likewise, despite ART damage of the 
lymphoid organs are irreversible and skewed memory B cell subset frequencies such as 
elevated TLM B cells cannot be completely restored (Moir, Buckner et al. 2010; Estes 2013). 
The elevated CXCR3 expression after prolonged period of ART in the late treatment group 
we defined in the present study indicates that phenotypic alterations persist despite 
prolonged period of therapy when ART is initiated at advanced disease stages and these 
persisting phenotypic alterations could have functional consequences for memory B cells. As 
a consequence early initiation of ART must be viewed as beneficial for the B cell 
compartment (Moir, Buckner et al. 2010; Moir and Fauci 2013).  
The analysis of the plasmablast population we conducted revealed increased levels of 
almost all chemokine receptors and IL-21R except for CCR7 on plasmablasts during HIV-1 
infection and highlighted a substantial phenotypic diversity of plasmablasts (Chapter 6; 
Figure 6). Plasmablasts and plasma cells are known to have an altered expression of 
chemokine receptors in chronic inflammation (Tarlton, Green et al. 2012; Buckner, Moir et al. 
2014). In addition, CXCR3 and CXCR4 expression can be observed after stimulation of 
memory B cells and plasmablast formation in vitro and upon vaccination (Muehlinghaus, 
Cigliano et al. 2005; Odendahl, Mei et al. 2005). Interestingly, steady-state plasmablasts 
originate from mucosal tissues expressing IgA and mucosa-associated chemokine receptors 
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such as CCR10 whereas upon vaccination IgG-expressing plasmablasts emerge with a 
distinct expression pattern of chemokine receptors (Mei, Yoshida et al. 2009). These 
observations provided a first indication on the phenotypic diversity of plasmablasts and 
plasma cells and show that plasmablast phenotypes can be associated with unique immune 
states such as steady-state, vaccination or inflammation. 
To further explore the diversity within memory B cells and plasmablasts revealed by the t-
SNE analysis I used SPADE in combination with Ward’s hierarchical clustering (Chapter 6; 
Figure 1A, 2A, 7 and Supplementary figure 5 and 6). This approach identified 30 memory B 
cell and 10 plasmablast clusters (Chapter 6; Figure 7A). The recent advent of mass 
cytometry and new computational analysis tools provided unprecedented insight into the 
diversity of B cells in periphery and tissues (Hansmann, Blum et al. 2015; Nair, Newell et al. 
2016; Pejoski, Tchitchek et al. 2016). The study presented in chapter 6 of this thesis 
contributes to these results by showing that memory B cell populations classified by the 
expression pattern of CD21 and CD27 contain highly diverse subsets (chapter 6; Figure 7 
and Supplementary figure 5 and 6). Clustering analysis do not always result in clearly 
defined populations based on CD21 and CD27 expression emphasizing that the definition of 
some clusters relies on distinct markers. However, in general the clustering analysis resulted 
in accurate definition of memory B cell subsets defined by CD21/CD27 expression. Our 
results suggest that memory B cells consist of phenotypically variable subsets beyond 
isotype and CD21/CD27 expression. Nevertheless memory B cell subsets defined based on 
CD21/CD27 can be associated with specific expression pattern such as IL-21R, which was 
observed mainly in clusters within TLM B cells (Chapter 6; figure 7A). It will be interesting to 
explore the functional characteristics of these subsets in future studies.  
Interestingly, memory B cell subpopulations show divergent dynamics in HIV-1 infection 
highlighting that HIV-1 dependent memory B cell alterations are complex. For IM B cells only 
subsets characterized by low IL-21R expression are decreased in acute and chronic HIV-1 
infection (Ward cluster #3 and #26; Chapter 6; Figure 7A and C). Interestingly, these subsets 
show different kinetics with Ward cluster #3 gradually decrease during the course of infection 
while Ward cluster #26 show the lowest frequency already at the acute stage (Chapter 6; 
Figure 7A and C). Within clusters showing a CD21/CD27 expression pattern consistent with 
TLM B cells only cells expressing CXCR3, IL-21R, CXCR4 and high levels of CD19 are 
elevated. However, as only few cells were assigned to Ward cluster #21 this low-frequent 
subset has to be re-evaluated in independent studies. 
Evaluation of plasmablasts by the clustering analysis revealed classical plasmablasts defined 
by high expression of CD27, CD38 and Ki-67 (Chapter 6; Figure 8A) [reviewed in (Fink 2012)] 
and in addition CD38highKi-67high plasmablasts that lack CD27. Functional properties of this 
213
Chapter 9  Discussion 
 
 
plasmablast type that was recently also described to emerge in response to an oral vaccine 
against Shigella are not yet known (Toapanta, Simon et al. 2014). Interestingly, chemokine 
receptors CCR7, CXC3 and CXCR5 were differently expressed on the distinct plasmablast 
clusters (Chapter 6; Figure 8A). This is in agreement with prior reports that found that 
plasmablasts and plasma cells express a variety of chemokine receptors which determine 
their migratory potential (Kunkel and Butcher 2003; Muehlinghaus, Cigliano et al. 2005; 
Odendahl, Mei et al. 2005; Buckner, Moir et al. 2014; Toapanta, Simon et al. 2014). The 
majority of plasmablast clusters we defined expressed CXCR3 which allows these cells to 
migrate to inflamed tissue while only few clusters expressed CCR7 and thus might possess 
the potential to enter lymphoid organs (Hauser, Debes et al. 2002; Kunkel and Butcher 2003; 
Nakayama, Hieshima et al. 2003; Muehlinghaus, Cigliano et al. 2005; Griffith, Sokol et al. 
2014).  
Collectively the results obtained by the high-dimensional mapping of the B cell repertoire in 
Chapters 5 and 6, provides in-depth insight into the dynamics of the B cell compartment in 
healthy and HIV-1 infected individuals. The definition of subpopulations that go beyond the 
conventional B cell subsets not only illustrate the heterogeneity of the B cell repertoire but 
also provide means for future studies to dissect functional properties of B cell sub-species in 
shaping immune responses and in particular bnAb responses to HIV-1.  
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